

PHYSICIAN-FOCUSED PAYMENT MODEL TECHNICAL
ADVISORY COMMITTEE (PTAC)

+ + + + +

PUBLIC MEETING

+ + + + +

Virtual Meeting Via Webex

+ + + + +

Monday, June 22, 2020

PTAC MEMBERS PRESENT

JEFFREY BAILET, MD, Chair
GRACE TERRELL, MD, MMM, Vice Chair
PAUL N. CASALE, MD, MPH
CHARLES DeSHAZER, MD
KAVITA PATEL, MD, MSHS*
ANGELO SINOPOLI, MD
BRUCE STEINWALD, MBA
JENNIFER WILER, MD, MBA

STAFF PRESENT

STELLA (STACE) MANDL, Office of the Assistant
Secretary for Planning and Evaluation
(ASPE)
AUDREY MCDOWELL, Designated Federal Officer,
(DFO), ASPE
SALLY STEARNS, PhD, ASPE

CONTRACTOR STAFF PRESENT

ADELE SHARTZER, PhD, (Urban Institute)
LAURA SKOPEC, (Urban Institute)

*Present via telephone (partial)

A-G-E-N-D-A

Opening Remarks	5
Seema Verma, Administrator, Centers for Medicare & Medicaid Services (CMS) Remarks.....	6
Chairman's Update	14
Deliberation and Voting on Eye Care Emergency Department Avoidance (EyEDA) submitted by the University of Massachusetts Medical School	
PRT: Paul N. Casale, MD, MPH (Lead) Harold D. Miller, and Kavita Patel, MD, MSHS Staff Lead: Sally Stearns, PhD	
PTAC Member Disclosures	32
Preliminary Review Team (PRT) Report to PTAC - Paul N. Casale, MD, MPH.....	34
Clarifying Questions from PTAC to PRT	52
Submitter's Statement.....	61
- David Polakoff, MD, MSc - Clifford Scott, OD, MPH - Jay Flanagan, MHL	
Public Comments	90
Voting	103
- Criterion 1	
- Criterion 2.....	
- Criterion 3	
- Criterion 4	
- Criterion 5	
- Criterion 6	
- Criterion 7	
- Criterion 8	
- Criterion 9	
-Criterion 10	
- Overall Vote	
Instructions on Report to the Secretary	116

Brad Smith, Deputy Administrator and Director
of CMMI Remarks.....128

**Deliberation and Voting on Patient-Centered
Asthma Care Payment (PCACP) submitted by the
American College of Allergy, Asthma &
Immunology (ACAAI)**

PRT: Angelo Sinopoli, MD (Lead)
Jeffrey Bailet, MD, and
Bruce Steinwald, MBA
Staff Lead: Sally Stearns, PhD

PTAC Member Disclosures 137

Preliminary Review Team (PRT) Report to PTAC
- Angelo Sinopoli, MD..... 139

Clarifying Questions from PTAC to PRT 159

Submitter's Statement..... 162
- James Tracy, DO
- James Sublett, MD
- Bill Finerfrock

Public Comments 197

Voting 211
- Criterion 1 212
- Criterion 2..... 213
- Criterion 3 214
- Criterion 4 215
- Criterion 5 216
- Criterion 6 217
- Criterion 7 217
- Criterion 8 218
- Criterion 9 218
- Criterion 10 219
- Overall Vote 222

Instructions on Report to the Secretary 231

Discussion: Reflecting on Models Deliberated on
By PTAC 233
- Adele Shartzter, PhD
- Laura Skopec

Chairman's Closing Remarks 249

Adjourn 251

P-R-O-C-E-E-D-I-N-G-S

10:01 a.m.

*** Opening Remarks by Chair Bailet and
CMS Leadership**

CHAIR BAILET: Good morning and welcome to this meeting of the Physician-Focused Payment Model Technical Advisory Committee, known as PTAC. Welcome to our first ever virtual public meeting.

We've been working very hard over the last few months and chose to hold our meeting virtually rather than further delay evaluating submitted proposals. We will begin that work later on in our agenda.

But first, we are very excited today to be joined by the Administrator of the Centers for Medicare & Medicaid Services, Seema Verma.

In her role as the Administrator she oversees a trillion dollar budget representing about a quarter of the total federal budget, administers health coverage programs for more than 130 million Americans and oversees the quality and safety for all providers

1 participating in Medicare.

2 Nominated by President Trump on
3 November 29, 2016—the seventh nomination by the
4 President-elect—and confirmed by the U.S.
5 Senate on March 13, 2017, she is one of the
6 longest-serving Administrators in modern
7 history.

8 Administrator Verma is a graduate of
9 the University of Maryland and holds a Master's
10 Degree in Public Health from Johns Hopkins
11 University. Modern Healthcare ranked her as the
12 number one most influential person in health
13 care in 2019.

14 And with that, it is my pleasure to
15 welcome Administrator Verma.

16 * **Seema Verma, Administrator, Centers**
17 **for Medicare & Medicaid Services**
18 **(CMS) Remarks**

19 ADMINISTRATOR VERMA: Thank you,
20 Jeff. I appreciate the introduction and thank
21 you all for joining us virtually today. I'm
22 excited to kick off a new phase of partnership
23 between CMS¹ and PTAC.

1 Center for Medicare & Medicaid Services

1 Before we get into value-based care,
2 I'd like to take this opportunity to talk about
3 CMS's response to the coronavirus pandemic and
4 how we're responding in the context of value-
5 based care.

6 First of all, I want to extend my
7 sincere gratitude to everyone on the front
8 lines of this crisis. Caring for both the
9 physical and mental health is challenging in
10 times like this, and America is grateful for
11 our frontline workers and their service.

12 Those of you that have been working
13 around the clock in that capacity deserve every
14 ounce of support that we can muster. And that's
15 why at CMS we've been working to provide health
16 care workers with the tools that they need in
17 this unprecedented time.

18 During the pandemic, CMS has
19 expanded flexibility across the board. And the
20 first and best example of this is telehealth.
21 Telehealth has been nothing short of a
22 lifeline.

23 It's allowed seniors to access care
24 that they need without leaving their homes and

1 risking potential exposure to the virus. And
2 it's also protected health care workers to
3 preserve PPE².

4 We have increased access to
5 telehealth visits, including by expanding the
6 types of telehealth visits we cover, and never
7 before has the health system adopted so rapidly
8 any change, especially one that so dramatically
9 transforms how care is delivered.

10 Since mid-March, nearly 7.3 million
11 Medicare fee-for-service beneficiaries have
12 used telehealth and that's up from
13 approximately 136,000 from January to mid-
14 March, an over 4,000 percent increase. And we
15 continue to hear very positive feedback from
16 both providers and patients.

17 And we've also removed regulatory
18 barriers so that the health care workforce can
19 practice at the top of their license consistent
20 with state laws. This effort was ensuring that
21 health systems across the country could have
22 all hands on deck.

23 We've allowed physicians affiliated

2 personal protective equipment

1 with hospitals to provide care in places like
2 skilled nursing facilities and inpatient rehab
3 facilities, and we've also changed some of the
4 requirements for nurse anesthetists.

5 Under the CMS' Hospitals Without
6 Walls initiative, we have taken multiple steps
7 to allow hospitals to provide services in other
8 health care facilities and sites that aren't
9 necessarily a part of the physical existing
10 hospital and to set up temporary expansion
11 sites to address patient needs.

12 For example, ambulatory surgery
13 centers with capacity can register as hospitals
14 for the duration of the emergency and receive
15 comparable compensation. And we've also changed
16 our testing policies.

17 So, we're allowing labs to go out to
18 nursing homes to collect samples. And we've
19 also expanded access to testing in pharmacies.

20 And finally, we have lifted scores
21 of regulations across the board to help our
22 health systems and provide more flexibility.
23 Anything from just removing some of the
24 reporting requirements to give our systems more

1 flexibility.

2 And we're also working hard to
3 support states as they seek to use new tools
4 available to them in order to respond to the
5 pandemic. CMS has approved over 365 requests
6 from states for waivers, amendments and
7 flexibilities in Medicaid state plans. And most
8 of these were done in a matter of days.

9 When it comes to our existing
10 payment models, we have announced important
11 flexibilities on implementation dates as well
12 as data reporting requirements to ensure
13 providers can focus on patients instead of
14 paperwork during the pandemic.

15 We've also made adjustments to
16 payment methodologies, including mitigating
17 risks during the emergency and modifying cost
18 targets and benchmarks to adjust for the
19 response to the virus. So providers aren't at
20 risk for costs solely due to this unprecedented
21 pandemic.

22 And you're going to hear more about
23 this from Brad Smith later on today. And of
24 course, this just scratches the surface. We

1 continue to solicit feedback from providers,
2 such as you, and we have ongoing meetings,
3 weekly meetings with provider types across the
4 board.

5 And as we reopen the country, we are
6 considering the impact of these flexibilities
7 and what should be a permanent part of our
8 Medicaid and Medicare programs. And some of
9 those changes will require Congress to act.

10 But we are looking at what we can do
11 through our regulations as well. I've been very
12 clear that I think that telehealth and
13 flexibilities around telehealth should be
14 maintained.

15 And as we assess the changes made to
16 our programs, we will also be looking at the
17 flexibilities we offer in Alternative Payment
18 Models and how to continue to encourage value-
19 based care.

20 This crisis brought to light
21 numerous vulnerabilities in our health care
22 system, including how a fee-for-service payment
23 in a time of falling non-COVID³ demand left many

3 The disease COVID-19, caused by the SARS-CoV-2 virus.

1 providers with serious revenue decline. By
2 contrast, Alternative Payment Models such as
3 population-based payment models may buffer such
4 abrupt revenue losses.

5 And as you know, improving value is
6 a top priority at CMS, a central plank of our
7 agency-wide agenda. We want to deliver high-
8 quality outcomes at the lowest cost.

9 A major component in the transition
10 to value-based care is the models we develop
11 and release. The process of crafting a model is
12 complex and requires significant investment of
13 time and resources.

14 PTAC plays a vital role in our
15 development of these models by providing
16 practical, well-vetted input and we are deeply
17 grateful for that. And conversations with
18 submitters who have gone through the PTAC
19 process have informed and enriched our thinking
20 on these issues.

21 Going forward, we want to continue
22 to hear from stakeholders on what they believe
23 to be care delivery issues and how they think

1 we can use value-based care to address those
2 issues, especially after their experiences
3 during the public health emergency.

4 And we want to leverage PTAC as a
5 place to gather valuable public input on
6 provider adoption of Alternative Payment
7 Models. Boosting participation in our existing
8 models and future ones that we plan to release
9 is a top priority.

10 Right now the application for Direct
11 Contracting⁴ is open and the Primary Care First
12 and Kidney Care Choices model applications
13 recently closed. We expect that these new
14 models will bring in many new providers to
15 value-based payments and Alternative Payment
16 Models when they begin next year.

17 And we look forward to providing
18 additional opportunities as more models are
19 announced. Again, this year we will be
20 reviewing a lot of the models that started at
21 the beginning of CMMI⁵, are now coming to
22 fruition in terms of their evaluations and

4 Direct Contracting Model
5 Center for Medicare & Medicaid Innovation

1 we'll be taking a long look at the results of
2 these early models and try to apply lessons
3 learned to the models that we develop in the
4 future.

5 So, thank you again for being here.
6 Your willingness to take time out of your busy
7 schedules to serve the American people in its
8 mission to improve the health and well being is
9 invaluable. And so, thank you and have a
10 wonderful conference.

11 * **Chairman's Update**

12 CHAIR BAILET: Thank you,
13 Administrator Verma and welcome. My name is Dr.
14 Jeff Bailet. I'm the Chair of the PTAC
15 Committee and we're incredibly thankful to the
16 Administrator for joining us and giving us her
17 public remarks.

18 We appreciate you taking the time
19 out of your very busy schedule to articulate
20 your vision for this renewed sense of
21 cooperation between PTAC and CMS, and we are
22 here as eager and willing partners.

23 I would like to welcome members of
24 the public who are participating today whether

1 it be Webex, phone, or livestream. Thank you
2 all for your interest in today's meeting.

3 Should you have technical questions
4 during the meeting or decide you would like to
5 make a public comment on one of the proposals
6 during the meeting, please reach out to the
7 host via the chat function in Webex, or email,
8 or call PTAC at the registration -- PTAC
9 registration staff -- per your logistics email
10 and your name will be added to the end of the
11 preregistered list of commentators for the
12 specified proposal.

13 You can also email
14 ptacregistration@norc.org with any questions.
15 Again, that's ptacregistration@norc.org.

16 We extend a special thank you to the
17 stakeholders who have submitted proposed
18 models, especially those who are participating
19 in today's meeting.

20 We recognize that many PTAC
21 stakeholders are directly involved in
22 responding to the pandemic and we are grateful
23 for your service to our communities across the
24 nation, especially to those on the front line.

1 We are also thankful for the
2 privilege of your time and attention today.
3 PTAC has long been committed to supporting a
4 submitter-driven process and we recognize that
5 our stakeholders and potential future
6 submitters may have their focus directed in
7 other areas presently.

8 So, I would remind anyone who is
9 considering submitting a proposal that PTAC
10 accepts proposals on a rolling basis. So, you
11 don't have to worry about submitting a proposal
12 within a certain timeline.

13 In addition to the future, to the
14 front-line providers, we also want to thank the
15 multitude of other providers, support staff,
16 caregivers, family members, and others
17 supporting patients during this crisis.

18 This pandemic has highlighted many
19 challenges within our health care system that
20 we knew existed to varying degrees but really
21 were brought to the forefront, the inconsistent
22 resilience of our health care system and the
23 many gaps that exist.

24 Some involve payment reform and

1 clinical redesign, work that is the focus of
2 the models PTAC is evaluating and can play a
3 significant role in addressing.

4 This public health emergency has
5 taught us much about our current fee-for-
6 service system and that value-based Alternative
7 Payment Models, as the Administrator has said,
8 can play a significant role in addressing those
9 weaknesses.

10 In a fee-for-service system
11 providers must rely on their patients' ability
12 to present for appointments and procedures in
13 order to support their financial business
14 model.

15 The pandemic challenged this
16 delivery structure with a sudden, staggering
17 decline in revenue for many types of providers
18 across the country. A variety of alternative
19 payment methodologies such as capitation or
20 value-based payments offer providers continued
21 revenue in the face of declining patient
22 visits.

23 Alternative Payment Models are an
24 important part of healing the health care

1 system, accentuated during this crisis as are
2 other key solutions that have played an
3 important role in supporting patients and
4 providers, such as telehealth.

5 Now is most certainly an important
6 time for PTAC to ensure that our processes and
7 approach to model evaluation are well designed
8 to encourage stakeholders to engage with us to
9 strengthen the resilience of our health care
10 system.

11 In addition to submitting proposals
12 for Alternative Payment Models, we are
13 exploring new ways of sharing your ideas with
14 the committee that will be announced in the
15 coming months.

16 Although today's meeting is being
17 held virtually, PTAC Members are actively
18 engaged, participating from their various parts
19 of the nation and eager to hear from our
20 submitters today.

21 While our goal is for a seamless
22 virtual experience, the potential exists for
23 technical challenges such as sound delays or
24 background noise. So, we appreciate your

1 understanding should such challenges arise.

2 I want to note that this is PTAC's
3 tenth public meeting that includes
4 deliberations and voting on proposed Medicare
5 Physician-Focused Payment Models submitted by
6 members of the public.

7 PTAC has been working hard since our
8 last public meeting in September, and I would
9 like to walk through some of that work before
10 we begin our deliberations. First, I would like
11 to introduce our newest PTAC Member as we
12 begin.

13 Dr. Charles DeShazer was appointed
14 by the U.S. Government Accountability Office in
15 October of last year. He is an internist by
16 training who joins us from Highmark Health Plan
17 in Pittsburgh, and we are pleased to have him
18 serving on the PTAC Committee. Welcome,
19 Charles.

20 DR. DESHAZER: Thank you.

21 CHAIR BAILET: We are expecting three
22 new appointments to PTAC in the coming weeks
23 and we will be sure to welcome those new
24 members at our public meeting, at our next

1 public meeting this September.

2 I would also like to take a moment
3 to reflect on the work of PTAC and how it has
4 evolved over time. PTAC was created within the
5 Medicare Access and CHIP Reauthorization Act of
6 2015, known as MACRA.

7 The first phase of the Committee's
8 work involved many public meetings where we
9 sought public feedback about how best to design
10 the Committee's proposal review process.

11 We also attended briefings about the
12 government's work in the Alternative Payment
13 Model space. The Secretary of HHS⁶ then released
14 the MACRA final rule which included the ten
15 criteria we were to apply to our review of
16 proposals.

17 In December of 2016, we began
18 receiving proposals from the public for
19 Physician-Focused Payment Models, moving us
20 into the next phase of our Committee's work.
21 We have received 36 models, delivering reports
22 to the Secretary on 24 of them.

6 U.S. Department of Health and Human Services

1 Each report represents significant
2 effort by the submitters drafting the proposal
3 and the Committee in its subsequent review.

4 PTAC has been receiving models for
5 three and a half years, long enough that we
6 wanted to reflect on the different models we
7 have reviewed, including evaluating who has
8 submitted ideas, what payment and care delivery
9 issues have they identified across the health
10 care system, and what solutions have been
11 proposed.

12 To this end, ASPE's contractor,
13 NORC, has compiled two reports that summarize
14 and provide an inventory of the proposals that
15 have been submitted and the extensive
16 evaluating reviews provided by PTAC. You can
17 find these reports on the ASPE PTAC website at
18 the top of the resource page.

19 The first report highlights themes
20 and common elements across proposals regarding
21 issues targeted and the proposed solutions.
22 The second report describes patterns in how
23 PTAC has assessed the proposals that have been
24 submitted to the Committee.

1 Taken together, the reports provide
2 a comprehensive look into breadth, objectives,
3 and variation of Alternative Payment Models
4 submitted by stakeholders and the findings
5 derived from the Committee's analysis of the
6 proposals relative to the Secretary's criteria.

7 I believe these reports synthesize
8 the extensive evaluative work conducted by our
9 Committee as we review the proposals designed
10 to address important issues in health care
11 delivery as raised by stakeholders in the
12 field.

13 These combined efforts can inform
14 stakeholders who may want to submit proposals
15 to PTAC, policy developers, the PTAC itself,
16 and the public at large.

17 Later today after we have voted on
18 the two proposals, the contractor will offer a
19 short presentation on these two reports that I
20 think you'll find very interesting.

21 Looking to the future, we reflected
22 on the history and the work of PTAC taking into
23 account the tremendous and important
24 stakeholder input on care delivery and

1 Alternative Payment Models.

2 We want to incorporate these
3 reflections to further activate and encourage
4 stakeholder engagement.

5 As we continue to evolve our work as
6 a Committee, we drafted a Vision Statement to
7 better communicate to the public how our work
8 fits into the transition to value-based care.
9 I would like to read that Statement now.

10 PTAC was created to contribute to a
11 national priority to improve the efficiency and
12 effectiveness of the U.S. health care delivery
13 system.

14 We believe that proposed solutions
15 from frontline stakeholders in our delivery
16 system can substantially enhance quality,
17 improve affordability, and influence policy
18 development and system transformation.

19 PTAC provides a forum where those in
20 the field may directly convey both their ideas
21 and their concerns on how to deliver high-value
22 care for Medicare beneficiaries and others
23 seeking health care services in our nation.

24 PTAC is committed to ensuring our

1 stakeholders have access to independent expert
2 input and their perspectives and innovations
3 reach the Secretary of Health and Human
4 Services.

5 PTAC will continue to submit
6 comments and recommendations regarding
7 Physician-Focused Payment Models submitted by
8 stakeholders to the Secretary, as required by
9 statute.

10 In addition, we will expand our
11 communications with the Centers for Medicare &
12 Medicaid Services, CMS, and stakeholders to
13 identify our opportunities to further inform
14 and prioritize the work CMS, including the
15 Center for Medicare & Medicaid Innovation
16 (CMMI) and other policy makers are undertaking
17 to modernize health care.

18 This statement serves as the
19 framework for our, for other changes you will
20 see both today and in the future. We want to
21 remain thoughtful and leverage collaborative
22 opportunities that encourage stakeholders to
23 provide their ideas on how to address care
24 delivery challenges through expanding value-

1 based care.

2 We also want to broaden our
3 knowledge foundation, including gathering
4 information through public dialogue on various
5 cross-cutting themes and topics raised across
6 proposed models, such as telehealth. We believe
7 such input will serve to better inform our
8 recommendations to the Secretary.

9 Also, shortly we're releasing an
10 updated version of our Proposal Submission
11 Instructions that are designed to expand the
12 number of and types of proposals that are
13 submitted to PTAC.

14 We have found that while certain
15 proposals may have strengths within some
16 criteria and weaknesses in others, when
17 evaluated as a whole, these proposals may raise
18 important care delivery, payment, or policy
19 issues.

20 Therefore, PTAC encourages
21 stakeholders to submit Physician-Focused
22 Payment Model proposals that address the
23 innovative approaches in care delivery,
24 regardless of the level of sophistication of

1 the payment methodology.

2 These updated Instructions reflect
3 the Committee's vision to encourage engagement
4 and to activate stakeholders who wish to convey
5 care delivery and payment challenges along with
6 proposed solutions.

7 We are eager to elicit real-time
8 input to help inform the Committee about
9 specific issues the stakeholders are
10 experiencing in the field. We hope that these
11 new Instructions will encourage more
12 submissions.

13 As the Vision Statement expresses,
14 submitting to PTAC is an opportunity to help
15 inform the policy community about what you have
16 experienced on the front lines and suggest
17 potential approaches to address any issues.

18 In addition to these efforts, we are
19 looking forward to having theme-based
20 discussions during future public meetings to
21 foster dialogue and insights on specific broad-
22 based challenges whose impacts are not limited
23 to a single proposal.

24 These discussions will occur in

1 addition to the current deliberative public
2 process which happens after proposals on any
3 topic have been reviewed by a PTAC Preliminary
4 Review Team and then by the full Committee.

5 I want to be very clear that we will
6 continue to accept all proposals on any topic
7 at any time. PTAC is always open for business.

8 We are hard at work preparing for
9 our first theme-based discussion which we are
10 hoping to hold in September. This will be,
11 excuse me, focused on telehealth.

12 Included in this session will be
13 holistic reflections on previous proposals that
14 included elements related to telehealth, tying
15 together how alternate payment models and
16 telehealth may play a more important role as
17 features that can further transform our health
18 care system.

19 We also intend to invite public
20 input on this topic in the future as well as
21 continue to evaluate submitted proposals that
22 are ready for deliberation, as has been done in
23 the past. As today's comments convey, your
24 input is very important to us.

1 In addition to the efforts I just
2 shared, at the end of the day we will pose some
3 questions about challenges in care delivery,
4 payment model design, and other important
5 challenges members of the public are
6 experiencing. A detailed list of these
7 questions will be posted on the ASPE PTAC
8 website.

9 Comments by email will also be
10 accepted. Your input will inform our future
11 work, and we will report out the comments
12 received related to this inquiry at a future
13 public meeting.

14 Together, all these efforts just
15 described serve to further inform PTAC's work
16 and help enhance our efficiency and
17 effectiveness on behalf of the stakeholder
18 community and the beneficiaries they support as
19 we continue to evaluate alternative payment and
20 clinical redesign models.

21 As a reminder, in order to receive
22 updates about these various opportunities to
23 engage with PTAC, please join the PTAC
24 listserv, which you can find on the contact

1 page of the ASPE PTAC website.

2 Moving on, PTAC published a report
3 to the Secretary with our comments and
4 recommendations on the proposal entitled
5 "ACCESS Telemedicine: An Alternative Healthcare
6 Delivery Model for Rural Cerebral Emergencies,"
7 that we deliberated and voted on last
8 September, which had been submitted by the
9 University of New Mexico Health Sciences
10 Center.

11 Our Preliminary Review Teams have
12 also been working hard to review multiple
13 proposals, two of which we are scheduled to
14 deliberate and vote on today.

15 To remind the audience, the order of
16 activities for review of a proposal is as
17 follows. First, PTAC Members will make
18 disclosures of any potential conflicts of
19 interest. We will then announce any Committee
20 Members not voting on a particular proposal.

21 Second, discussions of each proposal
22 will begin with a presentation from the
23 Preliminary Review Team or PRT charged with
24 conducting a preliminary review of the

1 proposal.

2 After the PRT's presentation and any
3 initial questions from PTAC Members, the
4 Committee looks forward to hearing comments
5 from the proposal submitters and the public.

6 The Committee will then deliberate
7 on the proposal. As deliberation concludes, I
8 will ask the Committee whether they are ready
9 to vote on the proposal.

10 If the Committee is ready to vote,
11 each Committee Member will vote electronically
12 on whether the proposal meets each of the
13 Secretary's 10 criteria. After we vote on each
14 criterion, we will vote on our overall
15 recommendation to the Secretary of Health and
16 Human Services.

17 And finally, I will ask PTAC Members
18 to provide any specific guidance to ASPE staff
19 on key comments they would like to include in
20 PTAC's report to the Secretary.

21 A few reminders as we begin
22 discussions of today's first proposal. First,
23 if any questions arise about PTAC, please reach
24 out to staff through the ptac@hhs.gov email.

1 Again, that email address is ptac@hhs.gov.

2 We have established this process in
3 the interest of consistency in responding to
4 submitters and members of the public and
5 appreciate everyone's cooperation in using it.

6 I also want to underscore three
7 things. The PRT reports are reports from three
8 PTAC Members to the full PTAC and do not
9 represent the consensus or position of the
10 PTAC.

11 Second, PRT reports are not binding.
12 The full PTAC may reach different conclusions
13 from those contained in the PRT report. And
14 finally, the PRT report is not a report to the
15 Secretary of Health and Human Services.

16 After this meeting, PTAC will write
17 a new report that reflects input from the
18 public as well as PTAC's deliberations and
19 decisions today which will then be sent to the
20 Secretary.

21 PTAC's job is to provide the best
22 possible comments and recommendations to the
23 Secretary, and I expect that our discussions
24 today will accomplish this goal.

1 I would like to thank my PTAC
2 colleagues, all of whom give countless hours to
3 the careful and expert review of the proposals
4 we receive. Thank you again for your work, and
5 thank you to the public for participating in
6 today's first ever virtual meeting.

7 * **Deliberation and Voting on Eye Care**
8 **Emergency Department Avoidance**
9 **(EyEDA) submitted by the University**
10 **of Massachusetts Medical School**

11 Let's go ahead and get started. The
12 first proposal we will discuss today is called
13 "Eye Care Emergency Department Avoidance."
14 This proposal was submitted by the University
15 of Massachusetts Medical School.

16 * **PTAC Member Disclosures**

17 PTAC Members, let's start by
18 introducing ourselves and at the same time,
19 read your disclosure statements on this
20 proposal. Because this meeting is virtual, I
21 will prompt each of you.

22 I'll start. Jeff Bailet, CEO of
23 Altas, nothing to disclose. Next is Grace.

24 VICE CHAIR TERRELL: Grace Terrell,

1 CEO of Eventus WholeHealth, nothing to
2 disclose.

3 CHAIR BAILET: Paul.

4 DR. CASALE: Paul Casale,
5 cardiologist and Executive Director of New York
6 Quality Care, the ACO for New York-
7 Presbyterian, Columbia, and Weill Cornell,
8 nothing to disclose.

9 CHAIR BAILET: Charles.

10 DR. DESHAZER: Charles DeShazer,
11 chief medical officer for Highmark Health.
12 Nothing to disclose.

13 CHAIR BAILET: Kavita.

14 DR. PATEL: Kavita Patel, internist
15 and fellow at the Brookings Institution.
16 Nothing to disclose.

17 CHAIR BAILET: Angelo. Angelo may be
18 on mute.

19 DR. SINOPOLI: Angelo Sinopoli, a
20 pulmonary critical care physician and Chief
21 Clinical Officer for Prisma Health, South
22 Carolina.

23 CHAIR BAILET: Bruce.

24 MR. STEINWALD: Bruce Steinwald, a

1 health economist here in Washington, D.C.
2 Nothing to disclose.

3 CHAIR BAILET: And finally, Jennifer.

4 DR. WILER: Jennifer Wiler, Chief
5 Quality Officer, UHealth, Denver Metro and
6 professor at University of Colorado School of
7 Medicine in Denver, Colorado. Nothing to
8 disclose.

9 CHAIR BAILET: Thank you. I would now
10 like to turn the meeting over to the lead of
11 the Preliminary Review Team for this proposal,
12 Dr. Paul Casale, to present their findings to
13 the full PTAC, Paul.

14 * **Preliminary Review Team (PRT) Report**
15 **to PTAC**

16 DR. CASALE: Thank you, Jeff. Before
17 I get started on the presentation, I wanted to
18 state that Harold Miller who, as you can see
19 was a member of the PRT for this proposal,
20 resigned from the PTAC on November 19, 2019.

21 He did participate in the PRT, and
22 his input is reflected in the report that is
23 about to be shared. Next slide.

24 So, just as a reminder about how PRT

1 works, the PTAC Chair and Vice Chair assign two
2 to three PTAC Members, including at least one
3 physician, to each complete proposal to serve
4 as the PRT.

5 The PRT identifies additional
6 information needed from the submitter and
7 determines to what extent any additional
8 resources or analyses are needed for the
9 review. The PRT determines, at its discretion,
10 whether to provide initial feedback on a
11 proposal.

12 After reviewing the proposal,
13 additional materials are gathered and public
14 comments received. The PRT prepares a report of
15 its findings to the full PTAC.

16 As Jeff already mentioned, the PRT
17 report is not binding on PTAC. PTAC may reach
18 different conclusions from those contained in
19 the PRT report. Next slide.

20 So, some background on the EyEDA
21 proposal. It's based on a Transforming
22 Clinical Practices Initiative award assisting
23 over 1,600 optometry practices across the U.S.
24 to increase the number of patients with eye-

1 related symptoms who make visits to a practice
2 rather than an emergency department for urgent
3 eye conditions.

4 The submitter asserts this approach
5 improved the quality of care for patients and
6 reduced the cost for treating urgent eye-
7 related conditions for both payers and patients
8 because the payment for an office visit is
9 significantly less than the payment for an
10 emergency department visit.

11 The goal of the EyEDA proposal is to
12 encourage treatment of selected eye-related
13 symptoms through office visits with
14 optometrists and ophthalmologists rather than
15 visits to hospital ED⁷.

16 The Alternative Payment Model
17 entities are licensed optometrists and
18 ophthalmologists as well as organizations
19 employing optometrists and ophthalmologists.
20 Next slide.

21 The core elements of the proposal:
22 Financial risk is in the form of an eight
23 percent reduction for all urgent care visits.

7 Emergency Department

1 These are identified by ICD-10⁸ diagnosis codes
2 relative to payments under the normal physician
3 fee schedule.

4 Shared savings payment at the
5 conclusion of the performance year is based on
6 the participating provider or practice's number
7 of qualifying urgent office visits relative to
8 a target level and the reduction in ED visits
9 in area hospitals for the same diagnoses
10 relative to a base year period.

11 Performance on two quality measures
12 are also taken into account: patient experience
13 and patient safety. These area quality
14 threshold in order to participate in the model
15 and receive shared savings payments. Next
16 slide.

17 The eight percent reduction for
18 initial office visits will be for specified
19 ICD-10 codes in the categories of ED avoidable
20 conditions such as conjunctivitis, corneal
21 injury, corneal injury with a foreign body, a
22 stye, acute posterior vitreous detachment, eye
23 pain, and other eye conditions.

1 The submitter believes that the
2 number of patients making urgent care visits to
3 the practice instead of the ED will increase by
4 educating patients about the desirability of
5 receiving urgent eye care from optometry or
6 ophthalmology practices and by expanding the
7 office hours for those providers.

8 The proposed model does not,
9 however, require that participating practices
10 use any specific approach to encourage these
11 visits. Next slide.

12 In terms of the payment model in
13 order to receive shared savings bonus payments,
14 providers must meet minimal thresholds on the
15 two quality measures. They include patient
16 experience, assessed through a patient survey,
17 and patient safety, which is defined as the
18 seven-day adverse event rate for the ICD
19 diagnosis codes for which they were seen.

20 Adverse events include unscheduled
21 ED visits, hospital admissions or observation
22 stays, blindness, or permanent visual
23 impairment or death.

24 The target number of visits for each

1 participating practice or provider would be
2 developed based on historical volume of visits
3 for these conditions, which would then be
4 increased by some percentage.

5 Practicing, sorry, participating
6 practices or providers could receive shared
7 savings payments if there were a reduction in
8 ED visits for the proposed urgent eye-related
9 conditions.

10 The proposal does not specify the
11 percentage of the savings that would be shared
12 or the method for identifying the service area.

13 Each participating physician or
14 practice would receive a share of the savings
15 for distribution based on the increase in
16 urgent care visits at that practice as a
17 percentage of the total increase in urgent care
18 visits across all participating practices. Next
19 slide.

20 The experience with the TCPI⁹
21 program provided technical assistance, as I
22 mentioned, to over 1,600 optometry practices
23 nationwide.

1 From October 2017 through May of
2 2019, optometrists enrolled in TCPI reported
3 more than 330,000 visits to the ED were avoided
4 through same day office-based appointments and
5 after-hours triage. These reports were based on
6 ICD-9¹⁰ codes for office visits rather than
7 tracking of changes in ED visit rates.

8 Feedback from TCPI provider
9 participants indicates that many of these
10 optometrists would participate in the EyEDA
11 model.

12 So, to summarize, the PRT review is
13 seen here. And what I'll do rather than walking
14 through this slide I will go through each of
15 the criteria in detail. Next slide.

16 The key issues identified by the
17 PRT. The eight percent reduction in fees for
18 urgent care visits may discourage participation
19 and cause problematic financial losses for
20 practices that cannot successfully meet targets
21 for increased number of visits.

22 Payment is still fee-for-service
23 based on office visits, with no flexibility in

10 International Classification of Diseases, 9th Revision

1 payment to support different approaches to
2 services. Payment reductions and visit targets
3 tied to specific diagnosis codes could result
4 in undesirable incentives to code incorrectly.

5 The model does not attribute
6 patients to practices. The methodology for
7 determining shared savings and attributing the
8 savings to participating providers is not
9 clearly defined.

10 The proposed model does not require
11 or encourage care coordination with primary
12 care providers or other specialists. And many
13 of the problems with the payment model arise
14 due to challenges that the submitter faces in
15 trying to craft a model to meet the
16 requirements that CMS has established for an
17 Advanced APM¹¹. Next slide.

18 So, for Criterion 1, scope, which is
19 a high priority, the PRT conclusion was does
20 not meet. This was a majority conclusion.

21 In reviewing this criterion, no
22 Alternative Payment Models in the CMS portfolio
23 specifically address eye-related conditions or

11 Alternative Payment Model

1 focus on care delivered by eye specialists.
2 So, that was one of the considerations in
3 regard to scope from a provider point of view.

4 Specialty participation in APMs is
5 important but should broaden existing
6 opportunities. The particular clinical issue of
7 urgent eye visits might be appropriate in a
8 broader risk-based model such as an ACO¹² or
9 Bundled Payment Model as opposed to a stand-
10 alone model.

11 The model narrowly focuses on
12 changing the site of treatment for one
13 particular set of health problems rather than
14 taking a more holistic approach to the
15 patient's needs.

16 And finally, ED visits for eye-
17 related conditions occur primarily among those
18 under age 65. It's not clear if practices would
19 be able to increase their provision of urgent
20 care in the office if the model is not
21 implemented for more payers beyond Medicare.
22 Next slide.

23 Criterion 2, quality and cost, also

1 a high-priority criteria. The conclusion from
2 the PRT is that it meets this criterion. This
3 was unanimous.

4 Treatment of patients in an office-
5 based setting for the proposed eye conditions
6 rather than an ED when appropriate would reduce
7 costs for both payers and patients.

8 Increased access to care in the most
9 appropriate setting would potentially improve
10 health care quality. The model includes two
11 quality measures designed to ensure that urgent
12 conditions receive high-quality care in an
13 office setting.

14 However, the proposed measures have
15 limitations that may not adequately ensure the
16 highest quality care. Patient satisfaction does
17 not necessarily ensure that a condition was
18 treated in the most appropriate way.

19 The patient safety measure captures
20 only adverse events that occur within seven
21 days, and only those related to the same ICD-10
22 diagnosis as the original office visit. The
23 rate of adverse events is unlikely to be a
24 statistically valid measure for small

1 practices.

2 And finally, some conditions may not
3 represent urgent needs but instead are
4 emergencies that cannot be safely treated in an
5 office setting. Next slide.

6 Criterion 3, payment methodology,
7 also a high priority. The PRT conclusion was
8 that it does not meet the criterion. This was
9 unanimous.

10 The proposed payment model would
11 provide a strong financial incentive to
12 increase the number of urgent care visits for
13 eye conditions. However, the approach to
14 setting performance targets raises concerns.

15 It would penalize practices whose
16 patients already come to them for urgent care
17 needs. And small practices could have a low or
18 a high baseline rate based on random variation.

19 The proposal does not require any
20 mechanism to document the nature of the
21 presenting symptom or to identify the reason
22 the visit should be deemed urgent.

23 The shared savings calculation is
24 based on a reduction in ED visits without

1 attributing the reduction to participating
2 practices. The proposal does not specify how
3 adjustments would be made when eligible
4 patients in the service area change over time.

5 And finally, the proposal does not
6 provide any upfront payments to support the
7 ability of participating payments to deliver
8 more and better urgent care. Next slide.

9 Criterion 4, value over volume. The
10 PRT concluded that it meets this criterion and
11 was unanimous.

12 The proposal creates an incentive
13 for optometry and ophthalmology practices to
14 encourage patients to come to their office for
15 urgent care needs, which would likely decrease
16 ED visits for eye-related conditions.

17 The proposal includes a measure
18 indicating whether the ocular problem was
19 resolved and also tracks satisfaction of
20 adverse events. However, the small size of many
21 practices will make statistically appropriate
22 assessment of adverse event rates problematic.

23 Payments for urgent care services
24 and targets are still tied to office visits

1 with the physician. The practices would not
2 have the ability to address urgent needs
3 through phone calls, emails or non-physician
4 staff.

5 Finally, the model forces practices
6 to increase the number of office-based visits
7 in order to offset payment cuts and meet visit
8 targets, even if more visits are not needed.
9 Next slide.

10 Flexibility, the PRT conclusion was
11 that it met the criterion for flexibility. And
12 this was a majority conclusion.

13 The proposal would reward
14 optometrists and ophthalmologists for changes
15 in their care delivery processes in order to
16 better respond to patients with urgent eye
17 conditions, without dictating how the practices
18 should do this.

19 However, the proposal does not
20 fundamentally alter the fee-for-service
21 structure of payment for eye visits.

22 Providers would be paid only for
23 office visits, not for phone calls, emails with
24 patients, even if those services could resolve

1 the patient's needs, and not for care
2 management or other education activities that
3 would help patients avoid developing eye
4 problems.

5 The eight percent reduction in visit
6 payments and an uncertain shared savings
7 payment would make it more difficult for
8 practices to provide services that do not
9 qualify for fees. Next slide.

10 Criterion 6, ability to be
11 evaluated. The PRT conclusion was that it met
12 it this criterion. And the conclusion was
13 majority of the PRT.

14 The proposal's primary performance
15 measure is quantifiable and could be compared
16 with other providers. The information is
17 systematically collected through claims across
18 providers and over time.

19 The proposal uses standard ICD-10
20 codes to identify urgent visits, so the same
21 definitions of eligible visits could be used
22 for non-participating providers.

23 The adverse event metric could also
24 be determined from claims for participating

1 providers and compared with non-participating
2 providers.

3 To compare patient experience and
4 satisfaction between participating providers
5 and non-participants, patient survey data would
6 have to be collected from a comparison group of
7 patients who see non-participating providers.

8 The lack of attribution of patients
9 or ED visits avoided to participating providers
10 could make it difficult to evaluate whether
11 changes in ED visits were different between
12 participating and non-participating providers.
13 Next slide.

14 Criterion 7, integration and care
15 coordination. The PRT conclusion was does not
16 meet criterion. And this was a unanimous
17 conclusion.

18 The submitter reported that eye care
19 specialists informally make referrals among
20 themselves and to other providers to ensure
21 appropriate care.

22 However, participating providers
23 would be encouraged to see patients for urgent
24 care needs, even if they are not the most

1 appropriate provider to treat the condition.

2 There are no formal methods for
3 integration with primary care physicians or
4 other providers who may be initiating treatment
5 or treating a patient. Next slide.

6 Criterion 8, patient choice. The PRT
7 conclusion was that it meets this criterion.
8 And the conclusion was unanimous.

9 The proposed model would make it
10 easier for patients to receive appropriate
11 treatment for urgent eye conditions outside of
12 a hospital ED.

13 It is possible that a beneficiary
14 might not realize that they have the right to
15 seek care in another setting, such as an ED,
16 even if their optometrist or ophthalmologists
17 presents them with access in the office
18 setting.

19 Next slide, patient safety. The PRT
20 conclusion was it does not meet this criterion,
21 and it was a unanimous conclusion.

22 The proposed measurement of adverse
23 event rates and patient satisfaction scores
24 would help to ensure that eye problems are

1 being addressed appropriately during the urgent
2 care visits.

3 However, the proposed diagnosis
4 codes cover a broad range of eye conditions,
5 some of which are much more clinically serious
6 than others. Patients do not know their
7 diagnosis when they seek care for an eye
8 condition, only their symptoms.

9 The same symptoms -- such as eye
10 pain, impairment of a visual field, or redness
11 -- can result from conditions across a wide
12 range of clinical severity, not all of which
13 are appropriate for care by an optometrist or
14 in an office setting.

15 As a result, patients who need care
16 in the ED may not receive it, which has the
17 potential to harm patient safety. Next slide.

18 The final criterion, Criterion 10,
19 health information technology. The PRT
20 conclusion was that it met this criterion and
21 the conclusion was unanimous.

22 The TCPI project on which the
23 proposal is based led providers to use
24 electronic health records more extensively. If

1 implemented well, the proposal could encourage
2 providers to use technology to a greater extent
3 to inform care.

4 There is potential for providers to
5 incorporate telehealth services to expand
6 access and achieve the proposal's objectives.
7 However, the proposed model does not explicitly
8 require or encourage enhanced use of health
9 information technology. Next slide.

10 So, with that, Jeff, I thought I
11 would turn it over to Kavita for any additional
12 comments she may have on the discussion amongst
13 PRT.

14 DR. PATEL: Thanks, Paul. It's
15 Kavita.

16 I just wanted to just reinforce kind
17 of the process that we used because, as Paul
18 mentioned, we had three of us on the
19 Preliminary Review Committee and found our
20 interactions with the submitters and all the
21 deliberations kind of back and forth on the
22 Review Team very engaging.

23 And despite it being kind of pre-
24 COVID, I feel pretty confident that we can have

1 a great conversation now and wanted to thank
2 Paul for leading the PRT, as well as
3 acknowledge Harold's important input and the
4 submitter's time to take, to propose this
5 important model, and hopefully we can answer
6 any questions for the Committee as well.

7 *** Clarifying Questions from PTAC to PRT**

8 CHAIR BAILET: Thanks, Kavita, and
9 thank you, Paul, for leading the PRT. Before we
10 have the submitters provide their statements
11 and make themselves available for questions, I
12 just wanted to turn it over to other Committee
13 members that may have questions of the PRT,
14 Kavita or Paul, or clarification prior to
15 bringing up the submitters. All right.

16 VICE CHAIR TERRELL: I've got a
17 question, Jeff. This is Grace.

18 CHAIR BAILET: Go ahead, Grace.

19 VICE CHAIR TERRELL: My question is
20 related to some of the commentary back, in fact
21 some of the criticism back that was, I believe
22 from one of the associations related to
23 emergency physicians, where they were concerned
24 about many of the types of diagnoses that were

1 listed as being ones that were appropriate
2 within the setting of an urgent care.

3 And I was wondering if there was any
4 work done either with the background
5 information that was done by our contractors,
6 or otherwise, to look into that as being
7 something that was a concern that needed to be
8 taken into account or not?

9 Because there was a huge number of
10 diagnoses that were listed as being potentially
11 appropriate that looked appropriate to me as
12 far as I could tell. But there was some concern
13 from some of the outside public.

14 And I'm just wondering how you all
15 thought through that.

16 DR. CASALE: Yes, we did have a
17 discussion around that, and I'll ask Kavita to
18 comment as well. And I think, yes, it is a very
19 long list and many of them appear appropriate
20 for the office setting.

21 I think some of the concern was that
22 there are within that group of conditions some
23 that require, obviously, emergent care in that
24 the patient may not be in the position to

1 distinguish that.

2 And that for some of those
3 particularly time-sensitive conditions, being
4 seen in an office setting rather than an
5 emergency room may lead to adverse outcome.

6 DR. PATEL: And the only thing I
7 would add, Grace, there wasn't any, we just
8 basically had kind of a more transparent
9 discussion. I believe, it's probably somewhere
10 in our transcription minutes with the
11 submitter.

12 But just to emphasize that part of
13 the acknowledgment of this was because of this
14 work starting in the TCPI program that there
15 was definitely kind of a more, I would say hub
16 and spoke model so that there was kind of an
17 academic hub with spokes.

18 You know, this wasn't just kind of
19 the idea where this kind of started from came
20 from having kind of ED physicians and also
21 having kind of urgent care and ophthalmologists
22 and having an interdisciplinary approach.

23 And that was something that we
24 brought up that while that seems like an

1 incredibly robust model that was kind of worked
2 out through TCPI that may not necessarily
3 scale.

4 However, it would be something I
5 think in our comments to the Secretary's
6 report, no matter what the voting is, that
7 looking at that model would be critical because
8 it did offer something that was valuable to
9 training, you know, in the setting of ED
10 physicians as well as urgent care physicians.

11 MR. STEINWALD: This is Bruce. I have
12 a question.

13 CHAIR BAILET: Go ahead, Bruce.

14 MR. STEINWALD: I'm curious about the
15 proportion of emergency events that could be
16 addressed through the model in the physician's
17 office as opposed to emergency room.

18 The proposal states that the patient
19 invitation of extended hours is going to be the
20 principal means of encouraging patients to see
21 providers in their office. And yet a lot of
22 these events occurred in evening hours and
23 weekends.

24 And I guess I'm curious as to what

1 proportion of those events, like a foreign
2 object in an eye, I have heard actually be
3 seen in the office when these events often
4 occur during times when there is most unlikely
5 to be office hours.

6 DR. CASALE: Well, I think we would
7 look at the experience they had in the TCPI
8 model in which they, you know, they saw over
9 330,000 visits.

10 I don't believe and maybe I don't
11 really believe there was data around, you know,
12 the time of day for those visits that I recall.
13 But you're right.

14 I think we recognize that as one of
15 the concerns in terms of the education and
16 expanding hours. I mean, expanding hours will
17 certainly help, education might.

18 But as you said, when, even if these
19 happen during the day, having easy access -- it
20 would be critical. But to your original
21 question, I don't remember if there, I don't
22 recall we had data around the time of day that
23 these occurred.

24 DR. PATEL: I don't, either. It would

1 be good to ask the submitters that.

2 CHAIR BAILET: I had a, this is Jeff.
3 I had a follow on question, Paul. It sort of
4 follows onto Grace's initial point.

5 The Academy of Ophthalmology made
6 reference again to the long list. And I think
7 that is something that is in the process of
8 being reviewed and potentially pared back.

9 But there was also some comments
10 just about the safety. You know, creating or
11 conveying a message to patients that for some
12 of their eye complaints, urgent eye complaints,
13 that they could be seen in an office rather
14 than present to an emergency room.

15 And there were, you know, there were
16 some strong statements both from the
17 Ophthalmology Society and also from even the
18 Optometry Society as well. I'm just, I saw some
19 back and forth in the responses from the
20 submitters to your PRT.

21 Where does that sit? And we can get
22 a further clarification from the submitters
23 themselves?

24 But there seemed to be a reference

1 that sort of contention between those two
2 bodies had sort of got ironed out between the
3 submitters. Is that in fact true, Paul?

4 DR. CASALE: It's not clear to me
5 that it's been ironed out. I think they would
6 turn to the TCPI project and, you know, sort
7 of the experience they had there.

8 As, and again I would be interested
9 to hear directly from the submitters because
10 particularly from an ophthalmology letter also
11 raised this question of safety.

12 But again, I think from the
13 material, from the TCPI project, and from the
14 experience they had there, there were, again I
15 think the submitters felt that this model was
16 safe for the, you know, overwhelming majority
17 of patients who come, present with eye
18 symptoms.

19 DR. SINOPOLI: Paul, this is Angelo.
20 I'm sorry.

21 CHAIR BAILET: No. Go ahead, Angelo.

22 DR. SINOPOLI: Was there any
23 discussion during this around the potential for
24 some virtual real-time triage to make sure

1 patients got directed to the appropriate level
2 of care?

3 DR. CASALE: Well, we brought that up
4 in terms of our concern that really it's all
5 office-based fee-for-service in terms of how
6 this payment model would potentially work with
7 a sort of focus around office-based.

8 So, you know, I think we had some
9 discussion around it. But we didn't, other than
10 some suggestions as we put in our report, that
11 both from a triage and management point of
12 view, virtual care would potentially offer some
13 benefits.

14 But that I think was the extent of
15 our discussion.

16 CHAIR BAILET: Great. Any other
17 questions from the Committee?

18 DR. DESHAZER: Yes, this is Charles.
19 I just wanted to follow up with that too
20 because it wasn't clear to me, is there -- are
21 there strategies embedded within this model to
22 kind of get, I think to Angelo's point as well,
23 to get to a more proactive approach in being a
24 more flexible way of interacting with the

1 patients because I do see that as being part of
2 the challenge also.

3 And a part of this is going to be
4 changing care-seeking behaviors of the patient.
5 And I just wondered if there were thoughts
6 around how you would, you know, create that
7 within the model and how that would support
8 that.

9 DR. CASALE: Yes, again I think that
10 would be a good conversation with the
11 submitters.

12 I think again, because the payment
13 model is really based around the shift from ED
14 visits to office visits again, so that sort of
15 -- so to your point and Angelo's point and
16 certainly in the current era that we are in
17 where we're seeing, you know, back when we
18 first reviewed this or looked at this back in
19 September, virtual care was in a very different
20 place.

21 But having that been, even with that
22 said, you would see that there would be
23 opportunity here. But again, I think ultimately
24 the payment model was focused more around

1 office visit, ED visit.

2 CHAIR BAILET: Anyone else from the
3 Committee have any questions before we move on?
4 Okay. Hearing none, let's go ahead and have the
5 proposal submitters join us.

6 We have three representatives from
7 UMass¹³ joining us via Webex. If you guys could
8 introduce yourselves.

9 I know you want to make some opening
10 comments, which will be limited. We'll limit
11 those to ten minutes, and then we'll open it up
12 for questions. So, thank you all for being
13 here.

14 * **Submitter's Statement**

15 DR. POLAKOFF: Thank you. We'll go in
16 order as presented on the slide. This is David
17 Polakoff speaking. I led the TCPI team.

18 I'm an internist and geriatrician by
19 background and a professor of population and
20 quantitative health sciences at the University
21 of Massachusetts Medical School.

22 DR. SCOTT: And I'm Clifford Scott.
23 I'm an optometrist and a consultant to the

1 UMass Medical School and President Emeritus of
2 the New England College of Optometry.

3 MR. FLANAGAN: I'm Jay Flanagan. I
4 was the program director for the TCPI project
5 under Dr. Polakoff.

6 CHAIR BAILET: Welcome. You guys want
7 to start with your opening remarks?

8 DR. POLAKOFF: Thank you. This is
9 David Polakoff and I'll deliver the opening
10 remarks. But we will all as a team be available
11 to the PTAC for questions.

12 First, I want to thank PTAC for
13 hosting us and offering us this opportunity to
14 present, as well as express our gratitude and
15 appreciation to the PRT for the very careful
16 review and the process we went through during
17 the PRT review. It was helpful and very, very
18 thoughtful.

19 So, by way of background in 2015
20 UMass was awarded one of the 29 practice
21 transformation networks by CMMI under its
22 Transforming Clinical Practices Initiative or
23 TCPI.

24 The goals were to promote a broad

1 set of aims including improving the quality of
2 and access to care provided by 140,000
3 clinicians across the U.S. and specifically
4 assisting those clinicians in moving toward and
5 into successful value-based care arrangements.

6 The UMass network included more than
7 1,600 optometry and ophthalmology practices
8 representing almost 4,000 individual
9 clinicians. One of CMS's explicit goals for the
10 program was to facilitate the entry of enrolled
11 clinicians into advanced alternative payment
12 models or APMs.

13 Because there is no APM available
14 for these eye care specialties, UMass, with CMS
15 encouragement and approval, developed the APM
16 under consideration here today.

17 The Committee Members have reviewed
18 and analyzed the model, and I won't present the
19 model in detail during this short ten minute
20 presentation. However, at its core, as has been
21 noted this morning, the model is very simple.

22 It encourages and financially
23 incentivizes eye care professionals to have a
24 conversation with their established patients

1 about the availability of urgent care services
2 for ocular symptoms in the office or in the
3 clinic setting.

4 It further encourages the
5 professionals to expand the availability of
6 those services by expanding hours of service,
7 by enhancing after-hours availability, and
8 telephonic triage.

9 Finally, this model takes an
10 approach to reducing the use of emergency
11 departments for non-emergent services that is
12 far friendlier to patients and families than
13 other interventions that have been recently
14 publicized such as retrospective denial of
15 payment for unnecessary ED use or triage models
16 that redirect patients after they have arrived
17 at the emergency department seeking care.

18 I'll note that the one published
19 reference that assessed the epidemiology and
20 scope of the issue that this model addresses,
21 ED use for non-emergent eye conditions, is
22 based on data that are 10 to 15 years old.

23 In the process of developing the
24 model, we performed a very similar analysis to

1 Channa et al. using the most recent years
2 available from the same data set, NEDS¹⁴, and
3 found that there have recently, in recent years
4 been approximately three million such visits
5 each year representing charges of about \$3
6 billion annually for the five conditions
7 covered by the model: conjunctivitis, corneal
8 injury with or without foreign body, hordeolum,
9 acute posterior vitreous detachment, and eye
10 pain.

11 This is not a small scale or
12 uncommon issue. I would also like to emphasize
13 that this proposal is based on our experience
14 in TCPI with over 1,600 eye care professionals.

15 In that program we were able to
16 monitor the impact of these practices
17 implementing the care model without any benefit
18 from the financial incentives of a payment
19 model.

20 Now, even without any such
21 incentives, the majority of the participating
22 practices were able to implement the care model
23 with minimal or no up-front investment of

14 Nationwide Emergency Department Sample

1 resources and were able to demonstrate
2 increases in urgent care visits that averaged
3 20 to 25 percent over baseline over the first
4 year after implementation.

5 Again, this was accomplished without
6 the benefit of incentives. While the scope of
7 the model is indeed limited to two specialties
8 we observed in the TCPI implementation
9 secondary impacts that widen its scope.

10 Optometrists have long sought and
11 struggled to integrate their services more
12 closely with primary care providers. Primary
13 care providers are in many cases already
14 engaged in more holistic value-based payments
15 systems such as ACOs and capitation models.

16 And through those systems the
17 primary care providers are incented to control
18 unnecessary costs. After reduction of hospital
19 days, reduction of the utilization of emergency
20 departments for non-emergent care is a prime
21 target for such cost reduction.

22 The ability of eye care
23 professionals to contribute to the larger cost
24 goals at ACOs and other networks serves to

1 align and integrate these professionals more
2 closely into the medical neighborhood and has a
3 secondary effect of improving coordination of
4 care.

5 While difficult to measure, we did
6 anecdotally observe this impact in the TCPI
7 practices. Some of the concerns that have been
8 voiced regarding this model relate to the level
9 of risk assumption by participating clinicians
10 in the form of the discount on fee-for-service
11 reimbursement for urgent visits.

12 These concerns have run in both
13 directions. Comments from some individual
14 clinicians and from professional societies have
15 suggested that the eight percent discount is
16 excessive.

17 Comments from the PRT questioned
18 whether it is sufficient to truly meet the
19 criteria for an advanced APM. In the spirit of
20 Goldilocks, perhaps that suggested we found the
21 proper middle ground.

22 However, we do acknowledge that if
23 the model is broadly appealing that the
24 discount level might be subject to further

1 actuarial analysis and adjustment by CMS or
2 other interested payers.

3 In other words, the specific level
4 of discount is a variable feature of the model
5 and is subject to modification by any adopting
6 payer.

7 PRT Members and public comments,
8 including some of the discussion just minutes
9 ago, reflected some concerns regarding the
10 rather lengthy list of ICD-10 codes that are
11 included within the model.

12 We want to emphasize that this long
13 list in part reflects the nature of the ICD-10
14 classification system. When we began model
15 development, claims were still being submitted
16 under ICD-9 and the list was actually much,
17 much shorter by almost a factor of ten.

18 But the diagnosis codes are used to
19 reflect the payer perspective. We fully
20 recognize that patients present for evaluation
21 and treatment based on symptoms, eye pain, red
22 eye, blurry vision, et cetera.

23 For this reason we began our
24 development process around the five common eye

1 conditions that I've already listed. However,
2 in order for payers to be able to effectively
3 administer any such model, they need to be able
4 to analyze claims based on diagnosis codes.

5 And so, we convened an expert panel
6 of eye care professionals, chaired by Dr.
7 Scott, who can answer questions about the
8 panel. And that panel cross-walked the five
9 conditions to the ICD-10 codes.

10 The expert panel was instructed to
11 include only those codes that are clearly and
12 unequivocally within the scope of practice of
13 both optometry and ophthalmology, and also
14 unequivocally amenable to initial evaluation in
15 an office setting.

16 It was recognized there were some
17 instances these conditions might require
18 referral to an ophthalmologist for surgical
19 intervention or even to an emergency department
20 for emergent treatment.

21 It was also a criterion that even in
22 such event a code would not be included if the
23 additional step of initial evaluation in an
24 office setting would introduce a delay that

1 would pose a risk to the patient.

2 In other words, the expert panel was
3 instructed to exclude any code where the model
4 might create a risk to patient safety. Codes
5 were only included when the five member panel
6 unanimously agreed that the code met the
7 criteria.

8 We would like to emphasize that it
9 is standard practice for optometrists to refer
10 patients who present with conditions requiring
11 surgical intervention to ophthalmologists. And
12 as such, interventions are just not within
13 their scope of practice.

14 The typical practice makes such
15 referrals multiple times every week. And the
16 design of this model would not penalize them
17 for doing so.

18 If anything, the model provides
19 incentives for eye care professionals to triage
20 patients and provide or refer for appropriate
21 care earlier in the progression of disease.
22 And without a need for a more expensive visit
23 to an emergency department to get that
24 referral.

1 The financial incentives are modest
2 and are hardly sufficient to motivate a
3 clinician to jeopardize their licensure by
4 withholding a referral or exceeding their scope
5 of practice.

6 So, in closing, this model is
7 designed to accomplish several goals which have
8 been proven to be accomplishable in a large
9 scale pilot test of the care model: to provide
10 a vehicle for specialty practices to
11 participate in value-based care, to reduce
12 unnecessary use of emergency departments for
13 non-emergent services, and to provide eye care
14 professionals with new tools to facilitate
15 closer alignment with the medical neighborhood
16 and improve care coordination.

17 While this model is specific to two
18 specialties and a limited set of conditions, it
19 is not difficult to envision its replicability
20 for other conditions in other specialties. Eye
21 care is hardly alone in the overuse of
22 emergency departments for non-emergent care.

23 This overuse has been the subject of
24 extensive discussion in recent years in both

1 medical literature and in the broader media and
2 is receiving a great deal of attention from
3 private payers.

4 We believe we have presented a
5 relatively simple, novel, and elegant solution
6 which above all is patient-centered. Just
7 before I, and I would like to say that there
8 are several things that came up a few minutes
9 ago in the discussion between the PRT and the
10 other PTAC Members.

11 And we would be happy to respond to
12 some of those in the question period.

13 CHAIR BAILET: Great. Thank you, Dr.
14 Polakoff.

15 I think what I would like to do now
16 is open it up to the PTAC Committee members who
17 would like to ask questions, and we can revisit
18 the questions that we asked amongst ourselves,
19 as you suggested.

20 Each of the Committee members, if
21 you could just direct your questions to Dr.
22 Polakoff, then he'll determine who on his team
23 is best to go ahead and answer those questions.

24 And just please, it might be a

1 little awkward, but we'll see if we can make
2 this work. So, I'm going to go ahead and open
3 it up to the Committee members.

4 DR. SINOPOLI: Jeff, this is Angelo.
5 I have a question, if I may.

6 CHAIR BAILET: Please.

7 DR. SINOPOLI: So, one point of
8 clarity and one question. So, one is I think I
9 heard you say that the patients were limited to
10 established patients of the practice, and
11 therefore would not be taking patients who
12 otherwise might be considering the emergency
13 room and would call an office instead.

14 Is that correct?

15 DR. POLAKOFF: Thank you for that
16 question. It's not so much that we limited it
17 to established patients. But that is the only
18 way that it was being promoted.

19 The promotion of the model
20 essentially was a communication between the
21 participating clinicians and their established
22 patients.

23 Essentially, to make this very
24 concrete they, the practices, provided flyers

1 that were set on the reception desk and posters
2 that were posted in the office that essentially
3 said, "Did you know that we also treat urgent
4 eye conditions?"

5 "If you have an urgent issue, please
6 call us. Here's our phone number." That in a
7 nutshell is the promotion of the model. So,
8 while it is not closed to new patients, it's
9 not promoted to them.

10 DR. SINOPOLI: Thank you for that
11 clarification. And my question around that is
12 then in the payment construct, how do you
13 differentiate, or do you have patients that
14 would have been coming to your office anyway
15 for a number of these minor eye issues and
16 would not have been considering the emergency
17 room to begin with and therefore really not
18 decreasing in emergency room visit?

19 DR. POLAKOFF: In the TCPI model we
20 counted as an urgent visit only those visits
21 where the patient called and requested same day
22 or within 24 hours of the call service. It was
23 based on the patient's identification of the
24 need for urgent service.

1 DR. SINOPOLI: Thank you.

2 MR. STEINWALD: Can I follow up on
3 that?

4 CHAIR BAILET: Bruce, you have a
5 question. Go ahead.

6 MR. STEINWALD: Yes. It's the same
7 question I asked earlier and to follow
8 Angelo's. And so, I think we have a better
9 understanding now of the population of patients
10 that might change their behaviors.

11 My question is still what happens
12 when the event that leads to the potential
13 visit to the emergency room and is late at
14 night or the weekend?

15 Is there still the potential for
16 that patient to receive office services or does
17 the timing of the event really dictate where
18 the patient will receive the care?

19 DR. POLAKOFF: Thank you for that
20 question. There is still potential for that
21 patient to be seen in the office.

22 And to some extent that depends on
23 the individual practice's willingness to expand
24 their services. Many of the practices that

1 participated in our TCPI project were very
2 small offices in small towns.

3 The average practice size was 1.6
4 clinicians. So, in those instances sometimes
5 the doctors are willing to take the call in the
6 middle of the night and come into the office or
7 they'll say, you know, we open at 7:00 a.m.

8 If you can be there at 7:00, I'll
9 see you first thing at 7:00. But it really is
10 up to the individual practice to determine just
11 how broadly they want to open this up.

12 In general, there is an element of
13 telephone triage in many of these visits, both
14 during normal office hours and even after
15 office hours.

16 And so, you know, it could be that
17 the patient reaches the doctor directly or
18 through an answering service. And the doctor
19 ends up saying, you know, I think you need to
20 go to the ED for that.

21 MR. STEINWALD: Thank you.

22 CHAIR BAILET: Grace. You might be on
23 mute, Grace.

24 VICE CHAIR TERRELL: Can you hear me

1 now? In a former life I was, I ran a large
2 multi-specialty group that had ophthalmology
3 and optometry in it.

4 And I know that from that experience
5 quite often one of the things, as you
6 mentioned, in your proposal is true that the
7 equipment is actually better in the office than
8 in many emergency departments such that it's
9 actually superior care, not just less expensive
10 care.

11 And quite often when I've done
12 urgent care work in the past and spoke to an
13 optometrist or an ophthalmologist, they would
14 want us to, they would meet with the patient in
15 their office and would not want to see somebody
16 in the emergency room.

17 So, I perfectly understand where you
18 are coming from with respect to this being
19 potentially much better care.

20 My bigger concern or questions are
21 around the actual payment model itself because
22 this is essentially fee-for-service which you
23 have available now.

24 And so, I'm really more interested

1 in understanding the barriers to why this type
2 of urgent service is not being provided now by
3 eye care clinicians because essentially you
4 could do this now.

5 I mean, you could have extended
6 hours. You could create some, you know, word of
7 mouth. You could partner with primary care that
8 were in ACOs to make sure that this which is
9 just a site of service issue and probably a
10 more appropriate site of service in many
11 instances were done.

12 So, my biggest question for you is
13 if this is superior, which it quite often would
14 be, what's preventing eye care clinicians from
15 providing that service now?

16 DR. POLAKOFF: So, I'll give an
17 initial response. Thank you for that question.
18 And then I'm going to ask Dr. Scott to comment
19 as well.

20 My distinct impression from
21 interacting with these thousands of
22 optometrists through the TCPI program is that
23 it's more of a business issue related to their,
24 the business model of their practices.

1 And that's what we seek to interrupt
2 with, by providing new payment methods. We
3 should set optometry and ophthalmology apart in
4 this part of the discussion because the
5 services they provide are different, and
6 they're often reimbursed different.

7 But for the typical optometry
8 practice, their revenue is a mix of clinical
9 revenue and retail revenue from the sale of eye
10 glasses and contact lenses. And in most
11 practices the clinical revenue is actually a
12 minority.

13 And the reimbursement rates for fee-
14 for-service visits, to be perfectly blunt about
15 it, aren't sufficient to incentivize them to
16 want to expand their hours, come in, in the
17 middle of the night to see patients for urgent
18 visits.

19 They're more focused on the other
20 side of the house. And so, one of the things we
21 were hoping to do is to, in a very modest way,
22 disrupt those incentives and provide an
23 incentive to enhance the clinical services they
24 offer. Dr. Scott.

1 DR. SCOTT: Thank you. I agree, Dr.
2 Terrell. I think is a, it's a transitional time
3 right now between fee-for-service and other
4 payment methods that would be much more
5 efficient and better quality for the patients.

6 It exists already in certain venues.
7 The VA¹⁵, I spent a good part of my career in
8 the VA, and it's exactly how it worked.

9 Emergency rooms actually would, when
10 they had patients who had eye conditions that
11 weren't easy to manage, would call us in the
12 middle of the night and either we would go in
13 to see them, or if it was a condition that
14 could be managed, it was done that way.

15 One of the interesting things that's
16 happened recently is the acceleration of
17 triage, electronic triage, telemedicine,
18 telehealth, telephone that COVID has produced.
19 And I have some data that wasn't available when
20 we submitted this.

21 And that came from surveys that were
22 done. New England College of Optometry and the,
23 one of the large ophthalmology practices in

1 Boston, put together an ongoing continuing
2 education weekly seminar for managing COVID,
3 and it was available to optometrists and
4 ophthalmologists.

5 It became very popular. It was every
6 two weeks. But the way they kept people
7 interested in staying on the calls were they
8 had surveys.

9 And two pieces of information came
10 out that I was unaware of. One, was a question
11 about during the pandemic, "have you provided
12 care to patients through, that required
13 referral to a PCP¹⁶?"

14 And 102 people out of 400, give or
15 take, actually did that. And it sort of points
16 to the value of triage. Instead of seeing
17 somebody who has an eye symptom that manifests
18 a systemic condition, the patient did get
19 triaged correctly.

20 And then the other one was for
21 impact: "During the pandemic have you provided
22 care for a patient?"

23 And that meant either telephone or

16 primary care provider

1 more likely seeing the patient in the office of
2 someone who would have gone blind if they
3 hadn't come in? And it was about 100 out of 400
4 people who responded to that survey.

5 So, I think there is a reality
6 check, that desire to provide that kind of care
7 is there.

8 I would not have wanted to have been
9 on the, you know, the panel reviewing this
10 because of the complexity of it. I mean, it's
11 very convoluted how you can incentivize people
12 to do it.

13 And I realize that having all of the
14 ICD-10 codes has created a lot of confusion in
15 the people reviewing it and the people
16 observing it.

17 CHAIR BAILET: Thank you, Dr. Scott.
18 Grace, did that answer your question? Can we
19 move on? Yes.

20 So, my question is trying to wrestle
21 with the issue of scope. I commend the
22 submitters for trying to get the eye care
23 specialists on the field of value-based care
24 delivery.

1 I think it's a great effort on your
2 part and appreciate all the time that you've
3 put in to developing this proposal.

4 In the back and forth communication
5 with the PRT, I saw that the TCPI program and
6 just sort of the global collective of practices
7 you were working with, the urgent care visits
8 that occurred in that initiative that qualified
9 within the construct of this list were
10 somewhere between, as you said and this was all
11 payers and correct me if I've got it wrong, but
12 zero to one was a lot of variability.

13 But zero to one over 25 what were
14 classified as urgent care visits in a month.
15 And that was with all payers.

16 My concern or question is, a) is
17 that in fact correct? And then if you look at
18 this from a Medicare beneficiary standpoint,
19 would there be sufficient numbers of members
20 having these events that would make this a
21 worthwhile effort for the eye care specialist
22 to want to participate?

23 DR. POLAKOFF: That's a great
24 question. And I think that you've correctly

1 identified the TCPI that, while sponsored by
2 CMMI, was an all-payer initiative and the
3 instructions of the program were to collect
4 data on an all-payer basis, and so we did.

5 I think the model becomes more
6 viable the more different payers participate.
7 And whether there would be sufficient Medicare
8 only patients in a practice to make the model
9 viable and both statistically and financially
10 is somewhat of an open question.

11 I think it will be highly variable
12 among practices. It just depends on the patient
13 base of the particular practice.

14 I will say that part of that range
15 of, you know, zero to one patients per month to
16 25, and by the way that is per clinician and
17 that's not per practice. It's per clinician in
18 the office.

19 Some of that depends on the level of
20 interest of the practice in expanding urgent
21 visits. You know, most of our practices
22 implemented the model.

23 But they did so with varying levels
24 of enthusiasm. And, you know, so some of it is

1 just who their patients are and, you know, who
2 turns up and asks for care.

3 Some of it is how active and engaged
4 is the practice in promoting the model?

5 CHAIR BAILET: That's helpful.
6 Again, if you really drill down and try and
7 extrapolate the volume clearly, you would want
8 a model that would have sufficient numbers of
9 events that would, as you said, sort of
10 captivate the interest of the clinicians to
11 make it worth their while especially if you're
12 talking about after hours or, you know,
13 weekends, et cetera, non-traditional hours.

14 There would have to be sufficient
15 volumes to make it worthwhile especially if
16 you're talking about a reduction of the
17 magnitude of eight percent. And again, I
18 understand that's only for the visits in this
19 particular category.

20 But if there isn't enough volume and
21 enough dollars attributed to that it's going to
22 be challenging to get the physicians and the
23 clinicians activated to want to participate.

24 So, that's just a thing that you

1 guys are, you know, will have to, that will
2 have to have further evaluation and be
3 addressed. And obviously, as you said, more
4 payers that can participate the higher the
5 value of a model like this getting implemented.

6 DR. POLAKOFF: If I may just add one
7 other point. One of the things we found was
8 that the, just anecdotally, was that the
9 incentives that the participating practices
10 said motivated them were not solely financial.

11 The other motivation that came
12 across as very powerful in talking to the
13 clinicians and the owners of the practices was
14 that it provided an opportunity for them to
15 start to demonstrate how they create value in a
16 value-based health care system.

17 It allowed them to change their
18 conversation somewhat in both the setting of
19 negotiating managed care contracts because they
20 now had data on how they were creating value
21 and in developing their care coordination and
22 referral relationships with primary care
23 physicians.

24 Once again, they used these data to

1 demonstrate how they provided value, which was
2 something that previously they were really
3 stuck and stymied. Everybody around them is
4 engaged in a value-based care world and they
5 felt they couldn't participate in the
6 conversation.

7 CHAIR BAILET: Great point. Thank
8 you. Charles, do you have a question?

9 DR. DESHAZER: Yes. And actually, I
10 want to build on the last comment because you
11 alluded to this model in the context of the
12 medical neighborhood.

13 And I'm just wondering are, and you
14 kind of alluded to that point there, but, I
15 guess, is this model more effective in a bigger
16 context of a, you know, value-based
17 organization or, you know, are there ways that
18 it would be enhanced by that context?

19 I'm trying to think about how, you
20 know, being a part of the medical neighborhood
21 that this model would maybe be more, you know,
22 more effective or more enhanced. What are your
23 thoughts around that?

24 DR. POLAKOFF: Well, I can offer at

1 least one illustration from the TCPI program.
2 The TCPI was a broader program than just
3 getting clinicians into value-based payment
4 models, or APMs.

5 It also, you know -- we also worked
6 with the practices on improving quality,
7 improving outcomes, and a whole range of other
8 care coordination and care integration and
9 patient-centeredness strategies.

10 In the context of eye care
11 practices, one of the ways that played out is
12 that they do most of the eye exams that are
13 measured in some quality measures, such as the
14 diabetic eye exam measure, right?

15 They do those measures. But primary
16 care clinicians are accountable for those
17 measures.

18 And so, we assisted these practices
19 in their ability to electronically transfer
20 data back to referring primary care clinicians
21 that allowed the primary care clinicians to get
22 credit for the eye exams that the optometrists
23 had done.

24 In so doing, that builds the

1 relationship of the medical neighborhood. A lot
2 of these clinicians previously were in a world
3 where they were sending a consult letter back
4 by old fashioned snail mail to the primary care
5 doc reporting on the eye exam.

6 It never made it into the EHR¹⁷. And
7 as a result, the primary care physicians were
8 reporting really poor results on their diabetic
9 eye exams. We helped them fix that. That
10 facilitates the relationship.

11 Then we add on top of that this
12 reduction of costs for unnecessary ED use. And
13 the ability of the optometrist to display that
14 back to the primary care physician is a way
15 they're creating value.

16 These things integrate in a more
17 holistic way and start to enhance the medical
18 neighborhood and, essentially, to bring eye
19 care into the care team for the patient.

20 I hope that addresses the question,
21 Dr. DeShazer.

22 DR. DESHAZER: Yes, that's helpful
23 definitely. I see that capability in terms of

17 electronic health record

1 the integration and coordination to support
2 overall value-based strategies.

3 CHAIR BAILET: Thanks, Charles.
4 Seeing no further questions, I'd like to
5 personally thank the submitters for their time
6 today, and more importantly for their efforts
7 to try and create a model for the Committee to
8 review and potentially be implemented.

9 I'd like to just ask them to go back
10 -- and they'll be moved back from the
11 participant panel to the general audience and
12 they can return to a listening mode to continue
13 with the meeting.

14 * **Public Comments**

15 We have two -- actually we have two
16 public commenters who are signed up. And I'm
17 going to go ahead and work with the operator to
18 call them up.

19 The first is Dr. Steven Eiss. He's
20 an optometrist from the American Optometric
21 Association. Dr. Eiss?

22 DR. EISS: Hi, yes. Can you hear me?

23 CHAIR BAILET: Yes, we can.

24 DR. EISS: Okay, yes. Thank you.

1 Thank you for the opportunity to provide
2 comments today. Again, my name is Dr. Steven
3 Eiss. I'm a practicing optometrist in southeast
4 Pennsylvania.

5 And I'm representing the American
6 Optometric Association as a volunteer Chair of
7 the Third Party Center Committee. As
8 background, the AOA represents approximately
9 39,000 doctors of optometry, optometry
10 students, and paraoptometric assistants and
11 technicians.

12 Doctors of optometry serve more than
13 10,000 communities across the country and
14 counties that account for 99 percent of the
15 U.S. population. Recognized as Medicare
16 physicians for more than 30 years, doctors of
17 optometry provide medical eye care to more than
18 six million Medicare beneficiaries annually.

19 In support of evidence-based health
20 care and to serve the needs of the American
21 public, the AOA develops clinical practice
22 guidelines that meet the National Academies of
23 Science, Engineering, and Medicine Health and
24 Medicine Division, or NASEM, evidence-based

1 standards.

2 The aim of the PTAC proposal, how
3 doctors of optometry can help reduce
4 unnecessary hospital visits for eye emergencies
5 is such an important focus. As primary eye care
6 providers, doctors of optometry have long
7 played a role in serving their communities by
8 providing emergency eye health care.

9 This role for doctors of optometry
10 in the health care system has proven to be even
11 more impactful over the past several weeks, as
12 our country has been faced with the COVID-19
13 public health emergency.

14 According to data collected by the
15 AOA, during the public health emergency 79.2
16 percent of doctors of optometry surveyed were
17 providing emergency care through the public
18 health emergency.

19 These doctors of optometry estimate
20 that nearly 60 percent of patients they treated
21 during the crisis would have sought care in
22 emergency department or other urgent care
23 settings had they not been available to provide
24 care.

1 During the pandemic reducing strain
2 on overburdened hospitals was even more
3 critical to our health system and to slowing
4 the spread of the virus.

5 However, even outside of the
6 extenuating circumstances of the past few
7 weeks, doctors of optometry can increase
8 efficiencies in our health care system by
9 caring for patients with emergency eye injuries
10 to avoid unnecessary emergency room visits.

11 Recent analysis has shown that an
12 estimated 8.3 billion is spent each year on
13 emergency department care that could be
14 provided in another location. Additionally,
15 nearly 40 percent of all ED visits were for
16 non-urgent medical conditions, according to a
17 2013 study.

18 Unfortunately, many patients are
19 seeking care in EDs for ocular conditions that
20 could be treated in an office-based setting. A
21 2017 study found that nearly one-quarter of
22 enrollees who visited the ED for an ocular
23 problem received a diagnosis of a non-urgent
24 condition.

1 Better educating and incentivizing
2 patients to seek care for non-urgent ocular
3 diseases in an office-based setting could yield
4 yet considerable cost savings, without
5 adversely affecting health outcomes, and could
6 allow EDs to better serve patients with more
7 severe conditions.

8 Further, a JAMA¹⁸ Ophthalmology 2019
9 analysis of data from an electronic records
10 system found that patients with non-emergency
11 eye concerns would save \$782 in charges and
12 5.75 hours in visit duration by choosing same-
13 day outpatient care rather than an emergency
14 department visit.

15 It is clear that doctors of
16 optometry can play a key role in achieving
17 these types of cost savings.

18 Additionally, the AOA's Health
19 Policy Institute, or HPI, recently conducted a
20 descriptive epidemiological analysis of the
21 diagnosis codes reported nation-wide in
22 emergency department encounters and determined
23 that although urgent, most eye related

18 The Journal of the American Medical Association

1 conditions reported in the emergency department
2 may be treatable in an outpatient optometry
3 clinic or office.

4 The Agency for Healthcare Research
5 and Quality, AHRQ, sponsors the Healthcare Cost
6 and Utilization Project, HCUP, a family of
7 health care databases and related software
8 tools and products.

9 The nationwide emergency department
10 sample is contained in the tool called the
11 HCUPnet, useful for identifying, tracking, and
12 analyzing national hospital data.

13 Using the select set of eye and
14 vision related diagnosis codes, HPI queried the
15 HCUPnet tool and identified a rate of 4.5
16 visits per 1,000 persons, totaling 1.45 million
17 eye ED visits in 2016.

18 The CDC¹⁹ reports a national rate of
19 458 per 1,000 persons in 2016. So, eye visits
20 represent approximately one percent of all
21 emergency department visits in 2016.

22 Potential savings by transitioning
23 eye emergencies to optometry offices and

19 U.S. Centers for Disease Control and Prevention

1 clinics should be of key interest of health
2 care payers and policy makers. Most especially,
3 those shown by these data, who bear the brunt
4 of unavoidable eye-related emergency department
5 visits and charges.

6 These payers include private
7 insurance, which is about 29 percent, Medicaid
8 which is about 40 percent, and Medicare which
9 is about 12.5 percent.

10 For example, a 2013 study of 475,941
11 patients found that 91.5 percent of total cost,
12 totaling 18.4 million, could be saved by
13 diverting eye emergency department care to
14 optometry offices and clinics.

15 While we fully agree with the
16 University of Massachusetts that patients are
17 better suited to seek care for ocular diseases
18 and conditions in an outpatient, office-based
19 setting with a doctor of optometry, we have
20 concerns with certain aspects of the proposal.

21 We fully recognize that as part of
22 the alternative payment model, physicians must
23 take on some financial risk. However, we are
24 concerned that doctors participating in the

1 model are required to take a discount of at
2 least eight percent applied to all fee-for-
3 service rates on the emergency care-related
4 visits.

5 We know from previous research that
6 are significant cost savings when patients do
7 same-day outpatient care, rather than an
8 emergency department visit. We believe a more
9 equitable model would require doctors to pay an
10 eight percent payment penalty on pertinent
11 visits in the year following the performed care
12 if the savings were not truly realized.

13 The care that doctors of optometry
14 provide is valuable care, and we believe an up-
15 front payment discount devalues that care.

16 We are also concerned that the list
17 of diagnosis codes meant to assist in identify
18 - identification of visits that would be
19 considered in the EyEDA model, was too broad.

20 The 2019 JAMA Ophthalmology study
21 indicated that the top four ophthalmologic
22 diagnosis for ED patients were conjunctivitis,
23 corneal abrasion, iritis, and vision loss. We
24 recommend that the pertinent diagnosis code

1 list for the proposed payment model be further
2 revised and limited.

3 We also believe for this payment
4 model to be successful and equitable, there
5 would need to be additional policy incentives
6 in place. The policy proposal authors have
7 rightly noted that patients lack awareness of
8 the existence of alternatives to the ED for
9 urgent eye care conditions.

10 Hospitals lack incentives to
11 dissuade or redirect patients with non-emergent
12 conditions away from the ED.

13 CHAIR BAILET: Dr. Eiss, I don't mean
14 to interrupt. But you are - you're running a
15 bit long. I've given you some added time. But
16 if you could please close it out, that would be
17 greatly appreciated. Thank you.

18 DR. EISS: Okay. I'm just about to
19 finish. Thank you.

20 CHAIR BAILET: Super.

21 DR. EISS: We request that payers
22 have a 24 [hour] phone line support service for
23 questions for beneficiaries, and we believe the
24 EDs themselves should be part of the effort to

1 encourage patients to seek care with optometry
2 offices.

3 Without the engagement of other
4 players in the health care system, the payment
5 model would in practice target a single health
6 care provider which we believe may not meet the
7 goals of PTAC.

8 I also have a little exception with
9 the characterization that optometry is very
10 retail focused. Obviously, market forces have
11 really pushed optometry away from that, to
12 where many, many of the practices are much more
13 medical care.

14 And as a care provider, you know, we
15 just want to take care of our patients. You
16 know, our incentive is to see our patients to
17 provide the care they need.

18 We don't want to see them go to the
19 emergency room and get, you know, care that may
20 not address exactly what they may need or be in
21 their best interest.

22 So, again thank you for your time.
23 I apologize for running a little long, and I'll
24 be glad to answer any questions related to

1 care.

2 CHAIR BAILET: Thank you, Dr. Eiss.
3 I'd like to go ahead and turn it over to the
4 next commenter and that's Dr. Lori Grover, also
5 from the American Optometric Association. Dr.
6 Grover?

7 DR. GROVER: Good morning. Can you
8 hear me?

9 CHAIR BAILET: Yes, we can.

10 DR. GROVER: Thank you, Dr. Bailet,
11 and thanks to the Committee for letting us
12 comment today. I'm speaking a bit more today
13 from a 30-year clinical background as a doctor
14 of optometry, formerly with Johns Hopkins and I
15 also have doctoral training in health services
16 research and health policy.

17 I currently am the Director of the
18 Center for Eye and Health Outcomes at Memphis.
19 And I wanted to just share with you that we
20 understand and support the importance of the
21 role of APMs in improving health care
22 deliveries.

23 I do want to emphasize I think it's
24 important to view the eye care delivery role of

1 the doctor of optometry as a parallel to that
2 of family physicians within the health care
3 arena, especially when you're taking into
4 account the complexities, the stakeholder
5 incentives, payments, and delivery of quality
6 patient centered coordinated care; there is
7 much to think about in that role.

8 Doctors of optometry provide almost
9 80 percent of the primary care in the United
10 States. And we understand the recognition of
11 emergency eye care delivery as an area where
12 cost savings certainly can be achieved.

13 We recognize that primary care is
14 really a primary access point to the health
15 care system, and hence why I wanted you to have
16 that perspective of us as a parallel to our
17 physician colleagues in primary care.

18 The observations made earlier
19 regarding the suggested lack of clinical care
20 volume and the delivery of primary eye care
21 misrepresents the scope of the continuum of
22 care that is delivered by doctors of optometry
23 in the United States.

24 And I think that's just because of

1 observations limited to a small and narrower
2 network that isn't really representative of
3 current national continuum of eye care
4 delivery, especially with Medicare
5 beneficiaries.

6 So, aside from the data that
7 supports this, I also can support this with
8 personal experience. I've treated chronic
9 vision impairment and have always served a
10 larger, older adult population.

11 So, we embrace the area of emergent
12 and the urgent care not only as part and parcel
13 of what doctors of optometry deliver but also
14 as an area of great potential for
15 transformational approaches.

16 We support and appreciate the
17 recognition of optometrists and their important
18 national role in eye care. We value that
19 greatly and we feel it's time that we can help
20 to take our place with our colleagues in that
21 arena.

22 The details that are proposed here
23 unfortunately do require additional refinement
24 and collaborative input.

1 And ultimately we aim to ensure that
2 a wide range of clinicians, that includes not
3 only, as was mentioned earlier, both existing
4 ACO and other network models in which doctors
5 of optometry are engaged but also can include
6 small practices in rural areas, where we can
7 participate and have doctors benefit, have the
8 patients that are served benefit, and have care
9 delivery transformation that can be equitable
10 and efficient.

11 So, thank you for letting me
12 comment.

13 CHAIR BAILET: Thank you, Dr. Grover.
14 I'm just going to check with the operator; is
15 there anyone else who signed up for public
16 comment?

17 Hearing none, I turn back to the
18 PTAC Committee. Are we ready to vote? It sounds
19 like we're ready to vote.

20 * **Voting**

21 So, since there's no other comments
22 I would just like to review a few of the voting
23 system parameters, which haven't changed.
24 We're simply using an online version of the

1 same technology that you've seen us use in
2 typical meetings.

3 We appreciate your patience as we
4 use this tool virtually for the first time. It
5 may take a minute or so to make the transitions
6 and get people connected to the technology.

7 But I just want to review some of
8 the parameters of voting. We vote on -- first
9 electronically on the 10 Criteria. Member votes
10 roll down until a simple majority has been
11 reached.

12 A vote of 1 or 2 means does not
13 meet. A vote of 3 or 4 means meets. Five (5)
14 and 6 means meets and deserves priority. If
15 there's an asterisk that means it's not
16 applicable.

17 After we vote on all 10 Criteria, we
18 will proceed to vote on our overall
19 recommendations to the Secretary. We will use
20 the voting categories and process that we
21 debuted in December of 2018. We designed these
22 more descriptive categories to reflect our
23 deliberations for the Secretary.

24 So, first we will be voting using

1 the following three criteria -- or three
2 categories. Not recommended for implementation
3 as a physician-focused payment model; or
4 recommended; or referred for other attention by
5 HHS. We need to achieve a two-thirds majority
6 of votes for one of these three categories.

7 With a two-thirds majority vote to
8 recommend the proposal, we then vote on a
9 subset of categories to determine the final
10 overall recommendations to the Secretary.

11 And the second vote uses the
12 following four categories, or subcategories, if
13 you will. The proposal substantially meets the
14 Secretary's criteria for PFPM²⁰s, PTAC
15 recommends implementing the proposal as a
16 payment model.

17 Next, PTAC recommends further
18 developing and implementing the proposal, as a
19 payment model as specified in PTAC comments.

20 The third category is PTAC
21 recommends testing the proposal as specified in
22 PTAC comments to inform payment model
23 development.

20 physician-focused payment model

1 And lastly, PTAC recommends
2 implementing the proposal as part of an
3 existing or planned CMMI model. We need a two-
4 thirds majority vote for one of these four
5 categories.

6 * **Criterion 1**

7 So, now let's go ahead and vote for
8 the first criterion, which is scope, which is
9 considered a high priority item.

10 So, scope, aim to either directly
11 address an issue in payment policy that
12 broadens and expands the CMS APM portfolio, or
13 include APM entities whose opportunities to
14 produce -- to participate in APMs have been
15 limited.

16 Please vote. Audrey? It looks like
17 we -- can you go ahead, Audrey, and summarize
18 for us what you see, please? You're on mute.
19 Audrey, we're not hearing you, you're on mute.

20 MS. MCDOWELL: Okay. Can you hear me
21 now?

22 CHAIR BAILET: Yes, we can.

23 MS. MCDOWELL: Thank you. Zero
24 members voted 6, meets and deserves priority

1 consideration. Zero members voted 5, meets and
2 deserves priority consideration.

3 Zero members voted 4, meets. One
4 member voted 3, meets. Six members voted 2,
5 does not meet. One member voted 1, does not
6 meet. Zero members voted 0, not applicable.

7 So, we need a majority, which is
8 five votes. And so, the majority has determined
9 that the proposal does not meet Criterion 1.

10 * **Criterion 2**

11 CHAIR BAILET: Thank you, Audrey.
12 Let's go to Criterion 2, please, which is
13 quality and costs, which is also a high
14 priority designation.

15 Anticipated to improve health care
16 quality at no additional cost, maintain health
17 care quality while decreasing costs, or both,
18 improve health care quality and decrease costs.

19 Please go ahead and vote.

20 Go ahead, Audrey.

21 MS. MCDOWELL: All right. Zero
22 members voted 6, meets and deserves priority
23 consideration. Zero members voted 5, meets and
24 deserves priority consideration.

1 One member voted 4, meets. Seven
2 members voted 3, meets. And zero members voted
3 2 or 1, does not meet. And zero members voted
4 0, not applicable.

5 So, the majority has determined that
6 the proposal meets Criterion 2.

7 * **Criterion 3**

8 CHAIR BAILET: All right. Thank you,
9 Audrey. We're going to move on to Criterion No.
10 3, which is payment methodology which is also a
11 high priority designation.

12 Pay the APM entities with a payment
13 methodology designed to achieve the goals of
14 the PFPM criteria.

15 Addresses in detail, through this
16 methodology how Medicare and other payers, if
17 applicable, pay APM Entities, how the payment
18 methodology differs from current payment
19 methodologies, and why the physician-focused
20 payment model cannot be tested under current
21 payment methodologies. Please vote.

22 Audrey?

23 MS. MCDOWELL: Are you ready?

24 CHAIR BAILET: I am ready, Audrey.

1 MS. MCDOWELL: All right. Zero
2 members voted 6, meets and deserves priority
3 consideration. Zero members voted 5, meets and
4 deserves priority consideration.

5 Zero members voted 4, meets. Zero
6 members voted 3, meets. Four members voted 2,
7 does not meet. Four members voted 1, does not
8 meet. Zero members voted 0, not applicable.

9 So, the majority has determined that
10 the proposal does not meet Criterion 3.

11 * **Criterion 4**

12 CHAIR BAILET: Thank you, Audrey.
13 Let's go on to Criterion 4, which is value over
14 volume.

15 Provide incentives to practitioners
16 to deliver high quality health care. Please
17 vote.

18 All right, Audrey, please continue.

19 MS. MCDOWELL: Okay. Zero members
20 voted 6, meets and deserves priority
21 consideration. Zero members voted 5, meets and
22 deserves priority consideration.

23 One member voted 4, meets. Six
24 members voted 3, meets. One member voted 2,

1 does not meet. Zero members voted 2 -- excuse
2 me, 1, does not meet. And zero members voted 0,
3 not applicable.

4 So, the majority has determined that
5 the proposal meets Criterion 4.

6 * **Criterion 5**

7 CHAIR BAILET: Thank you, Audrey.
8 Criterion 5 is flexibility. Provide the
9 flexibility needed for practitioners to deliver
10 high-quality health care. Please vote.

11 Audrey?

12 MS. MCDOWELL: Zero members voted 6,
13 meets and deserves priority consideration.
14 Zero members voted 5, meets and deserves
15 priority consideration. Two members voted 4,
16 meets. Six members voted 3, meets. Zero members
17 voted 2, does not meet, or 1, does not meet, or
18 zero, not applicable.

19 So, the majority has determined that
20 the proposal meets Criterion 5.

21 * **Criterion 6**

22 CHAIR BAILET: Thank you, Audrey.
23 We'll go on to Criterion No. 6, which is
24 ability to be evaluated.

1 Have evaluable goals for quality of
2 care, cost and other goals of the PFPM. Let's
3 go ahead and please vote. Here we go.

4 Audrey?

5 MS. MCDOWELL: Zero members voted 6,
6 meets and deserves priority consideration.
7 Zero members voted 5, meets and deserves
8 priority consideration. Zero members voted 4,
9 meets. Seven members voted 3, meets. One member
10 voted 1 -- excuse me, 2, does not meet. Zero
11 members voted 1, does not meet. Zero members
12 voted 0, not applicable.

13 So, the majority has determined that
14 the proposal meets Criterion 6.

15 * **Criterion 7**

16 CHAIR BAILET: Thanks, Audrey. Let's
17 go to Criterion No. 7, which is integration and
18 care coordination.

19 Encourage greater integration and
20 care coordination among practitioners and
21 across settings, where multiple practitioners
22 or settings are relevant to delivering care to
23 the population treated under the PFPM. Let's go
24 ahead and vote, please.

1 MS. MCDOWELL: Zero members voted 6,
2 meets and deserves priority consideration.
3 Zero members voted 5, meets and deserves
4 priority consideration. Zero members voted 4,
5 meets. Three members voted 3, meets. Two
6 members voted 2, does not meet. Three members
7 voted 1, does not meet. And zero members voted
8 0, not applicable.

9 As we have indicated, we need a
10 majority, which is five votes. So, in this case
11 a majority has determined that the proposal
12 does not meet Criterion 7.

13 * **Criterion 8**

14 CHAIR BAILET: Thank you, Audrey.
15 Let's go to Criterion No. 8, patient choice.

16 Encourage greater attention to the
17 health of the population served while also
18 supporting the unique needs and preferences of
19 individual patients. Please go ahead and vote.

20 Audrey?

21 MS. MCDOWELL: Zero members have
22 voted 6, meets and deserves priority
23 consideration. Zero members have voted 5, meets
24 and deserves priority consideration. Two

1 members have voted 4, meets. Six members have
2 voted 3, meets. Zero members have voted 2, does
3 not meet; 1, does not meet; or 0, not
4 applicable.

5 So, the majority has determined that
6 the proposal meets Criterion 8.

7 * **Criterion 9**

8 CHAIR BAILET: Thanks, Audrey. And
9 we'll go ahead to Criterion No. 9, which is
10 patient safety.

11 Aim to maintain or improve standards
12 of patient safety. Please vote.

13 Audrey?

14 MS. MCDOWELL: Zero members have
15 voted 6, meets and deserves priority
16 consideration. Zero members have voted 5, meets
17 and deserves priority consideration. One member
18 has voted 4, meets. Zero members have voted 3,
19 meets. Five members have voted 2, does not
20 meet. One member has -- excuse me, two members
21 have voted 1, does not meet. And zero members
22 have voted 0, not applicable.

23 So, the majority has determined that
24 the proposal does not meet Criterion 9.

1 * **Criterion 10**

2 CHAIR BAILET: Thank you, Audrey.
3 And the last criterion, Criterion 10, which is
4 health information technology.

5 Encourages the use of health
6 information technology to inform care. Please
7 vote.

8 Audrey?

9 MS. MCDOWELL: Zero members have
10 voted 6, meets and deserves priority
11 consideration. Zero members have voted 5, meets
12 and deserves priority consideration. Two members
13 have voted 4, meets. Five members have voted 3,
14 meets. One members has voted 2, does not meet.
15 Zero members have voted 1, does not meet, or 0,
16 not applicable.

17 So, the majority has determined that
18 the proposal meets Criterion 10.

19 CHAIR BAILET: Thank you, Audrey.
20 Audrey, could you just summarize where we fell
21 out on the ten criteria, please?

22 MS. MCDOWELL: Yes. The Committee has
23 found that the proposal meets six of the ten
24 criteria. And that is Criteria 2, 4, 5, 6, 8

1 and 10.

2 And the Committee voted that the
3 proposal does not meet the remaining four
4 criteria, and that consists of Criteria 1, 3, 7
5 and 9.

6 * **Overall Vote**

7 CHAIR BAILET: Thank you, Audrey. We
8 are now ready to move into the next section of
9 voting, which is the overall recommendation.

10 So, you see here we have not
11 recommended for implementation as a PFPM;
12 recommended, which would require two-part
13 voting; or referred for other attention by HHS.

14 Those are the three categories.
15 We're going to go ahead and vote. Audrey?

16 MS. MCDOWELL: So, seven of the
17 Committee members have voted not recommend.
18 Zero Committee members have voted recommend.
19 And one Committee member has voted to refer for
20 other attention by HHS.

21 In this case you need a super
22 majority, which would be six. And so, the
23 recommendation of the Committee is to not
24 recommend this proposal for implementation as a

1 PFPM.

2 CHAIR BAILET: Thank you, Audrey.
3 And in light of the vote not to recommend there
4 is no requirement to have the second stage of
5 voting here.

6 * **Instructions on Report to the**
7 **Secretary**

8 So, I think at this point we would
9 like to have the individual Committee members
10 make comments that can be embedded in the
11 Secretary's report.

12 And so, what I'd like to do is,
13 because it's virtual, I'm going to go back to
14 the list of Committee members as we used in
15 opening for folks to introduce themselves and
16 disclose any conflicts.

17 So, the first person on that list is
18 Grace. And then we'll just go through the list,
19 finishing with myself. Grace, if you want to --

20 MS. MCDOWELL: Excuse me, Jeff?

21 CHAIR BAILET: Yes?

22 MS. MCDOWELL: I just want to confirm
23 that as they do that, that they're going to
24 indicate how they voted.

1 CHAIR BAILET: Correct. Thank you,
2 Audrey.

3 MS. MCDOWELL: Thank you.

4 VICE CHAIR TERRELL: So, I voted to
5 not recommend. And mostly it was not about the
6 care model, but it was about the payment model,
7 which I did not think was adequate for the
8 appropriate aims that they were bringing
9 forward.

10 I do believe that the ability to
11 have extended hours and getting people out of
12 the emergency department when there is a non-
13 emergent but urgent eye problem is appropriate.
14 And it was thoughtful many of the ways that
15 they put together their proposal as it relates
16 to that.

17 I did not think that the payment
18 model that was proposed would get them there.
19 And so, I think there's some others that might
20 be thought through, which is about other ways
21 of motivating people to have increased access.

22 Part of my concern was the need
23 based on numbers for it to be about more than
24 just Medicare. And I like the idea in the

1 original CMMI, it was an all-payer access.

2 But I wonder if care and
3 coordination fees, other types of bundled
4 payments, many of the other types of payment
5 models that are out there would actually
6 achieve their aims better than a discount for
7 volume.

8 And so, that's sort of where I
9 voted, and why I voted the way I did.

10 CHAIR BAILET: Thank you, Grace.

11 Paul?

12 DR. CASALE: Yes, hi. Yes, I also
13 voted to not recommend. Similar thinking to
14 Grace, I mean, it was really the payment model,
15 I think was where -- I think was most
16 challenging.

17 I do think that, as Grace just said,
18 increasing access at appropriate sites of care
19 that are lower cost, better equipment in the
20 office, all those would achieve higher quality.

21 But I think that the payment model
22 as currently described being sort of office-
23 based payment, I don't think -- I think there
24 are other ways of doing that. And I still

1 struggle with the scope.

2 I mean, I understand that, you know,
3 the eye care physicians haven't specifically
4 had a model. But it seems to me that this is
5 one that can be embedded in broader models,
6 effectively, and I would see that coordination
7 with primary care would benefit both, and of
8 course benefit the patient.

9 CHAIR BAILET: Thanks, Paul. We've
10 got Charles next.

11 DR. DESHAZER: Yes. I would just echo
12 the statements of Paul and Grace in that the
13 elements that I struggled with were the scope
14 and the payment model and those are two high-
15 priority criteria for us, which this model
16 fails on.

17 But again, I think that there are
18 elements that if you embed it within, you know,
19 a bigger context could be of value in terms of
20 the role of this strategy. So, I voted to not
21 recommend on that basis.

22 CHAIR BAILET: Thank you, Charles.
23 We have Kavita followed by Angelo. Kavita?

24 DR. PATEL: I voted to not recommend.

1 And the only thing I would add to be included
2 in the Secretary's report is some comment
3 regarding how best to carry forward outside of
4 a CMMI model what was learned and gained from
5 the TCPI program, in particular because of the
6 ability to demonstrate this type of practice
7 transformation is important to find a home for
8 within, kind of, the HHS enterprise.

9 CHAIR BAILET: Thanks, Kavita.
10 Angelo?

11 DR. SINOPOLI: Yes. I'll echo a lot
12 of what's been said. I did vote not to
13 recommend. And my main concerns were the scope
14 and the number of diagnoses automatically
15 listed there, and also very much the payment
16 model.

17 And I would also echo, I think
18 there's a lot of value otherwise in this model,
19 in terms of being able to provide high-quality
20 care outside the ER²¹. Sometimes there is
21 actually much better equipment that may be
22 better suited to be integrated into more of an
23 integrated model with a delivery system and a

21 emergency room

1 robust triage or referral system.

2 CHAIR BAILET: Thanks, Angelo. Bruce
3 followed by Jennifer.

4 MR. STEINWALD: I agree with the
5 comments so far, especially about scope and the
6 payment model. But I was the one person that
7 voted to refer, because I like to be different.

8 But the reason I did that is because
9 I was persuaded by some of the comments about
10 telemedicine and the potential for telemedicine
11 to be a source of both triage and referral and
12 care coordination for the population.

13 And since that's a high priority
14 that Secretary [sic] Verma²² mentioned, I
15 thought this obviously could be covered in the
16 discussion section of the report. But to
17 identify this as a potential good area for the
18 application of telemedicine.

19 CHAIR BAILET: Thank you, Bruce.
20 Jennifer?

21 DR. WILER: Yes. I too voted not to
22 recommend. It's obvious the current payment
23 models don't encourage broad access to sub-

1 specialty eye care, as was described.

2 And the TCPI project had impressive
3 results. However, given the current proposal, I
4 too shared the concern that the payment
5 methodology would not garner participation of
6 providers or participants as currently
7 described, which then directly impacts a high-
8 priority area of scope.

9 The other thing I would add that has
10 not come up in this conversation is the issue
11 with regards to patient safety.

12 And my comment would be that the
13 patient safety metrics described in this
14 proposal are ones that don't appear to cross-
15 walk to what is standard complications related
16 to these ambulatory-sensitive conditions.

17 Specifically, those of observation,
18 inpatient visits, and deaths. So, it appears
19 that those quality metrics are a mismatch to
20 what's being described.

21 And I agree with one of the previous
22 speakers, that a global period that extends far
23 beyond seven days, if this were to be
24 considered, is more appropriate. Thank you.

1 CHAIR BAILET: Thank you, Jennifer.
2 And I also voted not to recommend, and agree
3 with the comments that have been made.

4 The only other comment I would make
5 is an earlier observation about the numbers of
6 encounters that qualify. When we were looking
7 at a small number of zero to one per doc, per
8 clinician, per month that would qualify, I'm
9 just concerned that there would be insufficient
10 scope.

11 I do commend the submitters for
12 trying to engage and get the optometry
13 community into the value-based world. I commend
14 that effort and think that more thought needs
15 to be placed on how to get a model out that
16 this specialty could participate in to get into
17 value-based care delivery more than they are
18 today.

19 So, that was closing out those
20 comments. I think it would be good, Audrey, if
21 there could be a read back of comments that the
22 Committee made just to ensure that we were
23 articulate and that those were captured to go
24 ahead and embed those comments into the

1 Secretary's report.

2 So, someone on the team want to
3 summarize what they heard, or ask any
4 clarifying questions? Yes.

5 MS. MCDOWELL: We'll turn that over
6 to Sally.

7 CHAIR BAILET: Right, thank you.

8 DR. STEARNS: Okay. So, let's see.
9 To summarize what I want to do is start with
10 some of the positive points that were made,
11 especially about the care model.

12 That historical data show that a
13 large proportion of ocular-related visits to
14 the ED often could be appropriately treated in
15 an office-based setting. And in particular,
16 offices may be, in many cases, better equipped
17 than EDs for some of the ocular problems.

18 Also, the report will emphasize the
19 TCPI experience showed interest and ability of
20 many practices, including small practices, to
21 expand their clinical services for the five
22 categories or conditions identified.

23 And also, the COVID experience over
24 the last few months, although not part of the

1 proposal, has further emphasized the value of
2 virtual and office-based services for ocular
3 conditions that can be appropriately treated in
4 an office-based setting.

5 However, the report is also going to
6 pay particular attention to the concerns on the
7 four areas where the voting did not support the
8 model. That would be scope, payment,
9 integration and care coordination, and patient
10 safety.

11 And some of the specific comments
12 there include the fact that the payment model -
13 - that the PTAC does not feel that the payment
14 model will get them to the point of being able
15 to really encourage practices to move these
16 services.

17 But there is a need for other ways
18 to get people to do this. And including
19 attention to broader models, such as ACOs, or
20 alternatives such as bundled payments.

21 Some of the other points and
22 concerns include, Jennifer mentioned some
23 patient safety concerns. And the broader
24 problem that the current payment models from

1 CMMI often don't encourage broad participation
2 by optometrists, but simply that something
3 broader is needed.

4 And I will also fall back on some of
5 the comments in the PRT report on those
6 specific four areas, where the voting was not
7 supportive of the model.

8 CHAIR BAILET: Thanks, Sally. If
9 there are no other comments from the Committee
10 members, we have completed the first
11 deliberation of the morning session.

12 We are reconvening at 12:45. We at
13 that point will have Brad Smith from CMMI
14 provide some opening remarks.

15 I am on the second PRT. So, I am
16 going to turn the gavel over to Grace at that
17 time, so that I can fully participate as a
18 member of the PRT.

19 So, we are going to end this
20 session.

21 I want to thank the commenters.
22 Also, more importantly, want to thank the
23 submitters for their time and attention
24 developing this proposal working with the PRT

1 and providing their input today, and also all
2 of the members and stakeholders across the
3 country who have participated in the session
4 this morning.

5 We're going to go ahead and adjourn
6 until 12:45. Thank you.

7 (Whereupon, the above-entitled
8 matter went off the record at 12:19 p.m. and
9 resumed at 12:45 p.m.)

10 VICE CHAIR TERRELL: Okay. It's
11 12:45. So good afternoon, and welcome back to
12 this PTAC meeting. I want to extend a special
13 welcome to anyone who has just joined for the
14 afternoon.

15 I'm Grace Terrell. I'm the Vice
16 Chair of PTAC. I will be handling some of
17 Jeff's²³ facilitation duties this afternoon
18 because he's on the PRT for the proposal that
19 we're going to discuss this afternoon.

20 But before we do that, at this time,
21 we are honored to be joined by a member of the
22 HHS leadership.

23 I'm excited to introduce Brad Smith,

1 who's the Senior Advisor to Secretary Azar for
2 Value-Based Transformation, a Deputy
3 Administrator for the Centers of Medicare &
4 Medicaid Services, and the Director for the CMS
5 Innovation Center.

6 Mr. Smith joined HHS in January 2020
7 after serving as the Chief Operating Officer of
8 Anthem's Diversified Business Group. He brings
9 with him extensive experience innovating in the
10 care delivery and value-based care spaces.

11 Mr. Smith co-founded and served as
12 the CEO of Aspire Health, a health care company
13 focused on providing home-based palliative care
14 services to patients facing serious illnesses.

15 And with that, it's my pleasure to
16 welcome Mr. Smith. I think you're on mute
17 there, Brad. Not hearing you.

18 CHAIR BAILET: Grace, I don't think
19 he knows, I don't think he's hearing anybody.
20 Someone's going to have to text him and tell
21 him he's on mute.

22 VICE CHAIR TERRELL: Yes. So can
23 somebody text him, please?

24 * **Brad Smith, Deputy Administrator and**

1 **Director of CMMI Remarks**

2 MR. SMITH: Okay. Can you guys hear
3 me okay? Sorry about that.

4 VICE CHAIR TERRELL: You were on mute
5 until just this instant, so --

6 MR. SMITH: Yes, okay. I was talking
7 to myself. It's like when you're on the call,
8 except you can see yourself, so it's even more
9 confusing, but I'll kind of, kind of start
10 over. So you know, again, thank you guys for
11 having me. I deeply understand how important
12 the work of PTAC is, and just to give you guys
13 a little bit of background, prior to coming
14 into the administration, I was running a health
15 care company that did palliative care, and we
16 were part of a coalition of folks who brought a
17 model through C-TAC²⁴ to PTAC.

18 And through that process, you guys
19 gave us really helpful feedback. We refined our
20 model a lot, and as many of you may remember,
21 you also approved another palliative care model
22 around the same time.

23 You know, and then CMMI, before I

1 was ever there, took those two models that came
2 up from PTAC, other ideas they were hearing,
3 and put together the SIP model, the serious
4 illness population model, that they've recently
5 announced.

6 So I've had the opportunity to
7 firsthand see the importance of PTAC, see the
8 way that it can make participants and folks who
9 are bringing models to improve their models,
10 and then seeing how CMMI can use that
11 information to roll out a model for the whole
12 country.

13 And so I just want to start by
14 saying I deeply understand how important your
15 work is, how important it can be for providers
16 across the country, and how important it can be
17 from, for CMMI and CMS, in informing everything
18 today. I'll start just by talking a little bit
19 about sort of my time so far. So as you guys
20 know, I joined in January, and I spent the
21 first two months going through all of the
22 models that we have done.

23 It's about over 45 models now, and
24 trying to understand the impact that they had

1 had and lessons that we had learned.

2 Over the past few months, I have
3 obviously been holding to the COVID work,
4 almost working full-time on it in March and
5 April, but now I'm probably about 70 to 80
6 percent back to my CMMI job, and excited to dig
7 back in with the folks from PTAC, with the CMMI
8 team.

9 As we think about the next, the rest
10 of this year and going forward, maybe I'll
11 highlight a couple of areas that we're thinking
12 about, and some of the things that may be
13 helpful for your all's conversation.

14 So one piece is that as we went back
15 and reviewed all of the models, I think we had
16 a bunch of really important lessons learned.

17 So we've learned a lot about how to
18 think about benchmarking, the importance of,
19 for example, back-testing benchmarks on data to
20 make sure that they're fair and accurate, both
21 to participants and to the government.

22 We've learned a lot about
23 operations, how to make sure that we're
24 implementing our attribution really well, how

1 to make sure that we're being thoughtful about
2 the investments we're making, how to measure
3 quality metrics.

4 And I think one of the things that
5 you're going to see us focused on the rest of
6 this year is really operationally making sure
7 that we're supporting participants well, that
8 we're making sure all the existing models that
9 we have are successful, and by successful, I
10 really mean driving one of two outcomes: either
11 one, helping lower costs, or two, helping
12 increase quality. The other piece is we, of
13 course, are going to be thinking about the
14 things that have happened as part of COVID and
15 some of the flexibilities we've gotten
16 generated.

17 I know Administrator Verma probably
18 talked about this earlier today. The way from
19 the CMMI perspective that we're thinking about
20 those COVID flexibilities is that we'll start
21 by CMS reviewing them and deciding which of
22 those flexibilities makes sense to continue as
23 part of the core Medicare program, and then of
24 the other flexibilities that they're not

1 planning to continue, we will then evaluate
2 those for potentially incorporation into our
3 CMMI models, and especially in models where
4 participants are taking capitated risk or two-
5 sided risk, those are models we're going to
6 look to give participants as much flexibility
7 as possible.

8 Just talking a little bit more about
9 PTAC, and I think the ways that we can work
10 together, you know, number one is the kind of
11 feedback that you all have provided on models
12 to providers and participants has been
13 extraordinarily helpful. And I think you all
14 continuing to do that, us sharing lessons that
15 we're learning around benchmarking, some of the
16 challenges of adverse selection, et cetera, I
17 think would be, would be really helpful, and
18 potentially maybe we could even come back and
19 even share some of those lessons learned with
20 you all at some point.

21 I think a second piece will be
22 helping us think about new areas that we should
23 consider launching models. As an example, you
24 know, to date, we haven't done anything in the

1 behavioral health space.

2 We've done a few things, but we want
3 to do more in the social determinants of health
4 space. We've done a lot around post-acute
5 bundles but want to do even more there. And I
6 think being able to hear from you all, and hear
7 from providers across the country, ideas they
8 have, models they've tested, that will be
9 extraordinarily helpful, and what we're
10 committed to is anyone that you all recommend,
11 you know, we want to meet with them.

12 We want to understand their
13 recommendation. Where appropriate, we want to
14 incorporate that with everything else we're
15 hearing from across the country to roll out
16 models.

17 So overall, I just want to thank you
18 all for being great partners. We are here to
19 work with you. We are highly committed to
20 value-based care, hopefully as you saw in the
21 model flexibilities that we had, and look
22 forward to building a great partnership with
23 you all.

24 With that, I don't know if anyone

1 has any quick questions, but just appreciate
2 being able to be here.

3 VICE CHAIR TERRELL: Thank you, Mr.
4 Smith. Any questions?

5 CHAIR BAILET: Thanks, Brad. I look
6 forward to working with you. It's Jeff.

7 MR. SMITH: Thanks, Jeff.

8 VICE CHAIR TERRELL: All right.
9 Well, thank you for providing those remarks,
10 and hearing nothing from anybody else, I hope
11 you'll continue to listen in this afternoon,
12 but let's proceed with the proposal that we're
13 scheduled for this afternoon.

14 So to remind the audience, I'm just
15 going to reiterate the order of activities for
16 our review of a proposal. First, the PTAC
17 Members will make disclosures of any potential
18 conflicts of interest, and then we will
19 announce any committee members not voting.

20 Second, we will have a discussion of
21 the proposal that will begin with a
22 presentation from the Preliminary Review Team,
23 or PRT, charged with conducting the preliminary
24 review.

1 After the PRT's presentation, and
2 any initial questions from the PTAC Members
3 back to the PRT, the committee looks forward to
4 hearing comments from the proposal submitters
5 and the public, and then we'll deliberate on
6 the proposal. And then we'll vote.

7 I'm not going to go into the details
8 of, with how we do that, with respect to that,
9 as we reviewed that this morning, and I want to
10 make sure that we've got time for our
11 deliberations this afternoon.

12 So with that, let's just go ahead
13 and proceed forward with the proposal that we
14 have in hand this morning --

15 CHAIR BAILET: Grace.

16 VICE CHAIR TERRELL: -- or this
17 afternoon, which is the thing. Yes?

18 CHAIR BAILET: I didn't mean to
19 interrupt, but I just wanted to make sure, I
20 think I saw Jennifer had a question -- just
21 circling back. Jen, it may have, the time may
22 have passed, but I just wanted to make sure --

23 VICE CHAIR TERRELL: Yes, sorry.

24 CHAIR BAILET: -- to give you an

1 opportunity.

2 VICE CHAIR TERRELL: You handed with,
3 for, so for whatever reason, it's been slow to
4 show you when you have questions on our,
5 because I think that happened to you this
6 morning. Was that for Brad Smith? Okay. All
7 right.

8 I apologize. Is he still available,
9 where we could get him back on? If not, my
10 apologies. Okay. All right. Well, Jeff, just
11 stop me quicker next time, okay?

12 CHAIR BAILET: Okay. Sorry, Grace.

13 * **Deliberation and Voting on the**
14 **Patient-Centered Asthma Care Payment**
15 **Proposal submitted by the American**
16 **College of Allergy, Asthma, &**
17 **Immunology**

18 VICE CHAIR TERRELL: Okay. So the
19 proposal that we are now getting ready to
20 discuss is the *Patient-Centered Asthma Care*
21 *Payment*. It was submitted by the American
22 College of Allergy, Asthma, & Immunology, or
23 ACAAI.

24 * **PTAC Member Disclosures**

1 VICE CHAIR TERRELL: So let's now go
2 through and read in, or declare any conflicts
3 of interest or disclosure statements. And just
4 as Jeff did this morning, I'm just going to go,
5 since it's virtual, I'm just going to go
6 through and prompt you one at a time.

7 So Grace Terrell, CEO of Eventus
8 WholeHealth, and I have nothing to disclose.
9 Next is Jeff.

10 CHAIR BAILET: Jeff Bailet, CEO of
11 Altais. I have nothing to disclose.

12 VICE CHAIR TERRELL: Paul?

13 DR. CASALE: Paul Casale, New York-
14 Presbyterian, nothing to disclose.

15 VICE CHAIR TERRELL: Charles?

16 DR. DESHAZER: Charles DeShazer, CMO
17 of Highmark Inc. Nothing to disclose.

18 VICE CHAIR TERRELL: Kavita?

19 DR. PATEL: Hi, Kavita Patel,
20 Brookings Institution. Nothing to disclose.

21 VICE CHAIR TERRELL: Angelo?

22 DR. SINOPOLI: Angelo Sinopoli, Chief
23 Clinical Officer of Prisma Health. Nothing to
24 disclose.

1 VICE CHAIR TERRELL: Bruce?

2 MR. STEINWALD: I'm a health
3 economist in Washington D.C., and have nothing
4 to disclose.

5 VICE CHAIR TERRELL: Jennifer?

6 DR. WILER: Jennifer Wiler, Chief
7 Quality Officer, UCHealth, Denver, and
8 professor at University of Colorado School of
9 Medicine.

10 VICE CHAIR TERRELL: Nothing to
11 disclose?

12 DR. WILER: Nothing to disclose.

13 VICE CHAIR TERRELL: Okay. All right.
14 Thank you all, and I'm going to now turn the
15 microphone to the lead of the Preliminary
16 Review Team for this proposal, Angelo Sinopoli,
17 to present the PRT's findings to the rest of us
18 on the full PTAC.

19 * **Preliminary Review Team (PRT) Report**
20 **to PTAC**

21 DR. SINOPOLI: First, welcome to the
22 afternoon session, and big thanks to my fellow
23 PRT committee members, Jeff Bailet, and Bruce
24 Steinwald.

1 If we could flip to the next slide,
2 and we're going to review the PRT composition
3 and roles, then the proposal overview, and then
4 the summary of the PRT review, identify and
5 discuss some key issues, and then we'll go
6 through each of the 10 criteria. Next slide.

7 So in terms of the team composition
8 and role, we did review some of this this
9 morning. So the PTAC Chair and Vice Chair
10 assigns two to three PTAC Members, including at
11 least one position to each complete proposal to
12 serve as the PRT.

13 One of the PRT members has to serve
14 as the lead reviewer. PRT identifies additional
15 information needed from the submitter, and
16 determines what extent, if any, additional
17 resources and/or analyses are needed for the
18 review.

19 Assistant Secretary for Planning and
20 Evaluation, ASPE staff, and contractors support
21 the PRT in obtaining these additional
22 materials. The PRT determines, at its
23 discretion, whether to provide initial feedback
24 on a proposal.

1 After reviewing the proposal,
2 additional materials gathered, and public
3 comments received, the PRT prepares a report of
4 its findings to the full PTAC. The report is
5 posted to the PTAC website at least three weeks
6 prior to the public deliberation by the full
7 committee.

8 Important to know that the PRT
9 report is not binding on the PTAC. The PTAC may
10 reach very different conclusions than those
11 contained in the PRT report. Next slide.

12 We'll briefly review the proposal.
13 So background, asthma across the United States
14 affects about 26.5 million people including
15 about 3 and a half million Medicare
16 beneficiaries.

17 The submitter estimates that
18 Medicare spends about 454 million on asthma-
19 related emergency room visits and about 1.1
20 billion on asthma-related hospitalizations.

21 If correctly diagnosed and managed,
22 asthma does not have to be a life threatening
23 and costly disease. The goal of this proposal
24 intends to give physicians specializing in

1 asthma care, primarily allergists and
2 immunologists, the resources and flexibility
3 they need to better diagnose and manage
4 patients with asthma.

5 The proposal seeks to save costs and
6 improve quality by avoiding unnecessary
7 hospitalizations and ED visits with better
8 diagnosis and management of patients with
9 asthma. Alternative payment model entity, and
10 they describe an asthma care team consisting of
11 an asthma specialist, such as an allergist or
12 an immunologist, a primary care provider, as
13 well as other providers, as needed. Next
14 slide.

15 The core elements of the program are
16 dividing asthma care into three categories for
17 varying levels of care. These are needed for
18 treatment stage, disease severity, and therapy.

19 Number one is diagnosis and initial
20 treatment for patients with poorly controlled
21 asthma. The next phase would be continued care
22 for patients with difficult to control asthma,
23 and the third would be continued care for
24 patients with well-controlled asthma.

1 Beneficiary eligibility and payment
2 around, excuse me, amounts from participating
3 ACT²⁵s differ in each category. The PCACP
4 excludes asthma patients with certain
5 comorbidities, such as COPD²⁶ and lung cancer,
6 and additionally, participating asthma patients
7 are excluded from all performance assessment
8 measures if they fail to stop smoking, obtain
9 certain prescription, or fail to obtain
10 prescription medications or attend scheduled
11 appointments.

12 Performance on service utilizations,
13 spending, and quality is assessed relative to
14 other participating ACTs, with adjustments to
15 the PCACP payments based on performance.

16 ACTs must meet minimum quality
17 standards to receive the bundled payments in
18 Categories 1 and 2. The next slide.

19 We'll go into a little bit more
20 detail about the various categories. The
21 category one is defined as the diagnosis and
22 initial treatment for patients with poorly-

25 Asthma Care Team

26 chronic obstructive pulmonary disease

1 controlled asthma, and eligibility for this
2 criteria is a new patient with asthma symptoms
3 without a diagnosis in the last year, or those
4 with poorly-controlled asthma, or are on
5 treatments that are not consistent with the
6 current guidelines, or, and are enrolled by
7 physicians at the initial visit.

8 Payment, bundled monthly payments for up to
9 three consecutive months, replacing some fee-
10 for-service billing for evaluation and
11 monitoring in E&M²⁷ codes for asthma-related
12 clinical services and collective tests.

13 Payments are stratified in this
14 particular category, and up to five levels
15 based on patient risk. Initial adjustments and
16 payment would be up or down five percent,
17 payment based on performance increasing to up
18 or down nine percent over time.

19 Performance measures would include
20 care quality, percent of patients with improved
21 asthma symptoms, improved spirometry measures,
22 reduced ED or urgent care visits, and ratings
23 on practice access.

27 Evaluation & Management

1 Service use and spending, the
2 average number of months to diagnosis of
3 asthma, the price-standardized average total
4 per patient spending on allergy testing, asthma
5 medications, urgent and ED visits for asthma
6 symptoms, and asthma-related hospitalization.
7 Next slide.

8 So the next category was care for
9 those, continued care for patients with
10 continued difficult to control asthma. The
11 eligibility here, beneficiaries who do not have
12 well-controlled asthma after medication trials
13 are those taking certain essentially high-risk
14 medications or with recent severe symptoms or
15 hospitalizations or significant comorbidities.

16 The payment, again, is a bundled
17 monthly payment replacing some fee-for-service
18 billing in E&M codes for asthma-related
19 services and selected tests.

20 The payment in this category is
21 stratified into four levels based on patient
22 risk. Initial adjustment, again, is similar to
23 the previous phase, up or down five percent, or
24 increasing to up or down nine percent over

1 time.

2 The performance measures here are
3 care quality, as it relates to improved asthma
4 control, decreased control, and rating of
5 active access.

6 The service utilization and spending
7 performance measures are assessed using the
8 price-standardized measures, as outlined
9 previously in category one. Next slide.

10 Category three is defined as
11 continued care for patients with well-
12 controlled asthma, and eligibility here,
13 patients with well-controlled asthma who were
14 previously enrolled in categories one or two.

15 From the payment perspective,
16 monthly supplemental payment that covers non-
17 face-to-face visits and communication between
18 physician. The performance measures here around
19 quality and just a percent of patients with
20 decreased or worsening asthma control, percent
21 of patients rating access to physician practice
22 as very good or excellent. Service utilization
23 and spending measures use price-standardized
24 average total per patient spending on allergy

1 testing, asthma medication, urgent and ED
2 visits for asthma symptoms, and asthma-related
3 hospitalizations as described in categories one
4 and two. And that is a very high level review
5 of the proposal.

6 As we walk into the summary of our
7 PRT review, I would like to start out by saying
8 that there was a great appreciation of this
9 submitter trying to move us forward with our
10 first specialty-oriented APM, and there's
11 clearly a lot of attention to detail in this
12 submission, particularly related to sticking to
13 well-known asthma guidelines from a clinical
14 stratification model that was very detailed.

15 The PRT committee did find some key
16 issues that influence our thoughts as we review
17 the criteria, so if we move on to the next
18 slide, we'll be starting to go through some of
19 that.

20 So just at a high level, some of the
21 key issues that we identified was that the
22 proposed model lacks sufficient scope for
23 implementation as a stand-alone APM.

24 We'll talk about that in a little

1 more detail as we move forward. With three
2 separate phases, diagnosis, difficult to
3 follow, and controlled follow up, each having
4 monthly evaluation and within each having four
5 to five different payment levels in each phase,
6 determined the patient clinical stratification,
7 we thought that this was a highly complex
8 model. The program includes the potential to
9 maximize bundled payments through patient
10 selection, because the patients are selected at
11 the end of the month after, or at least
12 assigned to a payment model, after the month of
13 care.

14 The proposal also falls short in its
15 approach to care coordination. In regards to
16 its lack of focus on social determinant, the
17 transportation, copayments, et cetera, in a
18 Medicare population who is known to have more
19 comorbidities, and debility and needs support
20 than most other younger patients might need.
21 Next slide.

22 The proposal does not clearly
23 identify how the Medicare fee-for-service
24 payment system, as it exists today, causes

1 failures and ability for a doctor to make an
2 accurate diagnosis, and throughout the
3 document, refers frequently to a focus on the
4 need for increased fee schedule rate.

5 And next, the proposal may overstate
6 the possibility of saving, citing a 50 percent
7 reduction in ED visits and hospitalization in
8 this Medicare population.

9 Inclusion of some tests, but not all
10 tests, increases complexity and could further
11 reduce potential savings. Allocation of the
12 payment from the specialist to the primary care
13 physician in the second phase was left
14 unspecified and not clear as to what specific
15 changes in activity this would aim to improve.
16 With that, we'll go into the individual
17 criterion. Go to the next slide.

18 So scope, the PRT committee felt
19 that from a scope perspective, this did not
20 meet [the] criterion, and the decision there
21 was unanimous. We did agree that no APM and CMS
22 today specifically addressed asthma, and it is
23 a chronic condition with a high prevalence in
24 the general population.

1 However, looking at various data
2 sources, as you look at patients above 65, the
3 CDC, for example, estimates that from an ER
4 visit standpoint, that there may only be
5 126,000 visits a year, with about 24,000
6 admissions, and that the cost of those was
7 somewhat less than we suggested in the
8 proposal.

9 Also, with the exclusion of certain
10 cohorts from this asthma population, like those
11 that also have concomitants such as COPD would
12 significantly decrease the number of patients
13 eligible for this model, and then some of the
14 data discussed above 60 percent of all asthma
15 patients above 65 reduce the cost of care have
16 concomitant COPD.

17 Also, taking into consideration,
18 this age population who may already be enrolled
19 in Medicare Advantage or other models, which
20 may also exclude them from this model,
21 continues to push the number of eligible
22 patients even lower. And patients with asthma
23 and, it also participates in other APMs like
24 ACO, where those models were available. Next

1 slide.

2 So from a quality and cost
3 standpoint, again, the proposal recognizes the
4 need to facilitate physician engagement and
5 emphasized shared decision making between the
6 patients and provider.

7 However, the potential Medicare
8 savings, we felt, could be significantly
9 overstated by assuming that effects on improved
10 asthma care in this particular population would
11 be comparable to that in the younger
12 population. Most of the data was around younger
13 populations, and there was most specific data
14 related to the Medicare population.
15 Furthermore, using the submitters numbers of
16 about \$1.5 billion of total spent for the ER
17 and hospitalization, even if they were able to
18 decrease those costs by 50 percent, that would
19 result in \$750 million in savings, all covered
20 before you removed the patient with COPD, and
21 if only achieved a 20 percent, 25 percent
22 improvement would bring that down to 375
23 million. Even previous discussions we had with
24 Adam Boehler and CMMI on our goal of trying to

1 obtain a scale of \$10 billion -- that was a
2 significantly lower number than we thought
3 would hit that goal.

4 And again, the model does not
5 contain provisions to address social
6 determinants of health, as mentioned before.
7 And the model also, again, did not delineate
8 how the care between the primary care and the
9 specialist would look, and what that
10 specifically was trying to insinuate. Next
11 slide.

12 Criterion 3, the proposal model is,
13 in our opinion, highly complex with multiple
14 tracks assigned by provider assessment within
15 the three main categories, and this is then on
16 a monthly basis.

17 We felt like this complexity could
18 make it difficult for providers to participate,
19 and particularly for payers to administer. The
20 proposed payment models are based on a monthly
21 risk model, yet a participating provider has
22 discretion to determine which patients are
23 included at the end of each month.

24 No attribution or assignment is

1 preferred. Recent improvements in the Medicare
2 physician fee schedule are intended to support
3 these types of care in the PCACP's proposal.

4 The proposal does not identify, and
5 we felt that this was a significant question,
6 as the proposal does not identify how the
7 present Medicare fee-for-service payment system
8 causes failure in a physician to accurately
9 diagnose asthma or prevent them from ordering
10 the tests or prescribing the medication that a
11 patient needs to successfully manage their
12 asthma. Next slide.

13 The value over volume, PRT
14 unanimously felt that this does not also meet
15 criteria. The proposed model, sorry, the
16 proposed model provides a payment amount to
17 enable providers to tailor services to patient
18 need, certainly.

19 The monthly framework and the
20 ability [to] potentially enroll patients that
21 would be financially beneficial to the provider
22 reduces accountability of the sole provider.

23 The mechanics of the proposal seem
24 insufficient to consistently drive more value

1 than is what's currently available in the
2 standard fee-for-service model.

3 The proposed model does not clearly
4 address major known drivers of improved health
5 among Medicare patients, again, determinants of
6 health. Next slide.

7 Flexibility, we did feel like it met
8 the criteria for flexibility. The proposed
9 payment model would give participating
10 providers and patients flexibility to provide a
11 broader range of services that could be
12 beneficial in diagnosis and controlling asthma,
13 although once the patient commits, the patient
14 is limited to receiving all of their care from
15 that particular specialist during that time
16 period.

17 However, it is still unclear how the
18 patient's primary care provider and asthma care
19 specialist would work together to improve the
20 flexibility and benefit to the patient. Next
21 slide.

22 Ability to Be Evaluated. The PRT
23 committee did not feel like this made the
24 criteria, met the criteria. The proposed model

1 recognizes the importance of evaluation and
2 notes that the types of data that would be
3 available for model participant, including
4 claims, patient-reported outcomes, and EMR
5 data. However, the complexity of the proposed
6 model is that the five payment levels within
7 each phase, and potentially one-month
8 intervals, during each, along the entire course
9 of patient care could make it difficult to
10 evaluate.

11 It would be hard to determine
12 whether or not the proposed model saves money,
13 given the proposal does not have a present
14 benchmark. Proposed evaluation comparison is to
15 performance by other ACTs, which don't exist
16 today, but even if they did, controlling,
17 comparing ACTs to another ACT, rather than to
18 standard asthma care, we thought was somewhat
19 problematic. Next slide.

20 Integration of care coordination, we
21 felt like this does not meet criterion. The
22 model emphasizes co-management between primary
23 care, yet does not specify how care would be
24 coordinated between primary care physicians and

1 asthma specialists beyond what happens, or
2 should be happening today, and how this is
3 improved on. The model does not elaborate on
4 care management outside the office, other than
5 an occasional contact by respiratory
6 therapists. Some practices, such as phone calls
7 to coordinate with other providers, we felt
8 were expected under current standard care.

9 The proposal also does not address
10 how care coordination might evolve over the
11 course of the model, such as when a patient
12 moves from a difficult to control phase to a
13 well-controlled phase.

14 Without clear guidelines, the
15 negotiations between the PCACP, payments
16 between providers in each circumstance could be
17 burdensome to providers and practice, and may
18 hinder the coordination.

19 The model does not identify specific
20 innovations in care delivery or approaches to
21 improve care for patients with asthma that
22 would be included beyond tools already
23 available in a fee for service model. Next
24 slide.

1 We did believe that patient choice,
2 that that criterion was met. The proposal notes
3 that this enhances patient choice by providing
4 an additional option and desirable services for
5 patients.

6 On the other hand, patients would be
7 required to commit to receiving all asthma
8 services during the month covered by the
9 payment, which could hinder patient choice from
10 that aspect. Next slide.

11 Patient safety standpoint, we did
12 believe that it met criteria. The submitters
13 expect that this model would promote early and
14 accurate diagnosis, encourage timely
15 development of care plans, educate patients,
16 facilitate identification of asthma
17 exacerbations early.

18 The proposal also notes that the
19 proposed minimum quality standard would protect
20 patients from under treatment. The emphasis on
21 provider/patient conversations determining
22 decision making is a strong element of the
23 proposal. Next slide.

24 From a health IT standpoint, we felt

1 that it met criteria The proposal indicates
2 that regular electronic communications between
3 specialists and primary care would be required,
4 and the payments in the proposed model could be
5 used to support outreach and remote monitoring
6 through the technology that helps manage asthma
7 and patient compliance.

8 So again, I would say in summary
9 that our biggest concerns were the scope of the
10 complexity of this payment model and the
11 concerns around how the present fee-for
12 service-model prohibits accurate diagnosis and
13 management of asthma patients today. That's my
14 presentation.

15 VICE CHAIR TERRELL: Thank you,
16 Angelo. Any comments from either of the other
17 two members of the team, where we ask any about
18 the rest of this if we've got questions for
19 you.

20 MR. STEINWALD: This is Bruce. I was
21 going to emphasize what Angelo did emphasize in
22 his final remarks, is that we don't, we won't
23 deny that there are certainly some Medicare
24 beneficiaries whose asthma won't be better

1 controlled over this model.

2 But I just want to condense that the
3 extent of the problem warrants in a larger
4 model this complexity and it's difficult to
5 evaluate that, and that's clearly the big
6 picture, a problem.

7 CHAIR BAILET: Yes. And so Grace,
8 this is Jeff. I just wanted to say that I think
9 it's noteworthy that the submitters are trying
10 to get a specialty-based model for allergists
11 and pulmonologists into the field.

12 I also think that their approach on
13 building out a model that really emphasizes
14 team-based care is important, and I think that
15 Angelo's summarized our overall assessment of
16 the, of the proposal, and I'll save the rest of
17 my comments to address with the submitters.
18 Thanks.

19 * **Clarifying Questions from PTAC to**
20 **PRT**

21 VICE CHAIR TERRELL: Okay. So I've
22 got, I received a message, and, during this
23 from the team that Dr. Kavita Patel lost video
24 and is on the phone.

1 So since I can't see a tent, I see
2 nobody else that's right now asking questions.
3 It looks like Paul has one. Jennifer, it seems
4 I keep missing you. Are you sure you don't have
5 one? But let's make sure that Kavita also is
6 able to communicate with us if she's got one or
7 not.

8 DR. PATEL: Thank you. I'll save my
9 question for the presenters.

10 VICE CHAIR TERRELL: Okay. Paul, do
11 you have a question for the PRT?

12 DR. CASALE: Yes. Just one of the,
13 one of the issues highlighted here was the
14 complexity, and well-described, and I just
15 wondered, in your communications with the
16 submitter, the submitter, I'd be interested in
17 their thoughts as well. But in your
18 communications with the submitter as you
19 evaluated with it, with them, was there any
20 thoughts around, or is it better, did you
21 obtain a better understanding of why it has to
22 be so complex?

23 I wasn't sure I clearly sorted that
24 out by reading the material. Is there a way to

1 simplify it, I guess?

2 DR. SINOPOLI: Yes, I think that's a
3 great question, and we'd be interested to see
4 how they respond.

5 In our communications with them, I
6 think their focus was that, from their
7 viewpoint, this seemed to be simpler than the
8 present ICD-10 criteria that doctors have to
9 document today, and so that was, that was their
10 rationale.

11 VICE CHAIR TERRELL: I'm not seeing
12 any other questions. If you had some, flap
13 your, flap your name. I don't see any. Okay.

14 Well, hearing or seeing no others,
15 then at this point, we're going to introduce
16 and move on to our actual presenters
17 themselves. So we have three new presenters
18 from ACAAI join us by Webex.

19 I would like all of you to introduce
20 yourselves, and you have 10 minutes to make
21 opening comments, and then we're going to open
22 it up for questions for all of the PRT members
23 to ask you for clarification of different
24 things about your proposal, and I want to thank

1 all of you for being here.

2 So we have three individuals that
3 are, that are going to be presenters. Dr. James
4 Tracy, Dr. James Sublett, and Bill Finerfrock.
5 So I'm going to just turn the mic over to you
6 all and let you have the 10 minutes to tell who
7 you are and tell us about your proposal.

8 * **Submitter's Statement**

9 DR. TRACY: Thank you.

10 (Telephonic interference)

11 DR. TRACY: My name is James Tracy.

12 I am the --

13 (Telephonic interference)

14 CHAIR BAILET: You've got, if you
15 could, if you could mute, just make sure that
16 you are, others on the phone, so you might be
17 getting some feedback from other folks. It
18 looks like, it looks like Bill is lighting up,
19 so he needs to mute. Thanks.

20 DR. TRACY: Thank you. Are we good?

21 CHAIR BAILET: Sounds good.

22 DR. TRACY: All right. Thank you.

23 The, I'm Jim Tracy. I am in private practice in
24 Omaha, Nebraska. I'm an Associate Professor of

1 Pediatrics at the University of Nebraska, and
2 Associate Professor of Internal Medicine at
3 Creighton University, and Dr. Jim Sublett's
4 also on the call. Jim, could you introduce
5 yourself, please?

6 DR. SUBLETT: I've got to unmute
7 myself. I'm Dr. Jim Sublett. I've been in
8 practice 41 years, still see patients in our
9 multi-site practice.

10 I'm the past president of American
11 College of Allergy, Asthma, & Immunology, was
12 Chief of Allergy and Immunology at the
13 University of Louisville for 20 years, before
14 stepping down a couple years ago.

15 I've been long interested in asthma
16 disease management, and some of the questions
17 and discussions we're having today date back
18 probably 30 years, when that first emerged in
19 the early '90s. We'll explain some of our
20 complexity issues later as we go along today.

21 DR. TRACY: Bill Finerfrock?

22 MR. FINERFROCK: I'm Bill Finerfrock.
23 I work as a consultant to the college and the
24 advocacy council on this project and a number

1 of other issues, and I've been involved in
2 health policy for about 40 years. Thank you.

3 DR. TRACY: All right. Thank you very
4 much. As, on behalf of American College of
5 Allergy, Asthma, & Immunology, I thank you for
6 the opportunity to discuss our patient-centered
7 asthma care payment proposal.

8 In my 40 years of practice in
9 medicine, I've been amazed by the number of
10 patients of all ages that come in to me
11 believing that they have a disease, and yet
12 really having that condition often due to
13 misdiagnosis.

14 Or conversely, patients who do not
15 know that they have a condition or disease, and
16 opportunities are missed. This is true to the
17 case with asthma.

18 In about 20 percent of the patients
19 labeled as having, as having asthma do not
20 come, do not actually have the diagnosis of
21 asthma. And about the same number are not
22 properly recognized as asthmatic.

23 In either case, the outcome can be
24 costly in terms of dollars, and of course

1 quality of life. Asthma is a condition that
2 spans all age groups.

3 It does not leave the elderly
4 untouched, and the consequences of missed
5 treatment or overtreating can be considerable.
6 The College's proposal is a novel APM, and the
7 first condition-based model designed to support
8 the timely and accurate diagnosis of the
9 chronic condition.

10 This model is designed for
11 collaboration between patients' primary care
12 physicians and asthma care specialists, holding
13 the asthma care team accountable for both
14 outcomes and costs.

15 And just as there are consequences
16 with a particular course of treatment, such as
17 cost or side effects, there's also similar
18 consequences in not taking the necessary course
19 of treatment.

20 Accurate diagnosis is critical, and
21 a necessary step impacting both the outcome and
22 the cost of this disease. This is the
23 cornerstone of the PCACP. The model is designed
24 to achieve multiple objectives.

1 The first, to ensure accurate
2 diagnosis of asthma, also to promote local
3 delivery of health care, and promote the
4 mechanism by which specialists most able to
5 care for the difficult to control asthma
6 patient are involved in their care.

7 Improve overall outcomes including
8 decreases in premature death, ER²⁸ visits, and
9 hospitalizations, obviously reducing overall
10 costs, and finally, to provide a value-driven,
11 integrated asthma care team held accountable
12 for meeting quality and cost measures --

13 (Telephonic interference)

14 DR. TRACY: -- specialist, primary
15 care provider, and community-based services.
16 The PRT and the review of January 20, 2020
17 reported that the PCACP did not meet criteria
18 in six of the 10 criteria specified by the
19 Secretary.

20 Three were specified as, quote,
21 "high priorities", those being scope, quality,
22 and cost, aim of methodology, and we'd like to
23 address those briefly right now.

1 The PRT notes that the limited scope
2 and applicability of asthma in Medicare
3 populations is about seven percent in 2018. We
4 do believe that, although the numbers can vary
5 between 3.5 and 4.4, this number is not a
6 trivial number.

7 The PRT suggested COPD should've
8 been included in our model. Yes, COPD is common
9 in this population, especially when considering
10 the overlaps combining asthma and COPD, thus
11 making the diagnosis of asthma even more
12 critical.

13 We chose to focus on asthma and
14 would be happy to discuss our reasoning during
15 the Q&A. As an example, just ask one of my
16 patients, Susan D. She is a 69-year-old retired
17 U.S. Air Force colonel, both underdiagnosed and
18 undertreated for well over 30 years. In her
19 case, she was part of a large integrated health
20 care system where the cost of care and
21 accessibility of care were clearly no obstacles
22 to care.

23 It was not until being evaluated and
24 managed by a small and attentive allergy

1 practice that adequate diagnosis and treatment
2 were achieved. Now, at 69 years of age, she's
3 actually able to be more active, sleeps through
4 the night, and has nearly normal lung
5 functions. In addition to a broad scope in
6 authorizing physician-focused payment model(s),
7 Congress specifically instructed CMMI to test
8 innovative models that are, quote, focused
9 primarily on physician services, by physicians
10 who are not primary care practitioners, and to
11 focus on practices of 50 or fewer
12 professionals.

13 Existing models, such as ACOs, are
14 geared towards large integrated practices or
15 health care systems that have a primary care
16 focus. Many small practices around the country
17 simply do not have the opportunity to
18 participate in these programs.

19 As Congress suggested, the PCACP
20 model is focused on physician services that
21 will be attracted to small single-specialty
22 medical practices, small multi-specialty groups
23 that may not be a part of an ACO or other large
24 health care system.

1 Under quality and cost, one of (the)
2 PRT's objections was that our APM probably
3 overstates the potential savings in the
4 Medicare asthma population by assuming the
5 effects of improved asthma care would marry
6 utilization, spending, and savings reported for
7 non-Medicare asthma population.

8 However, there is no evidence that
9 improved asthma care would be any less benefit
10 for older individuals than for younger adults.
11 In fact, the environmental scan produced by
12 PTAC states that individuals aged 65 and older
13 have the highest rate of asthma-related
14 hospital stays, and that the diagnosis of late
15 onset asthma among the elderly can be a
16 challenging problem and is often delayed.

17 This suggests potentially even
18 greater cost savings in the Medicare population
19 than with younger adults. Another PRT-stated
20 weakness is that most of the studies cited in
21 the proposal are for younger patients that may
22 not control for the fact that if a patient is
23 involved in a management program, say, due to
24 an exacerbation event, that their expenditure

1 may subsequently decline regardless of the, of
2 the treatment program that was implemented.

3 We'd like to point out that most
4 studies of health care interventions for all
5 types of diseases have the same issue. There
6 are no randomized control trials that support
7 current CMS APMs, so it's unreasonable to
8 criticize this proposal on that basis.

9 The PRT also states that the
10 program's quality measures could be improved by
11 adding objective measures of quality. This
12 model includes objective measures of quality,
13 including spirometry, fractional exhaled nitric
14 oxide, emergency room visits, and
15 hospitalizations. But also note, its subject
16 measures such as patient satisfaction and
17 perception of improvement are appropriate
18 outcome measures even in the MIPS²⁹ program.

19 Another weakness per the PRT is that
20 the PCACP does not address payment and care
21 management and how care and payment will be
22 coordinated between the primary care providers
23 and the specialists.

29 Merit-based Payment Incentive System

1 The proposal explains that patients
2 with well-controlled asthma would be managed by
3 a primary care provider with support by the
4 asthma specialist, and the difficult to control
5 asthmatic patients would be managed by the
6 asthma care team, assisting either of the
7 specialists or the primary care providers with
8 specialist support.

9 As more care is moved from the
10 specialist to the primary care provider, the
11 PCP would receive a larger share of the bundled
12 payment, although we do not believe it's
13 appropriate to be more specific, as divisions
14 of care may differ based on individual practice
15 and coordination arrangements.

16 Using evidence-based guidelines, our
17 model seeks to link stratified payment
18 methodology with shared risk, achieving cost
19 savings through fewer or no, preferably, ED
20 visits, hospitalizations, sick care visits, and
21 more efficient use of medications, as well as
22 to improve the quality of life for our
23 patients.

24 We want to acknowledge the PCACP

1 would be the first APM that explicitly requires
2 the team-based approach for the management of a
3 chronic condition. This shared team approach
4 would also include levels of shared risk,
5 making this approach especially appealing in
6 Medicare or any other carrier that we, and we
7 believe both specialty, primary care members
8 of, and primary care members of the team.

9 The PRT was critical of the PCACP's
10 payment model as being overly complex because
11 of three components of care. For those of us
12 that actually take care of these individuals,
13 this is the reality.

14 In point of fact, many patients do
15 not present with a chief complaint of asthma.
16 Often, it is something else, such as coughing,
17 or wheezing, or shortness of breath. And
18 unfortunately, many who come in with a
19 diagnosis really don't have asthma at all, but
20 they have something else.

21 Therefore, this appropriate
22 diagnostic issue is really a challenge, and
23 most challenging first step, and it allows for
24 cost savings by correct diagnosis. It's

1 noteworthy that there are approximately 26 ICD-
2 10 codes for asthma, but there is nearly 52
3 codes that may be presenting symptoms
4 eventually leading to the correct diagnosis.

5 We believe that the PCACP is the
6 type of model, the exact type of model that
7 Congress specifically wanted to see implemented
8 when it had enacted the model.

9 For that reason, we were surprised
10 that when critiquing our model that the PRT
11 suggested on more than one occasion that
12 properly managed ACO could perhaps achieve what
13 we were proposing through this model.

14 We do not believe that this should
15 be the benchmark against which the physician-
16 focused models are to be judged. We believe
17 that there are many weaknesses identified in
18 the, in the PRT are actually strengths in this
19 model.

20 Are there things that can be
21 improved that would increase the likelihood
22 that our proposal can add to the quality of
23 life for asthma patients and save even more
24 money to the system? Of course, but these

1 improvements will, we believe, evolve
2 organically as we learn the lessons of this
3 model and make adjustments and refinements.

4 But we cannot achieve this until we
5 put this model through a field test to make
6 adjustments where appropriate. Therefore, it's
7 our hope that you will see a sufficient merit
8 in this proposal to recommend the PCACP to the
9 Secretary for testing, so that we can learn
10 from it, make adjustments, [and] refine the
11 process.

12 We certainly appreciate the
13 opportunity to present our model today. It was
14 a very challenging format, and of course we
15 welcome questions. Thank you.

16 VICE CHAIR TERRELL: Thank you. And
17 you were right on time with 10 minutes, so I
18 don't know if you've practiced that or not, but
19 that was awesome.

20 DR. TRACY: We don't practice.

21 VICE CHAIR TERRELL: Anyway, thank
22 you, Dr. Tracy. At this point, I'm going to
23 open up the questions from my colleagues who
24 would like to ask them, and since we are in

1 this challenging virtual format, I'll be
2 calling on each of my colleagues who indicate
3 that they have a question or a comment. I'm
4 getting some text here, as is Jeff, to help us
5 state, to make sure we get anybody, because I
6 know we've missed at least Jennifer once in the
7 previous conversation. I'm just going to ask my
8 colleagues that if I say anymore, that you go
9 ahead and get off mute and just interrupt if I
10 miss you. And Dr. Tracy, we're going to
11 actually direct all the questions to you, and
12 then you can determine from your team who you
13 think best ought to answer it.

14 So with that, I'm going to look and
15 see what we've got going on. I've just heard
16 Jen is number one, so Dr. Wiler.

17 DR. WILER: Thank you very much.
18 Forgive me, but I have two questions. My first
19 question is based on some of the comments from
20 the PRT, so I would like to give you the
21 opportunity to respond.

22 The first is the concern around
23 patient selection, and this balance of
24 garnering patient engagement versus what could

1 be described as risk profiling that's favorable
2 to the provider, but not ultimately to the
3 patient.

4 Obviously this is an issue we see
5 often with regards to APMs, and that's patient
6 selection, and this balance of feasibility of
7 the payment model to be successful, and then
8 also adequately taking on risk.

9 That's my first question. And then
10 my second question is with regards to the
11 concern around scope. Obviously, asthma, large
12 problem in the United States, but when we're
13 thinking about payment models that may be
14 specific to Medicare beneficiaries, you
15 addressed this, but I'm curious, why not expand
16 it to other respiratory conditions, including
17 COPD.

18 And what I'm wondering is, is it
19 because of this concern of taking on risk for a
20 patient population where the outcomes may be
21 more challenging versus that of an asthma
22 population? Thank you.

23 DR. TRACY: Yes. Thank you. I'll go
24 ahead and get started, then I'll pass it off to

1 my colleagues. One of the disadvantages of
2 being in this virtual setting, if we were
3 actually in one of these committees, as I am
4 with the FDA³⁰, I could just kick him under the
5 table.

6 So I can't do that today. So kind
7 of, I'm going to start with that first
8 question, and there's no doubt that cherry-
9 picking can be an issue, and it's certainly
10 not, as you've pointed out, limited to the APMs
11 with asthma.

12 One of our, one of our hopes were
13 that we would have already tested this model
14 before we came to you and kind of work out some
15 of those details.

16 And so no, we recognize that that
17 can happen, and how we control for that is a
18 kind of, was actually a bit of a work in
19 progress. Circling back to the COPD, we looked,
20 before we chose asthma as the diagnosis that we
21 were going to work on the APM, we looked at a
22 number of disease states, and the problem is
23 that as you add complexity, how you measure

30 Food and Drug Administration

1 success also becomes more complex, so we wanted
2 to take a disease, in this case, asthma, that
3 had fairly decent outcome data with it, and
4 also some fairly stringent issues as far as
5 stratifying between mild, moderate, and severe.

6 Every time you throw in something
7 else into the mix, you could, you increase that
8 complexity. We, one of the big deals that we
9 faced was that there are a lot of conditions
10 presenting as asthma, for us as immunologists,
11 including ABPA³¹ and certainly bronchiectasis.
12 Those are fundamentally different.

13 They behave differently, both in the
14 clinical sense but also in the practical sense.
15 Dr. Sublett, would you like to kind of comment
16 on the other points that she raised?

17 DR. SUBLETT: I'd like to make a
18 couple of comments about COPD and asthma. You
19 know, we mentioned that they're, and we've
20 recognized certainly that overlap as a problem.

21 But the reports of this is, we often
22 will see the Medicare age group come in as
23 diagnosed as COPD but they're actually not

31 allergic bronchopulmonary aspergillosis

1 COPD, they're asthmatic.

2 I think there's a tendency for
3 primary care, urgent care, emergency rooms, et
4 cetera, when they see an elderly patient, or an
5 older patient with a chronic lung problem like
6 this, they immediately jump to COPD.

7 I'll give you an example. I have a
8 lady who I'd followed for a number of years.
9 Came in when she was 88 years old, had a lung
10 history of allergy, and her daughter brought
11 her in because she had been diagnosed as having
12 COPD. A non-smoker.

13 She had been homebound for a number
14 of years, and I saw her at 88, and was on only
15 albuterol bronchodilator nebulizations, PRN³².
16 We'd done an evaluation in the office.

17 Her lung function in the office
18 first day I saw her showed nearly a 40 percent
19 improvement. Fast forward six months later, she
20 was up at 70 percent. Fast forward two years
21 later, 100 percent.

22 She was not COPD. She was asthma,
23 and we see countless patients like this. But

32 When necessary, from the Latin pro re nata.

1 contrary to that, and this lady, by the way,
2 lived until she was 103 years old, 15 years
3 after I initially saw her with appropriate
4 asthma management, allergy management, et
5 cetera.

6 Contrast to that, COPD, the time
7 they hit the Medicare population are usually
8 pretty much fixed obstructive lung disease, and
9 they generally, as we all know, are on a pretty
10 much downward track.

11 And one of the unfortunate things we
12 see many times is that the people who have been
13 mislabeled are just expected to go on that
14 track, and we can change that. The other thing
15 that I'll comment on, the complexity of asthma
16 is by nature of the disease, and that's why our
17 plan is complex.

18 The way we look at this, when we
19 first see these patients, as Dr. Tracy
20 mentioned during his presentation, they come in
21 and we're often sorting out various parts of
22 what's going on with them.

23 Some, about 20 percent wind up not
24 being even asthmatic, and those will not stay

1 in this APM. They would be moved back over,
2 outside the APM, and hopefully treated for
3 their underlying disease.

4 What we call laryngotracheal reflux,
5 or vocal cord dysfunction, are frequently
6 misdiagnosed as having asthma, and they can
7 present as fairly severe asthmatics because
8 they're not recognized as having that
9 underlying problem.

10 So these patients will not remain in
11 the APM. Once they're in the APM, if they're
12 poorly controlled and we get them well-
13 controlled, we'll shift them over to the well-
14 controlled.

15 And I think that, as Dr. Tracy
16 mentioned, that is one of the key issues, is
17 these are not, we expect a number of these
18 patients to either, after the first phase, to
19 move over and out of that asthma track
20 entirely, and then the ones who do need
21 aggressive management will be on the poorly
22 controlled sector.

23 We get them controlled. We often
24 will be able to move them over. The other thing

1 I wanted to mention was the issues, or that you
2 asked for.

3 So we do have a number of these
4 patients, and by the nature of allergy
5 practices, that we deal with some of the issues
6 around indoor environments, smoking, et cetera,
7 as part of our practice, so that was probably
8 one reason we didn't emphasize that enough
9 maybe in our original proposal. And I'll turn
10 this over to either Jim or Bill, if they have
11 any other comments.

12 DR. TRACY: Bill, it's up to you.

13 MR. FINERFROCK: Thank you. I think
14 that, to go back a bit to the, what in essence
15 is the cherry-picking issue, and I think Dr.
16 Tracy referenced this, and it's a common
17 problem with many of the models, but
18 fundamentally, it stems from the fact that the
19 models don't appropriately take into account
20 the comorbidities or the social determinants of
21 health that impact the outcome of the patient
22 and create the incentive on the part of
23 providers to try and select patients that are
24 most likely to have the most positive outcome.

1 I think what's different here, and
2 has been referenced, is that the front end of
3 it, I'm trying to make sure that we have the
4 appropriately diagnosed patient, and also that
5 they get categorized into the proper area in
6 terms of the model, and the incentive to move
7 the patient from poorly managed to well-managed
8 and adjust the payments to take that into
9 account.

10 And if they're not managing it, if
11 that's going on, then they get penalized. So I
12 think those are important parts, and as Dr.
13 Tracy said, things that we see as strengths of
14 the model, the PRT seemed to think were
15 weaknesses, but we think if you think of it
16 differently, you'll agree with us that these
17 are actually strengths.

18 VICE CHAIR TERRELL: All right. I'm
19 going to move us along, because we had two
20 other questions that I see here, and I want to
21 make sure that we've got time to answer
22 everyone's, that you had time to answer
23 everyone's questions. So the next one is Dr.
24 Kavita Patel, I believe is next.

1 DR. PATEL: Mine's a simple one, and
2 I just, well one, I wanted to thank the
3 submitters. As one of those internists who has
4 gotten a diagnosis wrong myself, and made the
5 COPD diagnosis only to learn it was asthma,
6 yes, I do believe that there's some need for an
7 element of this somewhere.

8 I also struggled with some of the
9 things pointed out by the PRT. Question I had,
10 and I apologize, because I had a video crash,
11 so I missed about five minutes.

12 This could be for the submitters,
13 but anybody else in the PRT, if they have the
14 answer. Has there been aspects of this adopted
15 by private payers in any form? Just, we've been
16 talking about the Medicare population.

17 I could see, because of the
18 prevalence of asthma in commercial populations,
19 has this been something that has been adopted
20 in other places, and could you speak to how
21 that adoption has gone as a payment model?

22 DR. TRACY: I'll speak to that, Dr.
23 Patel. And then the other committee members --

24 (Telephonic interference.)

1 DR. TRACY: The, I -- the short
2 answer is, not that we're aware of. When we
3 crafted this, we actually started developing
4 this with that in mind that this wouldn't be
5 just a Medicare model, but this could be
6 extrapolated at a much broader scale.

7 But when we look back at it, we
8 can't find anything that blends in the shared
9 responsibility piece along with risk
10 stratification.

11 Kind of circling back to that
12 cherry-picker question, well so if we risk-
13 stratify our situation, and we, and we have
14 individuals who are going to be sicker, okay,
15 we, they're not going to be -- that will be
16 accounted for in your payment model.

17 So there's less incentive to cherry-
18 pick with this model because you're stratifying
19 it for the sicker patients. To be frank, we
20 want to take care of the sick patients.

21 We think we could do a good job, but
22 we also feel like there's a place for
23 stratification so that you don't cherry-pick.
24 Thank you. Anybody else can chime in here.

1 VICE CHAIR TERRELL: I'm going to
2 move us along, because I think you answered her
3 question. So I think Dr. Jeff Bailet is next
4 with a question.

5 CHAIR BAILET: Thanks, Grace. Again,
6 I want to compliment the proposed, the proposal
7 submitters for coming up with a specialty-
8 focused physician model, and again, compliment
9 the team-based approach, which I think is one
10 of the cornerstones of how the specialty and
11 primary care community can address better
12 serving patients.

13 My question, I'm trying to
14 understand the scope. You guys are, have
15 already clearly articulated why you didn't
16 include COPD, and when I looked at the senior
17 population, which this model is targeted for,
18 about 61, almost 62 percent of those folks have
19 COPD and asthma.

20 And then you also excluded lung
21 cancer, and that's another 3.5 percent. So just
22 on the math, about 65 percent of the population
23 of Medicare folks with a diagnosis of asthma
24 also have exclusion criteria.

1 In addition to that, there are folks
2 who get eliminated if they are smokers and they
3 don't cease to smoke. And just, again, in my
4 back of the napkin, and you guys can confirm
5 this, but from what I could be, what I could
6 ascertain about 18 to 20 plus percent, 20
7 percent, let's say, of seniors who have asthma
8 are smokers, and of those smokers with asthma,
9 it looks like -- the literature looks like
10 about 20 percent of those actually quit within
11 the first or quit and have quit by one year.

12 So I'm just trying to understand,
13 what is the universe of patients at the end of
14 the day that this model would apply to? Thank
15 you.

16 DR. TRACY: Dr. Sublett, you want to
17 take that?

18 DR. SUBLETT: Well I've already
19 mentioned the high rate of misdiagnosis. I
20 expect that some of those 61 percent of COPD-
21 ers are actually asthmatic.

22 My work over the years with disease
23 management, and I worked with a large managed
24 care company two years back, and they were

1 working on COPD, and I met with the group, and
2 I brought up the fact of overlap, and actually
3 that some of them were asthmatic, and there was
4 this deer in the headlights look, that it's not
5 even considered.

6 And I think that the numbers are
7 probably, you know, my feeling is they're not
8 accurate. I think as we get into this, we'll
9 find a lot more asthma that are not COPD-ers
10 than people realize.

11 As I mentioned already, a lot of the
12 diagnosis probably comes from primary care, who
13 don't have facilities in their practice
14 fulfilling the spirometry. The use of
15 fractionated nitric oxide has really helped in
16 determining whether patients, including those
17 who are smokers, and may actually be asthmatic.

18 I think the other thing, we're
19 seeing an aging population, and we know that
20 the numbers are actually probably pretty, I've
21 looked at the recent CDC data, and you can just
22 about roughly say that about 10 percent of the
23 general population are asthmatic.

24 Pretty much across the board, the

1 numbers fluctuate up and down a little bit year
2 to year, but if you look at the overall
3 numbers. So as we expect the Medicare
4 population to increase over the next few years,
5 we're going to see more and more likely
6 patients that are asthmatic.

7 The issue addressing smoking
8 cessation, that's been built into the practice
9 of allergists. That's what we do every day when
10 we look at patients, is their triggers, and
11 I've actually spent most of my career working
12 on things like small particulates, diesel
13 particulates, pollution, et cetera, that affect
14 asthma.

15 That's something we'll counsel
16 patients on. We're not going to give up on
17 them. I think, I think the issue in general was
18 non-adherence, and that's an important factor
19 in any kind of line of disease management, or
20 whether you keep beating your head against the
21 wall of people that are non-adherent.

22 We'd expect that number to be fairly
23 low in this kind of population management
24 approach. Bill, you may have some additional

1 information on the population we expect to see.

2 MR. FINERFROCK: Not of any great
3 amount. I mean I think your point was the one I
4 would've made, which is that, you know, we're
5 going to see a dramatic increase in the number
6 of Medicare beneficiaries, and there's no
7 indication that asthma is going to be any less
8 prevalent.

9 And so as those numbers go up, I
10 think it's going to be an even more significant
11 population, and the opportunities for savings
12 moving forward, not just looking at what we see
13 today, and looking in the, looking in the past,
14 but projecting forward that this is something
15 where there's a real opportunity to achieve a
16 different way of providing care, or provide
17 savings to the Medicare patient, and improve
18 the quality of life and the quality of care to
19 that population.

20 DR. TRACY: And I'll just, I'll just
21 add too that a lot of these issues, such as
22 smoking, we talked about this briefly,
23 compliance would be, we believe it would be
24 better in the integrated plan that we're

1 suggesting.

2 VICE CHAIR TERRELL: I have some
3 questions, but I want to make sure that Charles
4 and Paul and Angelo don't have any. I didn't
5 get any message that you did. Angelo, do you
6 have any questions? Somebody's telling me I'm
7 supposed to ask you that.

8 And we're not hearing you if you're
9 -- you may be on mute.

10 DR. SINOPOLI: Hello?

11 VICE CHAIR TERRELL: Hi.

12 DR. SINOPOLI: Can you hear me?

13 VICE CHAIR TERRELL: Yes.

14 DR. SINOPOLI: Okay. What I'd like
15 the team to comment on is how they feel this
16 Alternative Payment Model would solve what
17 sounds like an inability of the present fee-
18 for-service model to allow a doctor to make an
19 accurate diagnosis, and what about the fee-for-
20 service model impedes that accurate diagnosis?

21 DR. TRACY: Well there's several
22 things. First of all, and I should tell you,
23 this was kind of pre-COVID a little bit here,
24 but we, when we looked at this, a lot of the

1 things that we sort of feel should be a
2 critical element, which would include, by the
3 way, telemedicine, those really are not, again,
4 pre-COVID, were not particularly compensated
5 well for by Medicare.

6 And a lot of the other things that
7 we believe are part of the team, really
8 although some of them are technically included,
9 the practical reality is that the reimbursement
10 was pretty tough. And plus, there was a fair
11 amount of fragmented care.

12 I mean we hope that this will kind
13 of get to that point, but in any time when
14 you're having a fee for service, you're
15 incentivizing to see the patient perhaps even
16 more than you were before, and doing things
17 that you may not necessarily need to do or want
18 to do. Dr. Sublett, do you want to comment on
19 that at all?

20 DR. SUBLETT: I think, I think
21 looking at this from our standpoint of patients
22 we see, the fee-for-service discourages,
23 especially primary care from having the time to
24 spend with these patients for counseling.

1 We're talking about smoking
2 cessation, but one of the big factors is
3 avoidance of triggers and that sort of thing
4 that we can counsel.

5 Medication adherence, actually some
6 allergists actually have the ability to do
7 detailed environmental assessments, and now
8 that we have, you know, telehealth available,
9 that would be one aspect we could incorporate.

10 We talked about a lot of these
11 things theoretically, but I think it's -- Jim
12 just mentioned telehealth. In this, in the, you
13 know, the populations that we deal with,
14 there's a much higher rate of African Americans
15 who wind up in the hospital, who die from this
16 disease, about four times the rate of the
17 general population.

18 Those kind of patients, with some of
19 the other additional benefits of counseling and
20 so forth we bring to the table in our practices
21 would benefit, and working with primary care.

22 You know, primary care is interested
23 in this disease, but I think their time that
24 they can spend with the patient is so limited

1 that, especially in the difficult to control
2 patients, we're able to bring that to the
3 table, and working as a team results in much
4 better service than standard fee-for-service
5 that we see now.

6 VICE CHAIR TERRELL: Thank you. Any
7 questions from Paul or Charles? You don't have
8 to have any if you don't want to.

9 DR. CASALE: I don't have any
10 questions. Thank you, Grace.

11 VICE CHAIR TERRELL: Okay.

12 DR. DESHAZER: And no questions from
13 me. Thank you.

14 VICE CHAIR TERRELL: All right. I
15 have just a very quick question, and that's
16 related to the fact that this is very specific
17 to allergy and immunology and primary care, but
18 at least in my experience as an internist,
19 asthma involves other specialists quite often
20 as well, such as ENT³³ gets involved sometimes
21 as it relates to hoarseness or vocal cord
22 dysfunction.

23 Certainly, the pulmonologists take

1 care of a lot of asthma in my community, and
2 the gastroenterologists certainly do as a
3 result of the fact that 60 to 80 percent do
4 have GERD³⁴, at least in certain statistics, as
5 well as things like eosinophilic esophagitis.

6 So I guess my question is, by
7 limiting it to one specialty, which is really
8 intentional in that you're looking for a
9 specialty primary care-themed basis, my
10 question is: what is the role for the other,
11 rest of the team members that potentially may
12 need to be involved in the care, or in certain
13 communities, would be involved in the care of
14 patients with asthma?

15 DR. TRACY: You know, I am so glad
16 you asked that question. So when we started
17 this modeling, in your, in the initial
18 comments, when they were kind of going through
19 the model, I think we've talked about
20 allergists and immunologists.

21 So our starting point when we
22 started this thing was that it wasn't going to
23 be, even at the specialty level, just

34 gastroesophageal reflux disease

1 allergists and immunologists. It's asthma care
2 specialists.

3 Somehow pulmonologists got left off
4 the slide, but I want to make it really clear
5 that we include pulmonary in this. Basically,
6 in order to get CMS to buy off on this, which
7 would be our goal obviously, we have to, this
8 has to be attractive to all the stakeholders.

9 So when we looked at this, we looked
10 at it, so what would be attractive for
11 allergists and immunologists? Well that's what
12 we are, so we knew that was pretty
13 straightforward.

14 Definitely pulmonologists, for sure,
15 depending on where you are in the country, but
16 also to family doctors, pediatricians, and
17 internists. So that's the big picture. So let's
18 circle back to the other guys. So in GI³⁵, it's
19 definitely an issue. That's something that's
20 going to evolve with time. Clearly, that's
21 relevant. There's no doubt the ENT, and it's
22 not just with vocal cord dysfunction.

23 Sinus disease is probably even a

1 bigger player and very expensive. We actually
2 considered looking at sinus disease as one of
3 our APMs.

4 The complexity is colossal, and as
5 challenging as asthma is you start blending in
6 a surgical and a non-surgical specialty with
7 those two stakeholders, then you've got
8 conflict on you.

9 So we recognize that they're there.
10 How that actually evolves in the models, should
11 it be implemented, is definitely a work in
12 progress. Thank you.

13 * **Public Comments**

14 VICE CHAIR TERRELL: Okay. Well,
15 thanks, thank you, and if there are no, I'm
16 going to assume there's no other questions from
17 our commissioners, and we have four individuals
18 from the public who have signed up for public
19 comments, and I am going to open it up to each
20 of them in order.

21 And because of our time constraints,
22 I'm going to be pretty strict about this three-
23 minute rule here. And so I'm going to start
24 with Harold Miller, President and CEO of the

1 Center of Healthcare Quality & Payment Reform,
2 and look forward to your comments, Harold.

3 MR. MILLER: Thank you, Grace, and
4 thank you everyone for the opportunity to talk.
5 I sent you all a lengthy letter several months
6 ago, which I hope you had an opportunity to
7 read. I'm going to focus today just on a couple
8 of areas. At the very beginning of your
9 meeting, Administrator Verma talked about the
10 important role that telemedicine has been
11 playing over the past several months.

12 I think the broader lesson is how
13 dramatic the change in care delivery can occur
14 when CMS changes the payment rules. And it also
15 shows how Medicare, in fact, can lead when
16 everybody wants to know if the private sector
17 has done something first.

18 In this case, Medicare did it first.
19 The concern now is how do you actually continue
20 some of those services after the pandemic? And
21 you have a proposal here that specifically
22 allows telehealth as part of the payment model.

23 I was really disappointed to see
24 that the PRT report didn't even mention that

1 fact. And Administrator Verma and Jeff, at the
2 beginning of the meeting, talked about the
3 negative impact on physician practices with the
4 loss of office visit revenue.

5 This proposal has a monthly payment
6 model that would actually provide more
7 predictable revenue to the specialist, and the
8 PRT report, again, is actually inaccurate,
9 describing that aspect of the payment model.

10 The traditional concern about
11 telemedicine has been that it will increase
12 costs by creating yet more fees for services.
13 The concern about monthly payments has been
14 that they're too simplistic, and that they'll
15 actually decrease access for high need
16 patients.

17 So this proposal I think actually
18 does a really good job of trying to address
19 both of those things. Unlike any other model
20 the CMS has, under this model, there is no
21 payment at all if minimum quality standards
22 aren't met, and there's a clinically nuanced
23 risk stratification. I think it's very unfair
24 to criticize as overly complex something that's

1 trying to be nuanced and patient-focused and is
2 actually less complex than most of the other
3 existing CMS models are.

4 Finally, you know, there are very
5 few APMs for any specialist. Certainly none for
6 allergists or pulmonologists, and none
7 specifically for asthma, yet the PRT is
8 encouraging people to simply do this through
9 existing primary care medical home models and
10 ACO models, even though those models are
11 generally focused on trying to encourage PCPs
12 to keep patients away from specialists.

13 The APMs that specialists submit are
14 typically criticized because they fragment
15 care. This is the first APM ever that actually
16 proposes payments specifically designed to
17 focus specialty care on a subset of patients
18 who need it and to support coordination with
19 PCPs.

20 It could certainly work inside of
21 ACOs, but it can also work very well for small
22 practices in rural areas that don't have the
23 opportunity to participate in ACOs, or for
24 patients who don't need anything more than good

1 asthma care.

2 Jeff, at the very beginning,
3 described your vision as being a focus on front
4 line providers and their ideas. In this case,
5 that happens to be allergists that brought it
6 forward, a model focused on asthma, but I think
7 this model could be adapted to many other
8 specialties.

9 So I think the only way though we're
10 going to know really how it will work is to try
11 it, and we've seen what a dramatic change there
12 has been in the way carriers deliver recently
13 when we actually tried to do something
14 differently.

15 So I hope that you will actually
16 recommend doing that here, that CMS try this so
17 we can see how well it works rather than simply
18 speculating about that. Thank you.

19 VICE CHAIR TERRELL: Thank you.
20 Thank you, Mr. Miller, and I'm going to move
21 now to Sandy Marks, Senior Assistant Director
22 of Federal Affairs at the American Medical
23 Association.

24 MS. MARKS: Thank you. Good

1 afternoon. I'm Sandy Marks, and I'm pleased to
2 be making comments on behalf of the American
3 Medical Association. More than 25 million
4 Americans have asthma, including 4 million aged
5 65 or older.

6 Every year, there are more than a
7 million emergency department visits, and more
8 than 100,000 hospital admissions due to asthma.
9 Medicare is spending more than \$1 billion per
10 year on asthma-related hospitalizations.

11 Many of these ED visits and
12 hospitalizations occur because people with
13 asthma are not correctly diagnosed and treated.
14 Black and Latino people are disproportionately
15 affected by asthma.

16 Our Surgeon General, Jerome Adams,
17 has spoken eloquently about his own asthma and
18 the inequities in treatment for minorities.
19 Five years ago, the American College of
20 Allergy, Asthma, & Immunology began developing
21 a patient-centered approach to asthma.

22 They wanted to see asthma
23 specialists and primary care physicians working
24 together in teams to correctly diagnose

1 patients with asthma-like symptoms, and then
2 treat them in the most cost effective way.

3 They wanted more complex patients to
4 receive more intensive services in order to
5 reduce hospitalizations and mortality. They
6 found it impossible to deliver this patient-
7 centered approach under fee-for-service, so
8 they developed an APM to remove the barriers to
9 better asthma care.

10 The APM is designed to work for
11 diverse practices, large and small, and rural
12 and urban. We were disappointed that the PRT
13 failed to recognize the significant benefits of
14 this approach.

15 Most PTAC reports have been more
16 balanced, assessing strengths and weaknesses,
17 determining if the benefits outweigh any
18 concerns, and suggesting what could be done
19 differently.

20 The AMA³⁶ believes that proposed care
21 delivery model is exactly what is needed for
22 patients with asthma, and that similar
23 approaches are needed for other chronic

1 conditions.

2 Several major advantages of the
3 proposed APM were not recognized in the PRT
4 report. The APM is specifically focused on
5 improving health outcomes for patients with
6 asthma, not just reducing spending.

7 A significant flaw in other episode
8 models is that they assume patients are
9 diagnosed correctly, and that the treatments
10 are the right ones. The asthma proposal
11 explicitly supports diagnostic accuracy and the
12 effort involved in finding a treatment plan
13 that actually works.

14 Instead of treating all patients as
15 if they are the same, and penalizing physicians
16 who have higher risk patients, the proposed
17 model explicitly focuses resources on the
18 highest need patients.

19 We believe this kind of approach is
20 essential for improving health equity in this
21 country. For these reasons, the AMA urges you
22 to recommend implementation of the patient-
23 centered asthma care payment proposal. Thank
24 you.

1 VICE CHAIR TERRELL: Thank you, Ms.
2 Marks, and I'm now moving to Dr. Stephen
3 Imbeau, Allergist and Immunologist.

4 DR. IMBEAU: Thank you, Madame Chair
5 and committee. I am an allergist asthma doctor
6 in a small practice, in a small town, in a
7 small state, South Carolina.

8 Thirty percent of our patients are
9 Medicare, and that is, there's basically no
10 enhanced Medicare here. They're all just
11 regular Medicare. Thirty percent are Medicaid,
12 and that, on the other hand, the flip of
13 Medicare, is mostly managed care Medicaid.

14 And 40 percent are private
15 insurance, which happens, in South Carolina, to
16 be Blue Cross. I live in a region of a million
17 people.

18 There are no large employers, so we
19 have no ACOs, and we have, as I already
20 mentioned, almost all of just straight
21 Medicare. We, of course, are limited by the
22 Atlantic Ocean by our radius.

23 I must admit I have been surprised
24 this afternoon, listening to this, that it is,

1 the model is viewed as complex, and that we are
2 not handling environmental issues.

3 First of all, I am proud, there's
4 only 5,000 allergy asthma doctors in the United
5 States that are certified allergy immunology as
6 internists or pediatricians.

7 And so I'm really proud to be part
8 of a small specialty that has done this model.
9 For us, it's not complex. It's what we do every
10 day, and we do well at it.

11 So I certainly don't, as a sort of a
12 normal guy in the trenches, I don't view this
13 as complex. I'm also surprised about the
14 environment, because smoking is a big deal.

15 It triggers asthma, it can cause
16 other lung diseases, of course, but it's a
17 major trigger for asthma. We're about as anti-
18 smoking as any doctor you're going to find.

19 It's part of our normal deal, part
20 of our normal instruction, part of our normal
21 treatment and evaluation process, and including
22 diet and environmental issues, particularly
23 with mold and house dust.

24 It's interesting to me that,

1 particularly in the last six months, I have
2 seen an increased referral to our practice from
3 the Medicare population in my local community.
4 Several reasons.

5 One is, in this time of national
6 emergency, older patients who almost
7 immediately have pneumonia ruled out in the
8 emergency room are just sort of left there, and
9 then finally sent home on oral steroids, so
10 their family doctors say, you know, that's not
11 the right way to treat asthma, and they send
12 them to us.

13 Just last week, I saw a patient with
14 status asthma actually. Before I saw him of
15 course, he sat all day in an emergency room,
16 and then we were able to make the diagnosis and
17 offer substantial help.

18 We've been seeing that lady now
19 every week until we can get her stabilized. So
20 there's a real need for this kind of model and
21 cooperation with our family doctors and with
22 our emergency rooms.

23 I am surrounded, we are surrounded
24 here by two major competing hospitals in this

1 small town. They don't employ allergists
2 because we don't bring revenue to them, but we
3 can certainly work with their physicians and
4 their family doctors in particular are very
5 anxious for the education that they can get
6 from this model, and the understanding of what
7 we do. The value of spirometry, the value of
8 what we call FeNO³⁷, the value of methacholine,
9 the value of allergy testing and allergy
10 treatment, because even Medicare patients have
11 allergy, despite what you all might think. So I
12 think --

13 (Simultaneous speaking.)

14 VICE CHAIR TERRELL: -- stop now,
15 sir.

16 DR. IMBEAU: -- this model brings an
17 important thing to the small town and the small
18 rural environment. Thank you.

19 VICE CHAIR TERRELL: Yes. Yes, thank
20 you very much. I apologize, but we need to move
21 on to Dr. J. Allen Meadows, President of the
22 American College of Allergy, Asthma, &
23 Immunology.

37 fractional exhaled nitric oxide

1 DR. MEADOWS: All right. Thank you so
2 much for the opportunity to make comments. I am
3 president of the American College of Allergy,
4 Asthma, & Immunology, but I'm coming today as a
5 physician in private practice, a solo practice
6 here in Montgomery, Alabama, and like Dr.
7 Imbeau, it's a relatively rural area.

8 I helped with the development of
9 this, starting five years ago. I haven't been
10 involved with it very much recently, but with
11 the mind that anyone could participate in this,
12 whether you're in a big practice or whether
13 you're in a small practice.

14 And many of the top-down solutions
15 that have been proposed, I just can't
16 participate in them. I don't have access to
17 [an] ACO, and I am all in favor of payment
18 reform.

19 Oh my gosh, we need payment reform,
20 and I want to work with my primary care
21 physician, but they're just, some of the
22 solutions that are available now are just
23 something in a small community like mine, I
24 can't access.

1 The payment issues have been
2 mentioned. I mean, when, what an alternative
3 payment plan like this will open up for me is
4 that I'll be able to afford to buy a nitric
5 oxide machine.

6 The payments for the nitric oxide in
7 my community are so low that I can't even
8 pretend to break even. The same with
9 telemedicine or using a social worker to ensure
10 adherence.

11 Those are just things that I don't
12 have access to in a small area where we don't
13 have ACOs. I know there's been comments about
14 how complex this is, but like Dr. Imbeau said,
15 this is what we do every day.

16 This isn't complex to me. What's
17 complex to me is trying to form an ACO or join
18 an ACO and follow, and follow all those rules.
19 In closing, I'm just reminded of a patient in a
20 nearby community, that's actually Auburn-
21 Opelika, a smaller community than mine, but
22 they do have a large integrated group there,
23 and was referred a patient over there for
24 allergy testing, a lady that had COPD.

1 Well as it turns out, this lady
2 didn't have COPD. When we made the right
3 diagnosis and got her on the right medicines,
4 she had reversible lung disease, and her
5 quality of life improved dramatically. And the
6 big system failed her.

7 And so I would ask the committee,
8 and thanks so much for that, and give us a
9 chance on this one. We want to do something
10 different. This is a tremendous opportunity for
11 us, and I appreciate the opportunity to
12 comment. Thank you.

13 VICE CHAIR TERRELL: Thank you very
14 much to all of our public commenters, and we
15 had no other commenters after him, so before we
16 proceed to the voting, I want to make sure that
17 all of my fellow commissioners, do you have any
18 other comments, questions, or anything before
19 we move on?

20 Bruce, I apparently failed to ask
21 about you last time. For that, I apologize.

22 MR. STEINWALD: Apology accepted, but
23 I have no additional comments.

24 * **Voting**

1 VICE CHAIR TERRELL: Okay. All right.
2 So let's begin the voting process, and Jeff
3 went over this morning the methodology, and
4 unless there's an objection, I'm not going to
5 go over that again, but essentially we have 10
6 criteria we are going to vote electronically to
7 do that.

8 And then after we've gone through
9 the criteria, we will then vote whether to
10 recommend it with a recommended; or not
11 recommended with a recommended with high
12 priority; or whether to refer for further
13 attention on the part of CMS and CMMI.

14 So let's go ahead and go. I'm going
15 to have to go back down here and sign back into
16 my app, and we will go to the next criteria.

17 All right. And I have mine opened.
18 I'm going to assume everybody else has theirs
19 open too.

20 * **Criterion 1**

21 VICE CHAIR TERRELL: So the first
22 criteria is scope, high priority, aim to either
23 directly address an issue in payment policy
24 that broadens and expands to the CMS APM

1 portfolio, or include APM entities whose
2 opportunity to participate in APMS has been
3 limited.

4 Everybody go ahead and vote. All
5 right. They're all in. I'm going to turn it
6 over to Audrey.

7 MS. McDOWELL: I am going to expedite
8 the reading of the results. Zero members voted
9 6, meets or deserves priority consideration;
10 zero members voted 5, meets; two members voted,
11 excuse me, one member voted 4, meets; two
12 members voted 3, meets; four members voted 2,
13 does not meet; one member voted 1, does not
14 meet; and zero members voted, excuse me, 0, not
15 applicable.

16 We need a majority, which is, a
17 simple majority, which is five votes in this
18 case. And so in this case, for the Criterion 1
19 scope, the majority has determined that the
20 proposal does not meet Criterion 1.

21 * **Criterion 2**

22 VICE CHAIR TERRELL: All right.
23 Let's move to Criterion 2, please. This is
24 quality and cost anticipated to improve health

1 care quality at no additional cost, maintain
2 health care quality while decreasing cost, or
3 both improve health care quality and decrease
4 cost.

5 Go ahead and vote, please. Already
6 voted, so Audrey, tell us what we've got going
7 on here.

8 MS. McDOWELL: Zero members voted 6
9 or 5, meets and deserves priority
10 consideration; zero members voted 4, meets;
11 five members voted 3, meets; two members voted
12 2, does not meet; one member voted 1, does not
13 meet; and zero members voted 0, not applicable.
14 The majority has determined that the proposal
15 meets Criterion 2.

16 * **Criterion 3**

17 VICE CHAIR TERRELL: All right.
18 Let's move to Criterion 3, please. This is the
19 payment methodology, high priority criterion.

20 So the payment methodology, it would
21 pay the Alternative Payment Model entities with
22 a payment methodology designed to achieve the
23 goals of the PFPM criteria.

24 It addresses in detail through this

1 methodology how Medicare and other payers, if
2 applicable, pay the APM entities, how the
3 payment methodology differs from current
4 payment methodologies, and why the physician-
5 focused payment model cannot be tested under
6 current payment methodologies. Please,
7 everybody, go ahead and vote.

8 MS. McDOWELL: Zero members voted 6
9 or 5, meets and deserves priority
10 consideration; one member each voted 4, meets,
11 and 3, meets; five members voted 2, does not
12 meet; one member voted 1, does not meet; and
13 zero members voted not applicable. The majority
14 has determined that the proposal does not meet
15 Criterion 3.

16 * **Criterion 4**

17 VICE CHAIR TERRELL: Let's move to
18 Criterion 4, please. Value over volume, it
19 provides incentives to practitioners to deliver
20 high quality health care.

21 MS. McDOWELL: Zero members voted 6
22 or 5, meets and deserves priority
23 consideration; one member voted 4, meets; three
24 members voted 3, meets; three members voted 2,

1 does not meet; and one member voted 1, does not
2 meet; and zero members voted not applicable.

3 We need a simple majority, which is
4 5 votes. At this point, we do not have 5 in
5 either the meets or does not meet category, so
6 I don't know if you would like to have more
7 discussion.

8 VICE CHAIR TERRELL: Let's move
9 through all the rest of them and come back for
10 more discussion if we need to, okay?

11 MS. McDOWELL: Okay.

12 VICE CHAIR TERRELL: Let's move to
13 the next one. Can we do that?

14 MS. McDOWELL: Yes.

15 * **Criterion 5**

16 VICE CHAIR TERRELL: All right. The
17 fifth is flexibility. Provides the flexibility
18 needed for practitioners to deliver high
19 quality health care.

20 MS. McDOWELL: Zero members voted 6
21 or 5, meets and deserves priority
22 consideration; two members voted 4, meets;
23 three members, excuse me, six members voted 3,
24 meets; and zero members voted 2 or 1, does not

1 meet, or 0, not applicable. The majority has
2 determined that the proposal meets Criterion 5.

3 * **Criterion 6**

4 VICE CHAIR TERRELL: Let's go to
5 Criterion 6, please. Ability to be evaluated,
6 have evaluable goals for quality of care costs
7 and other goals of the PFPM.

8 MS. McDOWELL: Zero members voted 6
9 or 5, meets and deserves priority
10 consideration; zero members voted 4, meets; two
11 members voted 3, meets; five members voted 2,
12 does not meet; one member voted 1, does not
13 meet; and zero members voted not applicable.
14 The majority has determined that the proposal
15 does not meet Criterion 6.

16 * **Criterion 7**

17 VICE CHAIR TERRELL: Let's go to
18 Criterion 7. Integration and care coordination,
19 encourage greater integration and care
20 coordination among practitioners across
21 settings where multiple practitioners or
22 settings are relevant to delivering care to the
23 population treated under the payment model.

24 MS. McDOWELL: Zero members voted 6,

1 meets and deserves priority consideration; one
2 member voted 5, meets and deserves priority
3 consideration; zero members voted 4, meets; two
4 members voted 3, meets; four members voted 2,
5 does not meet; one member voted 1, does not
6 meet; and zero members voted not applicable.
7 Simple majority is five votes. Therefore, the
8 majority has determined that the proposal does
9 not meet Criterion 7.

10 * **Criterion 8**

11 VICE CHAIR TERRELL: Move on to
12 Criterion 8, patient choice. Encourages greater
13 attention to the health of the population by
14 also supporting the unique needs and
15 preferences of individual patients.

16 MS. McDOWELL: Zero members voted 5
17 or 6, meets and deserves priority
18 consideration; one member voted 4, meets; seven
19 members voted 3, meets; and zero members voted
20 2 or 1, does not meet, or 0, not applicable.
21 The majority has determined that the proposal
22 meets Criterion 8.

23 * **Criterion 9**

24 VICE CHAIR TERRELL: Okay. Criterion

1 9. Patient safety, aim to maintain or improve
2 standards of patient safety.

3 MS. McDOWELL: Zero members voted 6
4 or 5, meets and deserves priority
5 consideration; four members voted 4, meets;
6 four members voted 3, meets; and zero members
7 voted 2 or 1, does not meet, or 0, not
8 applicable. The majority has determined that
9 the proposal meets Criterion 9.

10 * **Criterion 10**

11 VICE CHAIR TERRELL: Criterion 10,
12 health information technology. Encourage use of
13 health information technology to inform care.

14 MS. McDOWELL: Zero members voted 6
15 or 5, meets and deserves priority
16 consideration; two members voted 4, meets; six
17 members voted 3, meets; and zero members voted
18 2 or 1 or 0, does not meet or not applicable.
19 The majority has determined that the proposal
20 meets Criterion 10, health information
21 technology.

22 VICE CHAIR TERRELL: Okay. All right.
23 I thought it might be helpful to do what we
24 just did, which was to go through all of them

1 before we go to the Criterion, what was it,
2 number 5, if we could go back to that slide
3 that we split on.

4 CHAIR BAILET: It was 4, Grace.

5 VICE CHAIR TERRELL: It was 4, okay.
6 And this was a high priority one, and we split
7 such that there was not a majority, as was
8 required between the eight of us, another
9 reason we need more members so that we won't
10 have that happen perhaps in the future.

11 I don't know that we need to spend a
12 lot of time on this, but I wanted to open it up
13 for any comments. We could certainly do
14 another, you know, round of voting, but I think
15 a larger issue is the, is the overall voting,
16 but I just wanted to open it up to comments, if
17 anybody had anything they wanted to add to
18 this, since we go through this whole process.
19 I'm not hearing any. Is that correct? Okay.

20 So I, we really don't have, do we,
21 these are the criterion. Do we have to come to
22 a consensus one way or the other on this by the
23 bylaws, or can we just say that it was a draw
24 and go onto the overall vote?

1 MS. McDOWELL: If we're not able to,
2 let's see here.

3 MR. STEINWALD: I think it, I think
4 it rolls down.

5 VICE CHAIR TERRELL: It rolls down.
6 Okay. Well, if it rolls down, then it would be,
7 it does not meet then. Okay. All right. Now,
8 let's go on to the, to the voting on the
9 overall recommendation.

10 So the next part of our voting,
11 we're going to vote again electronically, and
12 this is a two-part voting process.

13 So there's three categories that
14 we're going to vote on. The first is not
15 recommend for implementation as a PFPM. The
16 second one is recommended, and lastly, referred
17 for other attention by HHS.

18 So we need to achieve two-thirds of
19 a majority of votes for one of these
20 categories, and then if the two-thirds, we can
21 then vote on a subset to basically determine
22 the overall recommendation to the Secretary.

23 A second vote is for the following
24 four categories, which is the proposal

1 substantially meets its criteria. The second
2 category is that we recommend further
3 developing and implementing the proposal.

4 The third is that we would recommend
5 testing the proposal as specified in the
6 comments, and lastly, that we would recommend
7 it, implement it as part of an existing model,
8 but that part of the voting would only occur if
9 it was put forward or recommended to go forward
10 with it.

11 * **Overall Vote**

12 VICE CHAIR TERRELL: So I'm going to
13 now have everybody vote, and then we'll see
14 which way we go with this. Okay. Audrey, do you
15 want to go through the results there?

16 MS. McDOWELL: Sure. Three of the
17 members have voted not recommend for
18 implementation as a PFPM. One member has voted
19 recommended, and four members have voted
20 referred for other attention by HHS.

21 In this case, we need to have a
22 super majority, which would recommend, which
23 would represent six votes. We currently do not
24 have six votes in any of these three buckets.

1 MR. STEINWALD: This is Bruce. I
2 would like to hear what people had in mind when
3 they voted refer.

4 VICE CHAIR TERRELL: Yes. Yes, I was
5 going to say the same thing. So let's go around
6 and hear about the voting, and what people were
7 thinking, and then we will potentially have the
8 opportunity to re-vote.

9 I can tell you that I will start,
10 that I was the one that recommended that we
11 implement it. So I don't know that I agree with
12 the PRT about anything.

13 I do think that there is a component
14 of the model that's very important in that it
15 brings in more than one specialty. It's working
16 on a collaborative effort.

17 It's for a component that may not be
18 able to be part of an ACO or other types of
19 Alternative Payment Models, and I do think that
20 it could be something that, within a more
21 narrowed scope, would be appropriate to
22 recommend that CMMI work with.

23 I was a little concerned when, it
24 may have been Angelo or one of the other PRT

1 members, said that it didn't meet the current
2 criteria of the Secretary from the point of
3 view of scope, as that it was not a large
4 portion of the Medicare population.

5 I'm not sure that that particular
6 criteria, since it's not part of the 10. It's
7 one that I am going to be able to think through
8 as it relates to specialists, who, themselves,
9 may actually take care of a large number of
10 people like this.

11 So having said that, I will, I will
12 change my recommendation to refer. Now, that
13 won't get us to the two-thirds majority, but
14 that does let you know where I was coming
15 across from that.

16 And now, just to keep things going,
17 I'm going to turn it over to Jeff to talk about
18 his recommendations.

19 CHAIR BAILET: Yes. Thanks, Grace.
20 And I recommended to refer. I don't think the
21 model, as it stands, is sufficiently worked out
22 for implementation, but I do think there are
23 lots of elements, many of which have been
24 touched on today, that warrant further

1 exploration by CMMI, because I do agree that,
2 as the population ages, asthma will become more
3 prevalent.

4 It is a complicated diagnosis,
5 particularly in older patients. I think there
6 is some value on the payment and the savings,
7 and the amount of collaboration between the
8 specialists and primary care that still need to
9 be worked out.

10 So I do think the model warrants
11 further evaluation, not, I guess one other
12 comment I would make is we need to get
13 specialty models out in the field.

14 Harold's comments highlight that,
15 and I think there's enough, there's enough of a
16 framework here that, with CMMI's attention, I
17 think they could get a model out to serve this
18 up to the specialists listed here, and
19 potentially other specialists that take care of
20 asthma patients, as Dr. Tracy mentioned.

21 VICE CHAIR TERRELL: Thank you, Jeff.
22 I'm going to go to Paul now.

23 DR. CASALE: Yes, thank, Grace. My
24 comments would echo yours, and Jeff, I voted to

1 refer, and I do think, you know, specialty
2 models are needed.

3 On the scope end, you know, although
4 I understood the comments about not including
5 COPD, but in the Medicare population, I think
6 this model would actually be strengthened if
7 COPD would be included under the scope, and I
8 do think there is some work to be done,
9 particularly on the payment methodology.

10 So I certainly think there are
11 pieces of this that, as the PRT and the
12 submitters said, that could also be potentially
13 useful for other chronic conditions. So for all
14 those reasons, I voted to refer.

15 VICE CHAIR TERRELL: All right.
16 Thank you, Paul. I'm going to move to Charles
17 now.

18 DR. DeSHAZER: Yes. I also voted to
19 refer for some of the same reasons Paul and
20 Jeff have mentioned, and the thing that's
21 intriguing to me is the fact that I kept
22 hearing the issue of misdiagnosis, particularly
23 for the Medicare population, and I wasn't
24 completely convinced of the payment model, that

1 addressed that directly, but it does seem like
2 more collaboration and joint management would
3 support addressing that misdiagnosis aspect.

4 It does sound like this there is
5 built into it the consideration of social
6 determinants, and those factors, which was an
7 earlier concern. I do think that the complexity
8 issue can be worked through.

9 I don't think it's overly complex.
10 Coming from an informatics background, the
11 maturity of the data and analytics today should
12 be able to allow us to do assessment and for
13 those to be evaluated.

14 And I think the, you know, I think
15 also when I heard in the comments that this
16 will support smaller and rural practices as
17 well, to kind of get them onboard in terms of
18 disease management, from that standpoint, and
19 allow them to be able to invest in some of the
20 infrastructure, and overall, I just think it's,
21 it may, you know, full evaluation may provide a
22 way to begin to think about other specialty
23 APMs as well. So for those reasons, I thought
24 it was worth referring.

1 VICE CHAIR TERRELL: Thank you,
2 Charles. Moving to Kavita.

3 DR. PATEL: Yes. I initially voted to
4 not recommend, but I've been swayed by my
5 colleagues to change to the refer category.

6 VICE CHAIR TERRELL: Okay. Angelo?

7 DR. SINOPOLI: Similarly, I've noted
8 not to recommend, based on a lot of different
9 factors. I do agree that the need to have a
10 specialty APM is significant, and I do agree
11 that with some significant work, this could, I
12 believe, be turned into something that would be
13 easily administrable, and the payment model
14 could be worked on.

15 So whether the submitters worked on
16 that and resubmit it, or whether CMS or HHS
17 works on it, I think I'd be comfortable either
18 way. So if the group feels like referring is
19 the end result, I'm comfortable with that.

20 VICE CHAIR TERRELL: Okay. Moving to
21 Bruce.

22 MR. STEINWALD: I voted not to
23 recommend, but I intended to vote for refer.
24 I'm not really changing my mind, I'm changing

1 my vote. But I also think that this is
2 channeling Bob Berenson a little bit.

3 He was a previous member, but he
4 often said if we perceive that there is a
5 problem or a need, we ought not to exclude
6 looking at the fee schedule itself, rather than
7 PFPM.

8 And I think that ought to be part of
9 their referral is to make sure we examine the
10 fee schedule and determine whether some of the
11 issues raised by the presenter could be
12 addressed once a month with patient care.

13 And unfortunately, CMS is siloed in
14 this respect. The people who develop models,
15 and the people that manage them, and might
16 apply to fee schedule, or in different
17 countries and things, and often, they don't
18 have a chance to sort of debate what's the
19 better approach. And so I think that's
20 something we should note here.

21 VICE CHAIR TERRELL: Thank you,
22 Bruce. Moving finally to Jennifer.

23 DR. WILER: I voted for refer for all
24 of the reasons previously stated, and the other

1 that I will add is there's clearly engagement
2 and interest in the stakeholder community and
3 some valuable comments that were given to us
4 for consideration, and I thought it was
5 valuable to recognize that as an opportunity to
6 include this category of patients in another
7 payment model, or to refine both the care
8 delivery model, meaning expand the scope to
9 other respiratory conditions, or to refine the
10 payment model.

11 VICE CHAIR TERRELL: All right.
12 Thank you. I think, I'm hearing that refer is
13 going to pass this time, but let's go ahead.

14 Can we open the polling back up,
15 please, so we can officially do that? It still
16 says, okay, there it is. All right. Well, look
17 there. Audrey, do you want to give the results?

18 MS. McDOWELL: Eight members voted to
19 refer for other attention at HHS, and so the
20 finding of the committee is that the proposal
21 should be referred for other attention by HHS.

22 VICE CHAIR TERRELL: All right. So
23 that concludes this part of the PTAC. I believe
24 you got the comments from everybody, if we can

1 go offline subsequently, if, to make sure that
2 as we're writing the report, that all of the
3 points get made.

4 There was the opportunity, I
5 believe, if we had 15 minutes, which we do, for
6 a special sort of short presentation from NORC.
7 Is that still going to happen?

8 MS. McDOWELL: Yes. Grace, can we
9 just confirm that there are no other comments
10 that the committee members want to --

11 VICE CHAIR TERRELL: Sure.

12 MS. McDOWELL: -- have included in
13 the report to the Secretary?

14 VICE CHAIR TERRELL: Okay. Somebody
15 has a comment.

16 DR. STEARNS: Audrey, do you want me
17 to do any summary, or that would be later?

18 MS. McDOWELL: I guess the other
19 question would be, Sally, do you have any
20 questions for the Committee members, or do you
21 think it's pretty clear what they want included
22 in the report to the Secretary? Can you give us
23 a quick summary?

24 * **Instructions on Report to the**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Secretary

DR. STEARNS: Sure, I'll give you a very quick, I think it's very clear. PTAC appreciates and recognizes the development of a specialty-focused model that involved a team-based approach of, could be very beneficial, not only for asthma, but for other conditions.

A couple points about asthma being costly and often misdiagnosed. So in total, there is belief that an APM model that supports smaller and rural practices, as well as larger practices, is needed, possibly very, possibly especially specific.

There's also, in support of the model, there's evidence of engagement and interest in the stakeholder community. There are still a lot of concerns with the payment model, but by referring the model, some of those concerns could be worked out, and I've got some specific statements of those that will be in the report to the Secretary.

VICE CHAIR TERRELL: Thank you. All right. Do we still have time for the brief presentation?

1 MS. McDOWELL: Yes.

2 VICE CHAIR TERRELL: Okay.

3 * **Discussion: Reflecting on Models**

4 **Deliberated on By PTAC**

5 DR. SHARTZER: Hello, everyone. I'm
6 Adele Shartzter, and a member of the contractor
7 support team. I'm pleased today to present with
8 my colleague, Laura Skopec, highlights from two
9 analyses we conducted in February for ASPE and
10 PTAC, which were slated for presentation at the
11 March meeting.

12 We've made a few minor updates to
13 the slides since then. The full reports are
14 available on the resources page of the ASPE
15 PTAC website.

16 These slides and accompanying
17 appendix materials will be posted there as
18 well. I'll discuss findings from our review of
19 proposals submitted to PTAC as of December
20 2019. Next slide, please.

21 Between December 2016 and December
22 2019, 34 proposed physician-focused payment
23 models, or PFPs, were submitted to PTAC for
24 review.

1 This presentation focuses on the 24
2 proposed models that were deliberated and voted
3 on by PTAC, and for which reports had been
4 submitted to the Secretary as of December 31,
5 2019.

6 The remaining 10 proposals submitted
7 as of that date were either under active review
8 or had been withdrawn from consideration.
9 Since that time, two of the --

10 (Telephonic interference)

11 VICE CHAIR TERRELL: Lost sound
12 there.

13 DR. SHARTZER: -- review was
14 subsequently withdrawn, and one of the
15 proposals that had been withdrawn from
16 consideration was subsequently revised and
17 resubmitted. Next slide.

18 Overall, we find that PTAC has
19 activated the stakeholder community. The
20 submitted proposals targeted different types of
21 providers, clinical conditions, and --

22 (Telephonic interference)

23 DR. SHARTZER: -- practices and
24 individual physicians submitted more than half

1 of the proposals, and their submissions
2 addressed realtime care delivery needs of those
3 practicing on the ground. The --

4 (Telephonic interference)

5 CHAIR BAILET: Adele, your sound is
6 breaking up. So --

7 VICE CHAIR TERRELL: Yes, it's coming
8 in and out.

9 CHAIR BAILET: Could you see if you
10 could address that? Thank you.

11 MR. STEINWALD: Well, it's not going
12 in and out anymore.

13 CHAIR BAILET: Yes.

14 VICE CHAIR TERRELL: It's just --

15 DR. SHARTZER: -- CMMI model
16 development, describing --

17 (Telephonic interference)

18 DR. SHARTZER: Can you hear me?

19 VICE CHAIR TERRELL: We can now.

20 DR. SHARTZER: Okay. The proposals
21 also included innovations and Alternative
22 Payment Models that can inform CMMI model
23 development. I'll describe these more later.

24 Likewise, the fact that nearly all

1 proposals included two-sided risk
2 accountability approaches, can inform future
3 model development. As mentioned, the PTAC
4 process enables stakeholders to raise policy
5 issues related to care delivery and payment
6 reform. The review of their proposals by a
7 panel of experts generates an inventory of
8 information on these topics that can be used to
9 influence APM development, research, and
10 awareness. Next slide, please.

11 Next slide, please.

12 The findings I'm presenting today
13 are drawn from an analysis we conducted for
14 ASPE and PTAC. This particular report reviews
15 proposed models that were submitted to PTAC to
16 synthesize and describe gaps in care and
17 payment identified by submitters, and
18 identified key features and common elements of
19 proposed models and payment solutions.

20 We used a software program to review
21 and summarize findings with input from ASPE
22 project staff. Our main analysis focuses on the
23 24 proposals voted on by PTAC as of December
24 2019, with some exceptions, where noted. Next

1 slide, please.

2 In this slide, we assessed the types
3 of entities that had submitted proposals to
4 PTAC for review. Among the 34 proposals that
5 were submitted by December 2019, we find PTAC
6 proposals span a range of submitter types, most
7 commonly national provider associations or
8 specialty societies, with 10 submissions, and
9 regional or local single specialty physician
10 practices, with seven submitters. Next slide,
11 please.

12 In reviewing the 24 proposed models
13 that were included in a report to the Secretary
14 as of December, we identified three main focus
15 areas. Ten models focused on specific health
16 conditions, like cancer, asthma, or end stage
17 renal disease.

18 In addition, two models focused on
19 advanced illness and care for patients near the
20 end of life, but these models could apply to a
21 range of health conditions. Another subset of
22 11 models focused on a particular clinical
23 setting or type of practice.

24 These models focused on improving

1 primary care, delivering more care in patient
2 homes, enhancing access to care in skilled
3 nursing facilities, improving transitions in
4 care between inpatient, emergent, and home
5 settings, and supporting care delivery in rural
6 settings.

7 In addition, there were two
8 proposals that were broad end scope, and
9 covered a range of conditions or providers.
10 The American College of Surgery proposed PFPM
11 could apply to more than 100 conditions or
12 procedures, and the Dr. Yang proposal
13 represented a fundamental restructuring of
14 Medicare.

15 We found the proportion of proposals
16 focused on conditions and clinical settings was
17 nearly equal. Next slide, please.

18 Submitters were sometimes explicit
19 about perceived gaps in care delivery and
20 payment, and proposed submissions, and at
21 times, these issues were implicitly referenced.

22 These gaps overlapped and were not
23 exclusive, meaning proposed PFPMs could target
24 several of the issues we identified at the same

1 time.

2 In our review of the 24 proposals,
3 these are things we identified, and the gaps in
4 care delivery and payment they addressed. ED
5 visits and hospitalizations that could be
6 avoided with improved care delivery or payment,
7 inadequate support for care management, such as
8 time spent coordinating care with other
9 providers, transitions in care across settings
10 and condition phases that resulted in
11 disruptions in care, sub-optimal handoffs
12 between providers, and poor health outcomes.

13 Limited access to convenient
14 services for beneficiaries, such as services
15 near or in their home.

16 Payment for services that differed,
17 based on treatment site, such as physician
18 office versus hospital outpatient department,
19 incentives to deliver a high volume of
20 services, rather than value-based care, and
21 restrictions in current fee schedule codes or
22 existing APMS that submitters felt limited
23 providers' ability to use codes or participate
24 in models. Next slide, please.

1 In this slide, we focused on the
2 proposed approaches to payment for services and
3 care-related activities in the 22 PFPMs to
4 which the Secretary's criteria were applicable.

5 The first set of five proposed PFPMs
6 included additional or supplemental payments to
7 the fee schedule. Four of these proposals did
8 not include any downside risk for participating
9 providers.

10 The next set of nine proposed PFPMs
11 featured per beneficiary per month, or PBPM,
12 payments to support care delivery, and four of
13 these proposals capitated PBPM payment replaced
14 certain fee schedule codes, and providers were
15 at risk for care delivery expenditures that
16 exceeded the monthly payment.

17 In the remaining five PBPM
18 proposals, providers would continue to build a
19 fee schedule as usual, but would receive
20 supplemental monthly payments to support
21 additional activities, such as remote
22 monitoring or coordination of tests.

23 All of the PBPM models included some
24 element of shared risk for providers. Eight

1 proposals adopted an episode-based approach in
2 their proposed payment model.

3 Common across these proposals was a
4 target price for spending on a defined set of
5 services, and shared risk for performance
6 during the episode, based on spending and/or
7 quality objective.

8 Four proposals would continue fee-
9 for-service payments during the episode, with
10 retrospective reconciliation, and four
11 proposals would give participating providers a
12 fixed episode payment to cover activities
13 during the episode.

14 Overall, we find that PBPMs and
15 episode-based models were proposed in about
16 equal proportion, with a smaller number of
17 models proposing additional payments. Next
18 slide.

19 In assessing how the 22 proposed
20 PFPMs addressed performance-based risk for
21 participating providers, we find that only
22 three did not include any direct performance-
23 based provider risk.

24 One model included upside-only risk

1 for participating providers, and several others
2 include upside-only risk in initial phases of
3 the model, but would transition to shared risk
4 in subsequent years.

5 The remaining models all proposed
6 some variant of shared risk. Five proposed
7 models would adjust the APM payments provided
8 in the model, based on performance. For
9 example, overspending relative to the target
10 could mean a slightly lower PBPM in a
11 subsequent year.

12 Seven proposed models included two-
13 sided risk for base Medicare payments. In these
14 models, providers would receive a portion of
15 total savings, or be at risk for a portion of
16 total losses relative to the spending target.

17 We identified five models as
18 proposing full risk for providers, meaning that
19 providers would be at risk for the full cost of
20 care beyond the APM payment.

21 These models included capitated
22 PBPMs and episode-based models with fixed
23 episode payments. Next slide, please.

24 Here, we arranged the proposed

1 approaches to payment with the proposed models
2 focus area to identify whether certain types of
3 models, like condition-focused models, were
4 proposing similar types of payment solutions.

5 And key findings are that the
6 chronic condition-focused models proposed a
7 variety of different payment approaches,
8 including add-on PBPMs and episode-based
9 approaches.

10 Both advanced illness models were
11 capitated PBPMs, as were the primary care-
12 focused models. The setting-focused models
13 tended to include additional payments with no
14 downside risk, though two proposed add-on
15 PBPMs, and two others used an episode-based
16 framework.

17 The broadly focused ACS³⁸ proposal
18 also adopted an episode-based framework. My
19 colleague, Laura, will now share findings from
20 our synthesis of PTAC's expert review across
21 proposals.

22 VICE CHAIR TERRELL: And we're right
23 at two minutes to 3, so just reminding you that

1 we need to get this, get through this very
2 excellent proposal pretty quickly.

3 MS. SKOPEC: Great. Okay. So I'm
4 Laura Skopec, also a member of the contractor
5 team. Next slide, please.

6 I'm discussing a companion analysis
7 of PTAC voting patterns and comments on
8 proposed PFPs. The purpose of this analysis
9 was to identify themes and patterns in PTAC
10 analysis and review of proposed PFPs relative
11 to the Secretary's criteria.

12 We focused on 22 models deliberated
13 and voted on as of December 2019. We excluded
14 two proposed models for which the PTAC
15 determined that the Secretary's criteria were
16 not applicable.

17 Our analysis had two components.
18 First, we analyzed PTAC final votes recorded
19 for the 22 proposed models and reports to the
20 Secretary, including votes on each criterion,
21 and the overall recommendation.

22 We also assessed PRT votes as
23 recorded in the 22 PRT reports. Secondly is
24 NVivo12, a qualitative analysis software to

1 code PTAC comments and the reports to the
2 Secretary.

3 This analysis doesn't reflect all
4 comments from PTAC but gives an overview of key
5 themes that emerged from PTAC comments. Our
6 codes covered six domains that were related to
7 but not synonymous with the Secretary's
8 criteria, including scope and scalability,
9 quality, payment model, evidence and
10 evaluability, care coordination, care
11 integration, and shared decision making, and
12 health information technology. Next slide.

13 For a refresher, here are the
14 Secretary's 10 Criteria. The first three,
15 scope, quality, and cost and payment
16 methodology are the high priority criteria.
17 Next slide.

18 This table shows the number of
19 proposed models that did not meet that, or met
20 and deserved priority criteria consideration
21 for each of the 10 Criteria.

22 All or nearly all proposed models
23 deliberated and voted on by PTAC met the scope,
24 value over volume, flexibility, patient choice,

1 and patient safety criteria.

2 The major differentiating criteria
3 were payment methodology, met by only half of
4 the proposed models; integration and care
5 coordination met by about two-thirds of the
6 proposed models; and quality and cost, met by
7 about three-quarters of the proposed models.
8 Next slide, please.

9 Overall, payment methodology,
10 integration and care coordination, and quality
11 and cost were frequently the differentiating
12 criteria between recommended and not
13 recommended models.

14 Key themes from the scope and
15 scalability domain included praise for proposed
16 models that would provide new opportunities for
17 APM participation, that would provide new
18 services for Medicare beneficiaries, or that
19 identified problems in Medicare's current
20 payment structure.

21 In addition, PTAC recommended that
22 proposals addressed interaction with existing
23 CMMI models. Key themes from the quality domain
24 included praise for proposed models that tied

1 payment to quality.

2 PTAC also recommended designing
3 payment and care delivery models with a focus
4 on improving quality, and PTAC recommended that
5 some proposed models add measures of patient
6 experience and create formal quality assurance
7 procedures.

8 In the payment model domain, PTAC
9 emphasized that submitters should carefully
10 assess the positive and negative incentives
11 created by the payment model, including the
12 appropriateness of features like two-sided risk
13 and shared savings and penalties based on total
14 cost of care.

15 PTAC also suggested clarifying and
16 assessing the appropriateness of accountability
17 for care quality and for savings. For some
18 proposals, PTAC suggested exploring alternative
19 approaches to encouraging the proposed care
20 model, like a fee schedule change. Next slide.

21 Under the evidence and availability
22 domain, PTAC suggested that submitters provide
23 any available evaluation results from
24 previously tested models and strengthen

1 evidence for the model we're testing that had
2 been conducted.

3 In addition, PTAC recommended real-
4 world testing for several proposed models,
5 particularly those recommended to the Secretary
6 for limited scale testing.

7 Under care coordination, care
8 integration, and shared decision making, PTAC
9 suggested that submitters describe formal
10 shared decision making approaches.

11 For models targeting sensitive
12 populations, such as serious illness care
13 models, PTAC recommended describing in detail
14 how patient preferences and individual needs
15 would be considered.

16 Finally, PTAC recommended explaining
17 how integration and care coordination would be
18 incentivized and ensured and especially care
19 coordination focused on the whole patient, not
20 just the targeted disease.

21 In the health information technology
22 domain, PTAC praised the use of novel
23 technologies, where appropriate, but suggested
24 both avoiding proprietary technology and

1 developing approaches that would limit the
2 provider and beneficiary burdening, burden of
3 adopting new technologies.

4 PTAC also recommended that
5 submitters describe how any data collected by
6 new technologies would be used. This concludes
7 our presentation on proposed models deliberated
8 and voted on by PTAC as of December 2019. The
9 full reports are available on the PTAC website.

10 VICE CHAIR TERRELL: Thank you for
11 doing that so quickly and well, and I'm going
12 to turn the gavel back over to Jeff Bailet.

13 * **Chairman's Closing Remarks**

14 CHAIR BAILET: All right. Thank you, Grace. I
15 want to thank Laura and Adele, and NORC for
16 the, and the Urban Institute, for that
17 presentation.

18 You've clearly done a lot of work
19 reflecting the work of the committee, which was
20 not an easy feat, but thank you for that.
21 Thanks for all of the folks participating in
22 our first ever virtual meeting.

23 I know that sitting through a long
24 meeting is challenging, even in person, so I

1 appreciate all of you members, submitters, and
2 stakeholders hanging on until the end.

3 I have one more announcement before
4 we adjourn. I'll make this quick. As many of
5 you know, ASPE prepares an environmental scan
6 for every proposal reviewed by PTAC to give
7 members a good understanding of the clinical
8 and economic circumstances surrounding the
9 proposed model.

10 To even better inform our review, we
11 are seeking to expand the information included
12 in the scans, and do so, we are asking our
13 stakeholders to contribute additional
14 information for these scans.

15 PTAC seeks to build upon the
16 insights of stakeholders and use what issues
17 they believe are material to our review to
18 enhance our review and our recommendations to
19 the Secretary.

20 Therefore, we are looking for your
21 input on several questions to inform our
22 environmental scans in general, and we are also
23 encouraging stakeholders to consider these
24 topics when submitting public comments on a

1 particular proposal.

2 These questions will be posted on
3 the ASPE PTAC website, on the for public
4 comment page, soon, for the public to submit
5 responses via email.

6 The questions will also be emailed
7 out through our distribution lists, which you
8 can join on the ASPE PTAC website. We want to
9 hear from you.

10 We intend to review the input we
11 receive on these questions at an upcoming
12 public meeting if time allows and we plan to
13 post the input online.

14 * **Adjourn**

15 CHAIR BAILLET: Issuing that call to
16 action is our last order of business for today.
17 I'd like to thank everyone for participating
18 and for bearing with us as we've had our first
19 virtual meeting, and thank you all for taking
20 time out of your busy schedules to be with us.
21 Please stay safe, take care, be well. The
22 meeting is adjourned. Thank you.

23 (Whereupon, the above-entitled
24 matter went off the record at 3:06 p.m.)

C E R T I F I C A T E

This is to certify that the foregoing transcript

In the matter of: Advisory Committee Meeting

Before: PTAC

Date: 06-22-20

Place: virtual meeting

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.



Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701